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Abstract 
Obesity is recognized as a risk factor for adverse pregnancy outcomes. Maternal 
obesity prevalence has increased in parallel with that in the general population and is 
associated with an increase in morbidity and mortality for both mother and baby. 
Obese mothers are more likely to develop gestational diabetes, hypertensive 
disorders including preeclampsia, thromboembolic complications, miscarriage, and 
have an increased need for induction of labour. Babies born from obese mothers can 
be abnormally large (macrosomia) or small for gestational age, and have a higher 
risk of perinatal death and congenital malformation. Pregnancy induces marked and 
dynamic changes in energy metabolism, however, the direct effects of pregnancy 
adipose tissue biology in both normal lean and obese women is still largely 
unknown. The aim of this thesis was to delineate novel mechanisms by which 
pregnancy affects adipose tissue biology, and thus infer how obesity might adversely 
affect pregnancy outcomes.   
We used an animal model of obesity during pregnancy in which mice were given a 
high fat diet (HF) to make them obese. We identified that pregnancy was associated 
with an unexpected curtailment of visceral (mesenteric) adipose tissue mass in HF 
mice and with an attenuation, rather than worsening of the metabolic impairment 
expected from the combination of excess dietary fat and insulin resistance/glucose 
intolerance of pregnancy. To determine the underlying molecular mechanism 
contributing to this phenotype global gene expression microarray with subsequent 
pathway analysis and qRT-PCR validation was employed within the visceral adipose 
tissue. In visceral fat of HF pregnant mice, gene pathways for de novo lipogenesis 
and lipid storage, inflammation, retinol metabolism, insulin like growth factor and 
estrogenic signaling showed altered regulation. Given the known role of estrogen on 
adipose tissue and inflammatory cell function, a hypothesis was generated that 
altered estrogen receptor (ER)α expression/activation/increased estradiol presence 
within mesenteric fat formed a unifying molecular mechanism underlying the altered 
adipose biology and relative amelioration of the metabolic phenotype in HF pregnant 
mice. 
 
	   v	  
To test the ER α hypothesis, a female clonal adipocyte cell line, Chub-S7, and 
primary visceral and subcutaneous adipocytes from pregnant obese and lean patients 
were treated with the ERα selective agonist, PPT. PPT downregulated mRNA levels 
of key genes involved in de novo lipogenesis (ME1, FANS and SCD1 Dgat2), 
consistent with a direct role for ERα activation in curtailment of fat expansion.  
Although the primary human study lacked sufficient power to adequately address the 
hypothesis, PPT significantly suppressed SCD1 mRNA levels in visceral adipocytes 
of lean women.  
 
In parallel with the curtailment of mesenteric fat expansion, HF pregnant mice were 
found to have increased liver weight and liver triglyceride content. However, this 
“fatty liver” phenotype was not associated with increased mRNA levels of genes 
involved in hepatic triglyceride uptake or de novo lipogenesis. This increase in liver 
triglycerides may be due to an excessive influx of fatty acids from mesenteric fat 
through the portal vein. 
 
In conclusion, pregnancy in obese animals is associated with a beneficial curtailment 
in mesenteric fat expansion, normalization of metabolic disturbances and reduced 
adipose inflammation. Increased ERα activation within adipocytes may play a 
critical role in this phenotype. 
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Chapter 1: Introduction 
 
1.1 Obesity 
Obesity is a clinical condition characterized by excess accumulation of body 
fat. The most common clinical indicator of obesity is body mass index (BMI: 
weight/(height)2 of ≥ 30 kg/m2). The World Health Organization (WHO) and 
the National Institutes of Health (NIH) define normal weight as a BMI of 
18.5-24.9 kg/m2, overweight as a BMI of 25-29.9 kg/m2, and obesity as a 
BMI of ≥ 30 kg/m2. 
Before the 20th century, obesity was less common and only in 1997 did the 
WHO formally recognize obesity as a disease pathology and a global 
‘epidemic’ (Malik et al., 2006). The prevalence of obesity is rising worldwide 
and affecting both the developed and developing world (Tsigos et al., 2008) 
and both sexes. Projections by the WHO 
(http://www.who.int/mediacentre/factsheets/fs311/en/) indicate that by 2015, 
2.3 billion people will be overweight and approximately 700 million obese. 
Scotland has one of the highest prevalence of obesity in the world, secondly 
only to USA and Mexico, with 27% of adults and 15% of children obese 
(http://www.scotlandgov.uk/Publications/2010/02/17140721/4). Obesity is 
associated with an increased risk of developing various pathologies, such as 
type 2 diabetes, metabolic syndrome, cardiovascular disease, stroke, 
hypertension, obstructive sleep apnea and cancers (Mokdad et al., 2003; Guh 
et al., 2009).  
Obesity is influenced by both genetics and environment. In the last 10 years 
there was an increased effort to understand which alleles variations (gene 
variants or polygenes) variations were associated with obesity and with body 
weight control (extensively reviewed by (Hinney and Hebebr, 2008)). Two 
methods that have been used are: Genome-Wide Linkage Scans and Genome-
Wide Association (GWA) studies. The genome-wide linkage approach aims 
to identify chromosomal regions rich with potential candidate genes that 
contribute to a pathology; this approach has been successful in identifying 
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genes involved in monogenic disorders but has limited power to detects 
variation that determine small effects contributing to a complex disease such 
as obesity (Risch and Merikangas, 1996). In contrast, the GWA study, 
examines genetic variants in different individuals (i.e. lean vs obese) in order 
to identify which variants are associated with a trait (i.e. obesity). These 
studies often focus on the association between single nucleotide 
polymorphisms (SNPs) and traits of major diseases.  This approach allowed 
identification of two gene variants that have effects on body weight to be 
identified: melanocortin-4 receptor (MC4R) gene (Heid et al., 2005; Young et 
al., 2007) and fat mass and obesity associated (FTO) gene (Frayling et al., 
2007; Dina et al., 2007). 
 
` 
1.1.1 Obesity in pregnancy 
Obesity is an important factor in the obstetric population. The Centre for 
Maternal and Child Enquiries (CMACE) estimated in 2010 that 20% of the 
obstetrics population in the United Kingdom was obese and this number is 
rising in parallel with the global increase in obesity prevalence. 
More than 50 years ago obesity was also recognized as a risk factor for 
adverse pregnancy outcomes (Galtier-Dereure et al., 2000; Ramachenderan et 
al., 2008).  Maternal obesity is associated with an increase in morbidity and 
mortality for both mother and fetus. During pregnancy obese women are 
more likely to develop hypertensive disorders including preeclampsia and 
thromboembolic complications, gestational diabetes and miscarriage 
(extensively reviewed by (Denison et al., 2010)). During labour obese women 
face increased risk for the need of induction of labour, instrumental delivery 
and increased risk of haemorrhage. Fetuses born to obese mothers can be 
abnormally large (macrosomia) or show intrauterine growth restriction and 
have a higher risk of death, congenital malformation and neural tube defects. 
Offspring of obese mothers also have a higher risk of developing metabolic 
syndrome in childhood and adolescence (Boney et al., 2005). However, the 
mechanistic link between obesity and the increased risk of developing 
adverse outcomes during pregnancy is not understood.  
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1.1.2 Therapeutic intervention in obese subjects 
Therapeutic interventions to cure obesity have proven to be extremely 
challenging due to the complexity of this pathology. Obesity in fact is a 
condition characterised by the interaction of genes involved in weight 
maintenance, exposure to over-abundance of food, in particular to saturated 
fat, and limited physical activity (Poskitt, 2009).  
In terms of pharmacological strategies, anti-obesity drugs currently available 
are primarily those affecting appetite control, such as Sibutramine, inhibitor 
of serotonine and dopamine uptake, Rimonabant, cannabinoid receptor 1 
(CB1) agonist, or those targeting fat absorption by the gut, such as Orlistat 
which acts by inhibiting lipase action and subsequent dietary fat absorption. 
Despite the beneficial effect of these drugs on weight loss, serious side-
effects have led to their limited use: for example, the Scottish Medicine 
Consortium removed Rimonabant from use in obese patients due to increased 
risk of psychiatric events, mainly anxiety and depression (Moreira and 
Crippa, 2009). Similar to Rimonabant, Sibutramine is also no longer available 
on prescription for weight loss due to increased risk of psychiatric events. 
 
1.1.2.1 Management of obese pregnant subjects 
Guidelines from CMACE and the Royal College of Obstetricians and 
Gynaecologists (RCOG) suggest that during pregnancy the management of 
obese women is mainly done through weight management, in particular 
encouraging patient not to gain an excessive amount of body weight 
(http://www.llevadores.cat/html/publicacions/docs/Joint-CMACE-RCOG-
Guidelines---Management-of-Obesit.pdf). Due to the higher management cost 
and complexity of care for obese pregnant patients, new therapeutic avenues 
are desirable. To facilitate this, a better understanding of the molecular 
mechanisms contributing to obesity and its consequences is needed. Given 
that excessive fat mass leads to downstream metabolic pathology, one 
potentially fruitful route for discovering new therapeutic targets is within the 
affected adipose tissue. By specifically determining the changes occurring 
	   14	  
within the adipose tissue of obese pregnant subjects a more tailored 
pharmacological strategy may be possible, assuming distinct pregnancy 
associated changes occur. Potential treatments resulting from this basic 
understanding might also be better suited for use during pregnancy and in the 
wider the care of obese people.  
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1.2 Adipose tissue biology 
A hallmark of obesity is excess adipocyte size and number. Adipocytes are 
highly specialized cells that play an important role in energy homeostasis 
including: lipid storage, metabolism and release under the appropriate 
physiological conditions, and critical endocrine properties including the 
regulation of reproduction, appetite and energy balance and control of 
nutrient homeostasis.  
 
1.2.1 White and Brown adipose tissue 
Adipose tissue is composed by two functionally different type of fat: white 
and brown adipose tissue. The main purpose of White adipose tissue is to 
store and release fatty acids, that can supply energy to the body during 
intervals between meal, and to release adipokines and cytokines, that are 
responsible for modulation of insulin resistance and whole-body metabolism. 
Brown adipose tissue, instead, is responsible for thermogenesis by expressing 
tissue uncoupling protein (UCP) 1 in the mitochondria of brown adipocytes 
(Cinti et al., 1989; Ricquier et al., 1991). Brown adipose tissue is present in 
rodents throughout life and it has effects on body weight (Almind et al., 
2007), energy balance, and glucose metabolism (Lowell et al., 1993; Yang et 
al., 2003). In humans, brown adipose tissue is found primarily in infants and 
young children. Combined positron-emission tomography and computed 
tomography (PET–CT) has recently been used to identify adipose tissue with 
a high rate of uptake of 18F-fluorodeoxyglucose (18F-FDG) as putative brown 
adipose tissue, demonstrating that brown fat is also present in adult humans 
(Cypess et al., 2009).  
White and brown adipose tissues are not completely detached from each 
other: brown adipocyte-like cells are found in human and rodent white 
adipose tissue. These cells, expressing UCP-1, have been called by different 
names: brown-in-white (brite) cells, beige cells, or adaptive or recruitable 
brown adipocytes. Although the precise origin of these cells is not fully 
defined, the development of these cells in white adipose tissue is greatly 
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enhanced in response to chronic cold exposure or prolonged β-adrenergic 
stimulation (which increases UCP1 production) (Cousin et al., 1992; Himms-
Hagen et al., 1994; Guerra et al., 1998), and the occurrence of these cells is 
associated with resistance to obesity and metabolic diseases (Cederberg et al., 
2001; Leonardsson et al., 2004). Recently it has been demonstrated that 
enriched environment, consisting of physically and socially more complex 
housing, induces genetic, morphological and functional transformation of 
white adipose tissue to brown adipose tissue, mediated by hypothalamic 
brain-derived neurotrophic factors which link environmental stimuli, 
sympathetic outflow, and the switch from white to brown fat and subsequent 
energy dissipation (Cao et al., 2011). 
 
1.2.2 Cellular origins of the mature adipocyte 
Adipose tissue is composed not only of mature fat-storing adipocytes but also 
of precursor cells whose main function is to differentiate into fat cells when 
required such as during nutrient excess. The process by which preadipocytes 
turn into mature fat cells, adipogenesis, also follows a regular turnover 
physiologically. Peter Arner’s group calculated the median adipocyte 
turnover rate is 8.35±6.6% per year, with 50% of adipocytes replaced every 
8.30 years (Spalding et al., 2007) and approximately the 10% of fat cells are 
renewed annually (Spalding et al., 2008) and are replaced by their precursors 
through as yet unknown mechanisms in order to maintain cellular 
homeostasis. It has been estimated that preadipocytes account for 15%-50% 
of cells in adipose tissue (Kirkland et al., 1994). Notably, the number of 
adipocytes is set during early adulthood, with subsequent interventions such 
as bariatric surgery affecting only adipocyte hypertrophy (Spalding et al., 
2008). 
 
1.2.3 Preadipocyte differentiation 
Insulin-like growth factor (IGF)1 mediates proliferation and differentiation of 
preadipocytes in vitro (Smith et al., 1988; Boney et al., 1994; Scavo et al., 
2004; Grohmann et al., 2005) and in vivo (Holzenberger et al., 2001), in cell 
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lines and primary cultured cells. IGF1 after binding to its own receptor, 
IGFR, activates the extracellular-signal regulated kinase (ERK) and 
phophatidyl inositol-3 kinase (PI3K) signalling pathways. Activation of ERK 
pathways is necessary for IGF1 stimulated proliferation of 3T3-L1 
preadipocytes (Boney et al., 2000; 2001). In contrast, activation of PI3K 
pathway plays an important role in IGF1 stimulated differentiation (Miki et 
al., 2001; Aubin et al., 2005). PI3K activates protein kinase B (PKB) which 
also promotes adipocyte proliferation by activating Cyclin D1 (Muise-
Helmericks et al., 1998). 
Insulin-like growth factor binding protein 3 (IGFBP3) binds to IGF1 
prolonging its half life but also limiting its interaction with IGFR; in this way 
IGFBP3 can inhibit preadipocyte differentiation by limiting IGF1 interaction 
with its receptor. However, IGFBP3 itself can also inhibit peroxisome 
proliferator-activated receptor gamma (PPARγ)-dependent differentiation of 
preadipocytes. It is known that IGFBP3 can translocate to the nucleus in 
association with the importin-β nuclear transport factor (Schedlich et al., 
2000) and binds in this compartment different nuclear receptors, such as 
retinoid X receptor (RXR) (Liu et al., 2000), retinoic acid receptors (RAR) 
(Schedlich et al., 2004), vitamin D receptor (VDR) (Schedlich et al., 2007), 
and nerve-growth factor IB (NGFIB) also known as nur77 (Lee et al., 2007). 
A study by Chan et al. showed that PPARγ needs to form a heterodimer with 
RXR to be transcriptionally active: IGFBP3 inhibits the formation of this 
complex by binding PPARγ and inhibits the transactivation of peroxisome 
proliferator hormone response elements (PPRE), therefore preventing 
preadipocyte differentiation (Chan et al., 2009). PPARγ promotes 
preadipocyte differentiation also through regulation of CCAAT-enhancer 
binding protein (C/EBP)α, which is responsible for the transcription of genes 
involved in de novo lipogensis, in particular fatty acid synthase gene (FASN) 
(Liu et al., 2012). 
IGF1 and PPARγ are not the only two molecules responsible for 
adipogenesis: Krüppel-like factors, liver X receptor α and β, sterol regulatory 
element binding protein-1 transcription factor (SREBP1), endothelial PAS 
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domain-containing protein 1, signal transducer and activator of transcription 
(STAT)-5a, cyclic AMP response element-binding protein, aryl hydrocarbon 
receptor nuclear translocator-like protein 1 and glucocorticoid receptor, early 
growth response gene 2 are all involved and have positive effect on 
adipogenesis (as extensively reviewed by Farmer, 2006 and Rosen and 
MacDougald, 2006).  
Adipogenesis and preadipocyte proliferation is therefore a key process that 
impacts on adipose tissue expansion during physiological state (such as 
pregnancy) and pathophysiological conditions (obesity).   
 
1.2.4 Lipid Storage and Uptake 
One of the most important roles of the adipocyte is storage of dietary/hepatic 
lipids and de novo synthesis of triglycerides (TAG) or lipogenesis 
(extensively reviewed by (Shi and Burn, 2004)). 
Dietary lipids are initially digested in the stomach by gastric lipases. Large fat 
globules with hydrophobic TAG cores surrounded by polar molecules, 
including phospholipids (PLs), cholesterol (CL), and fatty acids (FAs) are 
formed. The digestive process is completed in the intestinal lumen, where the 
fat globules are mixed with lipid digestive enzymes contained in bile salts 
(BS) and pancreatic juice: the result of this process is the formation of an 
aqueous suspension of small fatty droplets. Monoacylglycerol (MAG), 
diacylglycerol (DAG), free fatty acids, bile salts, cholesterol, 
lysophosphatidic acid (LPA) and fat-soluble vitamins form mixed micelles. 
Fatty acids and monoacylglycerol are taken up by the enterocytes mainly by 
passive diffusion, although part of the process is facilitated by transporters, 
such as intestinal FA-binding protein (IFABP), CD36 and FA-transport 
protein-4 (FATP4). Lipid metabolites are then sequentially re-esterified inside 
by MAG acyltransferase (MGAT) and DAG acyltransferase (DGAT) to form 
TAG (Coleman and Lee, 2004). Phospholipids from the diet as well as bile, 
mainly LPA, are acylated by 1-acyl-glycerol-3-phosphate acyltransferase 
(AGPAT) to form phosphatidic acid (PA), which is also converted into TAG 
(Luan et al., 2002). Dietary cholesterol is acylated by acyl-CoA:cholesterol 
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acyltransferase (ACAT) to cholesterol esters (CE). TAG joins cholesterol 
esters and apolipoprotein B (ApoB) to form chylomicrons that enter the 
circulation through the lymph, this process is facilitated by microsomal 
triglyceride transfer protein (MTP) (see Figure 1.1). 
Free fatty acids (FFA) release from TAG-rich lipoproteins, chylomicrons and 
very-low- density lipoprotein (VLDL) is mediated by lipoprotein lipase 
(LPL), and their entry into the adipocytes is mediated by both passive 
diffusion and active transport. Once in the adipocytes, FFAs are carried by 
fatty acid binding proteins (FABPs) and are converted to acyl-CoA by acyl-
CoA synthase (ACS) in the cytoplasm, and subsequently used as a substrate 
by two parallel TAG-synthesis pathways in the endoplasmic reticulum (ER). 
Glycerol-3-phosphate (G3P) is generated by glucose metabolism, and is 
acylated by glycerol-3-phosphate acyltransferase (GPAT) and 
acylglycerolphosphate acyltransferase (AGPAT) and converted to DAG by 
phosphatidic-acid phosphohydrolase (PAP) in the ER. An alternative to this 
step involves the acylation of MAG by MGAT. The final key step for this 
series of enzymatic reactions is the acylation of DAG to TAG by DGAT2 
(Coleman and Lee, 2004). The lipid drops are initially coated with patatin 
(PAT) family proteins, as they form in the ER, and after their maturation they 
are mainly coated with perilipin (Tansey et al., 2003) (see Figure 1.2). 
During fasting, G3P can also be produced from lactate, pyruvate and alanine 
through glycerolneogenesis by the action of different enzymes such as 
pyruvate carboxylase, alanine and aspartate aminotransferases and the 
cytosolic form of phosphoenolpyruvate carboxykinase (PEPCK-C) 
(extensively reviewed by (Hanson, 2003)). In particular PEPCK-C plays an 
important role in this process by converting oxaloacetate (generated by 
carboxylation of pyruvate mediated by pyruvate carboxylase) into 
phosphoenolpyruvate which is then used for G3P formation.  
Adipocytes are also able to generate de novo lipids by de novo lipogenesis. 
This process starts with glucose uptake in the cells, which is metabolized by 
glycolysis generating Acetyl-CoA. This process relies upon conversion of 
malate to pyruvate and the subsequent generation of ATP by the action of 
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malic enzyme 1 (ME1). Acetyl-CoA is then metabolized in to Malonyl-CoA 
by the action of Acetyl-CoA carboxylase (ACC1), which is then converted in 
18.0-CoA by FASN and subsequent in to 18:1-CoA by stearoyl-CoA 
desaturase (SCD1). FA undergoes then in the endoplasmic reticulum to the 
action of GPAT, AGPAT, PAP and MGAT with the final step characterized 
by DGAT2 action and the subsequent TAG storage (see Figure 1.3). 
In parallel to this process, G3P can enter into the mitochondria where is 
acylated by the mitochondrial isoform of GPAT (GPAT1 or GPAM) 
generating lysophosphatidic acid (LPA). These molecules are then acylated 
by AGPAT generating phosphatidic acid (PA). LPA and PA produced in the 
mitochondria can then be transported into the ER participating therefore to 
the generation of TAG. 
The process of lipogenesis is tightly hormonally regulated. In particular, 
insulin plays a central role by increasing glucose uptake in adipocytes by 
recruiting glucose transporter 4 (Glut4) to the plasma membrane (Kaestner et 
al., 1991) and stimulating transcription of genes involved in lipogenesis 
through activation of SREBP-1 (Hua et al., 1993; Tontonoz et al., 1993; 
Assimacopoulos-Jeannet et al., 1995).  
In opposition to insulin, growth hormone (GH) can suppress lipogenesis by 
down-regulating FASN gene expression in adipose tissue (Yin et al., 1998). 
Similarly leptin, one of the most important and well characterized adipokines 
[see section 1.2.5.1], has a negative effects on lipogenesis through down-
regulation of key genes involved in FA and TG synthesis and stimulating FA 
oxidation which result in glycerol release (Bai et al., 1996; Siegrist-Kaiser et 
al., 1997; Soukas et al., 2001). 
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Figure 1.1 Process of dietary lipid absorption in enterocytes. Fatty acids 
(FA),monoacyl glycerol (MAG) and cholesterol (CL) enter the enterocytes 
(shown in purple) by passive diffusion or through transporters. MAGs are then re-
esterified subsequently by MAG acyltransferase (MGAT) and diacylglycerol 
transferase (DGAT) to form TAG. Dietary phospholipids (LPA) are acylated 
using FA by AGPAT to form PA, which is used in the conversion from 
diacylglycerol (DAG) to tryglicerides (TAG). Cholesterol (CL) is acylated by 
acyl-CoA:cholesterol acyltransferase (ACAT) to cholesterol esters (CE). TAG 
joins CE and apolipoprotein B (ApoB) to form chylomicrons (CM) and enter the 
circulation. This process is facilitated by microsomal triglyceride transfer protein 
(MTP).  




Figure 1.2 Lipid storage in adipocytes. Fatty acids (FA), released from very 
low denisity lipoprotein (VLDL) after the action of lipoprotein lipase (LPL), can 
enter the adipocytes by both passive or active transport. In the adipocytes they are 
immediately converted to Acyl-CoA by the action of acyl-CoA synthase (ACS) in 
the cytoplasm. Acyl-CoA is used as a substrate by two parallel pathways 
responsible for the generation of tryglicerides (TAG). Glycerol-3-phosphate 
(G3P), generated by glucose metabolism, is acylated subsequently by glycerol 3 
phospohate acyl transferase (GPAT) and acylglycerolphophate acyltransferase 
(AGPAT) and converted to diacylglycerol (DAG) by phosphatidic-acid 
phosphohydrolase (PAP). Alternatevely monoacylglycerol (MAG) is acylated by 
MAG acyltransferase (MAGT) generating diacylglycerol (DAG). Commonly to 
both pathways DAG is then converted by diacylglycerol acyltransferase 
(DGAT2) into TAG.  




Figure 1.3 De novo lipogenesis in adipocytes. After entering the adipocytes 
glucose is metabolized by glycolysis generating Acetyl-CoA. Conversion of 
malate to pyruvate by the action of malic enzyme 1 (ME1) and the subsequent 
released of ATP is critical for the generation of this metabolite. Acetyl-CoA is 
then metabolised by acetyl-CoA carboxylase 1 (ACC1) to form Malonyl-CoA, 
which is then metabolised to 18:0-CoA by fatty acid synthase (FASN) and then in 
to 18:1-CoA by stearoyl-CoA desaturase-1 (SCD1). 18:CoA are then metabolised 
in the endoplasmic reticulum by a series of enzymatic reactions previously 
described, already described in Figure 1.2, which lead to TAG formation by the 
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1.2.5 Lipolysis 
Adipocytes release free fatty acids from stored triglycerides under conditions 
of negative energy balance such as prolonged fasting (lipolysis).  
Obesity is normally associated with an increased basal rate of lipolysis 
(Reynisdottir et al., 1995) but also with decrease in catecholamine-stimulated 
lipolysis (Large et al., 1999). Impaired insulin sensitivity in adipocytes is one 
of the factors that may contribute to enhanced basal lipolysis in this condition 
(Duncan et al., 2007). Increased sensitivity of the lipogenic pathway may 
remain selectively in adipocytes despite insulin resistance leading to a net 
accumulation of lipids. 
In response to fasting and exercise, adrenaline and noradrenaline stimulate 
lipolysis by activating β1 and β2 adrenergic receptor (AR), and in rodents the 
β3 adrenergic receptor. The activation of these receptors activates adenylyl 
cyclase with the subsequent increase production of cyclic adenosine-3’,5’-
monophosphate (cAMP). The rise in intracellular cAMP concentration 
activates protein kinase A (PKA), which phosphorylates perilipin (lipid 
droplet associated protein), which can therefore interact with 1-acylglycerol-
3-phosphate O-acyltransferase (Abhd5), (Greenberg et al., 1993) and 
hormone sensitive lipase (HSL) (Fredrikson et al., 1981; Holm, 2003). The 
association of phosphorylated perilipin with HSL promotes the translocation 
of this protein from the cytoplasm to the lipid droplet surface (Egan et al., 
1992) resulting in the hydrolysis of TAG to FFAs. FFAs are then released 
from the adipocytes and re-esterified or oxidized in the mitochondria 
depending upon the prevailing nutritional and hormonal conditions in the 
organism.  Catecholamines can also inhibit lipolysis by activating α2-AR. α2-
AR that act through GTP-binding protein inhibits adenylyl cyclase action and 
cAMP production. In obesity it has been observed an impairment of PKA-
stimulated lipolysis which results in an accentuated stimulation of α2-AR 
(Wang et al., 2008).  
Desnutrin (ATGL) (Villena et al., 2004; Zimmermann et al., 2004) and MGL. 
Desnutrin/ATGL also perform important hydrolytic steps. ATGL catalyses 
the initial step in TAG hydrolysis, generating DAG and fatty acid. HSL 
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preferentially catalyzes hydrolysis of DAG, but it has also action on TAG and 
MAG. MGL catalyzes hydrolysis of MAG to form glycerol and fatty acid 
(see Figure 1.4).  
Other molecules that participate in this process in human adipocytes are 
natriuretic peptides, which, after binding to type A receptor, increase 
guanosine 3’,5’-monophosphate (cGMP) activation of PKG, which 
subsequently phosphorylates HSL and perilipin (Sengenès et al., 2000). 
Lipolysis stimulation through natriuretic peptide is known to be prominent 
during physical exercise (see Figure 1.4).  
Insulin is the most potent anti-lipolytic hormone. Insulin binds its receptor 
and activates insulin receptor substrate 1 (IRS1), phosphatidylinositol-3-OH-
kinase (PI3K) and phosphodiesterase 3B which degrades cAMP subsequently 
reducing PKA activation. IRS1 can also activate protein phosphatase-1 (PP1), 
which can dephosphorylate and thus inhibit HSL and perilipin blocking 
lipolysis (extensively reviewed by Carmen and Víctor, 2006).  
 
 




Figure 1.4: Stimulation and inhibition of lipolysis in adipocytes 
Signal transduction pathways for catecholamines via adrenoreceptor (AR), insulin 
via insulin receptor and natriuretic peptide via natriuretic peptide receptor A. 
Catecholamines binding to β-ARs stimulate cyclic adenosine monophosphate 
(cAMP) production from ATP. Subsequently after perilipin phosphorylation and its 
interaction with 1-acylglycerol-3-phosphate O-acyltransferase (Abhd5), adipose 
triglyceride lipase (ATGL) can be activated converting triglycerides (TAG) in to 
fatty acids (FA) diacylglycerol (DAG). In parallel cAMP-dependent protein kinase 
(PKA) is activated leading to hormone sensitive lipase (HSL) phosphoryilation 
promoting its translocation to the surface of lipid droplet (showed in pink). HSL 
converts DAG into FA and monoacylglycerol (MAG). MAGs are then converted in 
FA and glycerol by the action of monoglyceride lipase (MGL). FA after binding to 
FABP4 can be then released from adipocytes. In a similar manner natriuretic peptide 
after binding with its own receptor natriuretic peptide receptor A can stimulate HSL 
and perilipin phosphorylation through the activation of cGMP-dependent protein 
kinase (PKG). Catecholamines can also inhibit cAMP production by binding α2-AR, 
therefore inhibiting lipolysis. Insulin as well, after binding to its own receptor and 
activating insulin receptor substrate 1 (IRS1) and phosphatidylinositol-3-OH-kinase 
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(PP1), which dephosphorylates HSL and perilipin, inhibiting lipolysis. 
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1.2.6 Insulin resistance 
The primary metabolic actions of insulin are the acute stimulation of nutrient 
uptake (carbohydrate, lipids, amino acids) into tissues and suppression of 
release of stored nutrients (hepatic glucose output and lipolysis) after a meal. 
Obesity is associated with insulin resistance. Insulin resistance is mainly 
characterized by a reduced efficiency of a given level of the hormone to 
decrease blood glucose level. This is a direct result of reduced sensitivity of 
the insulin receptor to mediate glucose disposal largely in skeletal muscle and 
also in liver and adipocytes. Loss of insulin-mediated suppression of hepatic 
glucose production contributes to this effect. Variation in insulin sensitivity 
occurs physiologically during puberty, pregnancy and ageing. In obesity, an 
imbalance in the release of multiple adipokines (see 1.2.7) and cytokines that 
modulate insulin sensitivity contributes to insulin resistance. 
For example adiponectin, an adipokine (see 1.2.7), which has been linked 
with insulin sensitivity, it stimulates fatty acids oxidation through AMP-
protein kinase (AMPK) and peroxisome proliferator activated receptor 
(PPAR) α dependent mechanisms (Kadowaki et al., 2006). In contrast to 
adiponectin, production of adipose tissue retinol binding protein (Rbp) 4, 
another adipokine, is increased in obese subjects. Rbp4 induces insulin 
resistance by reducing PI3K signaling in muscle and increasing transcription 
of the gluconeogenic enzyme PEPCK in liver via a retinol dependent 
mechanism (Yang et al., 2005).  
In addition to adipokines, inflammation of adipose tissue and adipose tissue 
production of cytokines (see 1.2.5) constitute an important control mechanism 
for insulin sensitivity. Tumor necrosis factor (TNF) α and interleukin (IL) 6 
activate c-Jun N-terminal kinase (JNK) and the IkB kinase β (IKK-β)/nuclear 
factor –κβ (NF-κβ) pathways after binding to their receptors, causing 
increased production of inflammatory mediators and increase inflammation in 
adipose tissue which can lead to insulin resistance through serine/threonine 
phosphorylation of IRS-1 and other insulin signaling intermediates(Xu et al., 
2003; Kahn et al., 2006).  
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Moreover, FFAs modulate insulin signalling. Increased intracellular content 
of FA metabolites (i.e. DAG and fatty acyl-CoA) activate a serine/threonine 
kinase cascade (PKC) leading to phosphorylation of IRS 1 and 2, reducing 
therefore the ability of these molecules to activate PI3K and subsequently 
diminishing events downstream of insulin receptor signaling (Shulman, 2000; 
Kahn et al., 2006).  
 
1.2.7 Adipose tissue as an endocrine organ 
The adipose tissue produces a wide variety of proteins and hormones some of 
which are known as adipokines (Table 1) and which are involved the 
regulation of metabolic processes and also co-operate in the regulation of 
other important processes in the organism. Among the most important factors 
secreted from the adipose tissues there are leptin, adiponectin, sex hormones 
and glucocorticoids.  
 
1.2.7.1 Leptin  
The concept that adipose tissue is not merely a hormonally inert lipid storage 
site, was established in the ‘50s when it was discovered that morbidly obese 
mutant mice that arose at random within a mouse colony in the Jackson 
Laboratories (INGALLS et al., 1950), lacked a circulating factor that 
controlled their appetite and fat mass. These studies culminated in 1994 with 
the discovery of the adipose derived circulating hormone leptin by Jeffrey 
Friedman’s group at the Rockefeller University (Zhang et al., 1994). Leptin is 
a 16 kDa cytokine-like protein involved in regulating energy metabolism. 
Leptin was identified as both a powerful satiety agent in the brain and had 
other properties to increase energy expenditure effectively mediating the 
metabolic signal for energy sufficiency. Maffei and colleagues demonstrated 
that leptin controls adipose tissue growth through its action at discrete loci 
within the hypothalamus of the central nervous system (Maffei et al., 1995) 
and furthermore that local administration of leptin in hypothalamic regions 
reduced food intake and body weight in animals(Campfield et al., 1995). 
Leptin-sensitive neurones are located in the dorsal, ventral, median and pre-
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mammilary nuclei of hypothalamus; in this region leptin receptors control 
energy balance and satiety. Leptin receptors belong to the class I cytokine 
receptors family (Ghilardi et al., 1996) and are present not only in brain, but 
also in other organs and tissues such as liver, skeletal muscle, heart, kidney, 
and pancreas, among others (Hoggard et al., 1997; Löllmann et al., 1997; 
Morioka et al., 2007). Leptin concentration and expression is directly 
associated with adiposity and with weight changes. This protein is mainly 
produced by adipose tissue; however it can also be synthesized by brown 
adipose tissue, placenta (syncytiotrophoblasts), ovaries, skeletal muscle, 
stomach, mammary epithelial cells, bone marrow, pituitary gland and liver 
(Margetic et al., 2002). Immunohistochemical studies have shown that leptin 
is present only in mature adipocytes and not in preadipocytes. The production 
of this protein in adipocytes is continuous, in order to compensate for the 
amount of the protein secreted from the cells; adipocytes also express leptin 
receptors, which suggests an autocrine and paracrine role of this hormone. 
Regarding its autocrine function, in rodents leptin has been shown to convert 
adipocytes into mitochondria-rich adipocytes capable of oxidising high 
concentrations of stored lipids. Apart from its role in the lipid storage 
mechanism, leptin also stimulates angiogenesis and hematopoiesis, 
accelerates wound healing, regulates immune responses, and influences the 
sympathetic nervous system regulation of bone mass and blood pressure 
(Brook et al., 2007). Hyperleptinemia during obesity is often associated with 
leptin resistance, a condition in which fat storage capacity is augmented and 
lipid oxidation rate is diminished. This situation can lead eventually to 
ectopic accumulation of lipids in liver, skeletal muscle, heart and the 
endocrine pancreas. In liver this is exacerbated because leptin signaling in 
liver mediates upregulation of the PPARα gene, inducing the expression of 
genes encoding enzymes of lipid-oxidation. For these reasons, leptin 
resistance is proposed as an important cause of adipocyte dysfunction and 
lipid overload in non adipose tissues (Unger et al., 1999; Wilson-Fritch et al., 
2004).   
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Leptin and pregnancy 
Links between leptin and the processes acting during pregnancy are evident 
considering that this protein can be produced by both the placenta (Zhao et 
al., 2004), fetal membranes and the uterine tissue (uterine contractions are 
inhibited by leptin) (Moynihan et al., 2006) and that its levels rise during 
pregnancy and fall after labour (Tomimatsu et al., 1997). Leptin seems to play 
important autocrine and paracrine mechanisms in placental 
syncytiotrophoblasts (tissue responsible for the production of hormones 
necessary in the maintenance of pregnancy in primates) (Hauguel-de Mouzon 
et al., 2006). Leptin also plays a crucial roles in implantation, (Kirchgessner 
et al., 1997): intrauterine injection of a leptin peptide antagonist or a leptin 
antibody impaired implantation (Mise et al., 1998). In vitro it has been 
demonstrated that this protein can also enhance invasiveness of murine 
trophoblasts through up-regulation of matrix metalloproteinases (Grosfeld et 
al., 2002). Leptin has been linked also to the regulation of fetal growth, it 
correlated with infant length and head circumference and seems to be crucial 
in fetal bone growth, angiogenesis and pulmonary development in uterus 
(Hauguel-de Mouzon et al., 2006). A recent study showed that by day 13 of 
pregnancy, despite rising circulating leptin concentration, food intake is 
increased suggesting that normal pregnancy is associated with a state of leptin 
resistance (Ladyman et al., 2012). In this study, pregnancy was associated 
with decreased phosphorylation of signal transducer and activator of 
transcription 3 (STAT3) in the ventral and pre-mammilary nuclei of the 
hypothalamus compared with non pregnant mice, supporting the idea that this 
state of leptin resistance is is likely to helps the mother to increase food intake 
during pregnancy (Ladyman et al., 2012).  
 
1.2.7.2 Adiponectin  
Adiponectin is a 224 amino acid protein hormone encoded by the ADIPOQ 
gene that was first characterized in mice as an over-expressed protein during 
preadipocyte differentiation. Unlike leptin, adiponectin inversely correlates 
with fat mass and high levels are a signal of ‘healthy’ (not excessive) fat 
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stores and energy balance. Adiponectin circulates as multiple isoforms: low 
molecular weight (LMW), medium molecular weight (MMW) and high 
molecular weight (HMW) adiponectin (Hada et al., 2007), and is one of the 
most abundant proteins in plasma. Between the three isoforms, the HMW 
adiponectin is the most efficient activator of adenosine monophosphate 
activated protein kinase (AMPK) phosphorylation (Hada et al., 2007) an 
enzyme that drives oxidative pathways within tissues, and HMW adiponectin 
levels are hence more meaningful than the total adiponectin level in 
predicting insulin resistance and the development of metabolic syndrome 
(Hara et al., 2006). 
Adiponectin signaling activates three different type of receptor (AdipoR1, 
AdipoR2 and T- cadherin), depending on the target tissue and adiponectin 
isoform. This protein modulates a variety of metabolic processes, including 
glucose regulation and fatty acid catabolism. Adiponectin is secreted form 
adipose tissue and, unlike	   leptin, decreased plasma levels of this hormone 
were found lower in patients affected by type 2 diabetes, obesity [in particular 
in patient with insulin resistance (Klöting et al., 2006)], atherosclerosis and 
non-alcoholic fatty liver disease (Sargin et al., 2005). 
 
1.2.7.3 Sex Hormones  
Adipose tissue also metabolizes sex steroid hormones. In particular adipose 
stromal cells are involved into the interconversion of steroids: 17 β-hydroxy-
steroid (HSD17β) oxidoreductase converts androstenedione to testosterone, 
estrone to estradiol and cytochrome P-450-dependent aromatase mediates the 
conversion of androgens to estrogens. The HSD17β enzymes are 
differentially expressed in different tissues: in adipose tissue HSD17β12 is 
the major enzyme of this family responsible for the conversion from estrone 
to estrodial (Bellemare et al., 2009) Sex steroid hormones, in particular 
estrogens, are critical determinants for body fat distribution which in turn 
associates with altered adverse cardiometabolic risk: males generally deposit 
fat around their waists and abdomens (men have approximately 20% higher 
percentage of visceral fat), and women deposit fat around their hips and 
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buttocks (women have greater subcutaneous fat deposition) (Khor et al., 
2008). Body FFA flux appears to be grater in the upper-body compared to the 
lower body in both obese and lean subjects (Jensen, 1998). Females generally 
have a elevated percentage of total body adiposity compared with males (Enzi 
et al., 1986). Women have in general a lower amount of visceral adipose 
tissue compared to men, and this can contribute to the lower prevalence of 
dyslipidemia, hypertension, diabetes, and CVD in premenopausal women 
compared with men and postmenopausal women (Turgeon et al., 2006). The 
influence of sex hormones on body fat distribution seems to be related to 
tissue-specific expression of steroid receptors and to steroid hormone 
metabolism in adipose tissue. 
Estrogen regulates lipoprotein lipase, decreases lipolysis, and increases 
preadipocyte proliferation (Khor et al., 2008). Hormonal manipulation causes 
fat redistribution: female to male transsexual conversion causes a fat 
redistribution from subcutaneous fat to visceral fat, and the opposite occurs in 
the conversion from male to female (Vague et al., 1984; Elbers et al., 1997). 
After the menopause, low estrogen levels are associated with changes in fat 
distribution in women with a gain in visceral fat and decreased subcutaneous 
fat (Carr, 2003). The mechanisms by which estrogens affect adipose tissue 
metabolism and deposition are still unclear. However it has being shown that 
subcutaneous adipocytes from premenopausal women express higher levels 
of α2-adrenergic receptor than man and lower lipolytic activity in response to 
catecholamine compared to subcutaneous adipocytes from men (Richelsen, 
1986), suggesting an important action of estrogens in the control of lipolysis.  
Estrogens also influence food intake and body weight. For example, food 
intake patterns change during different estrus phases (Asarian and Geary, 
2006). Removal of estrogen through ovariectomy (OVX) in rodents results in 
increased food intake with subsequent increase in body weight (D'Eon et al., 
2005). More importantly estrogen replacement in OVX rats normalizes food 
intake and body weight to the levels observed in sham-operated animals 
providing direct evidence that estrogen controls food intake and body weight 
(Roesch, 2006).  Estrogen receptors (ER) α and β are expressed in both 
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subcutaneous and visceral fat tissues; however, ERβ appears to be 
preferentially present in subcutaneous adipose tissue (as reviewed by (Mayes 
and Watson, 2004)). Furthermore ERα knock-out mice are diabetogenic and 
obese with severe hepatic insulin resistance in the absence of any difference 
in energy intake (Heine et al., 2000); in contrast, ERβ deficient mice display 
improved glucose tolerance and insulin sensitivity and no change in body fat 
content (Foryst-Ludwig et al., 2008), suggesting that ERα plays an important 
role in metabolic control and adipose tissue biology.  
A single estradiol injection in female rats induced anorexia and body weight 
loss at day 12 post treatment, which was then reversed 2 weeks after 
treatment (Piermaría et al., 2003). At day 61 post- treatment there were 
increased E2 and leptin circulating levels, and reduced plasma TNFα 
concentrations (Piermaría et al., 2003). At this time point, there was lower 
gonadal fat mass containing a higher number of adipocytes that released more 
leptin in vitro; moreover treated animals showed increased insulin sensitivity 
compared to controls (Piermaría et al., 2003). This study supports the 
anorectic effect of estradiol and highlights its ability to modify adipose tissue 
function and insulin sensitivity.  
A study on fully differentiated 3T3-L1 adipocytes stably transfected with 
ERα, showed decreased triglyceride accumulation and reduced LPL 
expression (Homma et al., 2000).  Estradiol decreased lipogenesis and TG 
accumulation and liver in high fat diet (HF) fed leptin-deficient female mice 
(Bryzgalova et al., 2008) Furthermore, liver transcriptome analysis in ERα 
deficient mice highlighted increased expression of lipogenic genes and 
decrease transcription levels of genes involved in lipid transport (Bryzgalova 
et al., 2006). A separate study indicated that estradiol treatment decreased 
transcription of FASN, Scd1 and GPAM in liver of leptin deficient mice (Gao 
et al., 2006).  
 
1.2.7.4 Glucocorticoids 
In adipose tissue, cortisol produced locally from cortisone is mediated by 11-
β hydroxysteroid dehydrogenase type 1 (11β-HSD1). The effects of 
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glucocorticoids on adipose tissue depends on the depot and the acute 
nutritional state (extensively reviewed in (Morton, 2010)). In visceral fat 
there is a higher expression of glucocorticoid receptors (GR) (Pedersen et al., 
1994) and circulating glucocorticoids have a major effect on both adipokine 
production, local and systemic inflammatory effects and metabolic responses 
(insulin-resistance, lipolysis) on this fat depot compared to others. 
Glucocorticoids regulate a number of processes in the adipose tissue: they 
drive preadipocyte differentiation, adipocyte fat accumulation (Ailhaud et al., 
1991; Gaillard et al., 1991); decrease insulin-sensitivity (Sakoda et al., 2000) 
and elevate the release of fatty free acid via activation of hormone sensitive 
lipase (HSL)-mediated lipolysis (Slavin et al., 1994).  
In obesity, circulating levels of glucocorticoids are generally normal but this 
condition is characterized also by exaggerated dynamic cortisol responses 
(Pasquali et al., 1999) Single gene loss-of-function mutations in animal 
models of obesity (ob/ob and fa/fa mice see the following “section” Animal 
model of obesity) show increased levels of adipose tissue 11-β HSD-1, the 
enzyme that increases local glucocorticoid production (Livingstone et al., 
2000; Masuzaki et al., 2001; Morton et al., 2004). Some recent studies 
suggested that 11β-HSD1 mRNA levels can be also increased in visceral 
omental adipose tissue of obese women and this might represent a strong 
predictor of fat cell size in this visceral depot (Desbriere et al., 2006; 
Michailidou et al., 2007; Paulsen et al., 2007). The impact of altered 11-β 
HSD-1 activity varies with fat depot: higher levels of 11-β HSD-1 are 
expressed in peripheral adipose depots {Morton:2004ba} and these areas 
contribute most to the circulating levels of FFAs suggesting an important 
effect of this enzyme on this process. In contrast with the findings on single 
gene loss-of-function mutations animal model of obesity, polygenic animal 
model of obesity (see 1.2.8) have low (Morton et al., 2005) or equal (Klöting 
et al., 2006) adipose 11-β HSD-1, but elevated liver 11-β HSD-1 (Morton et 
al., 2005), which suggests that elevated adipose 11-β HSD-1 in obesity may 
not be universal in all animal model of obesity and human.  
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1.2.7.5 Cytokines and Chemokines 
One of the key changes in adipose tissues of obese subjects is an increase 
in cytokine and chemokine production which results in a low grade 
inflammation 	  state. Adipose tissue inflammation and the role of cytokines 
and chemokine production by adipocytes and resident inflammatory cells 
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Table 1.1: Adipokines and Cytokines/chemokines changes in obese subjects 
(Adapted from Denison et al., 2010)	  
Adipokines Change in obesity Functional effects References 
Hormones 
Leptin ↑ circulating levels 
Acts on hipotalamic neurons controlling food 
intake 
Stimulates fatty acid oxidation  
(Maffei et al., 
1995) 
Adiponectin ↓ circulating levels 
Stimulates fatty acid oxidation via AdipoR1 
Activates PPAR via AdipoR2 
Reduced hepatic gluconeogenesis 
Antagonises TNF actions 
Induced secretion of IL10 
(Arita et al., 1999) 
Visfatin 
↑ expression in 
visceral adipose tissue 
↓ expression in 
subcutaneous adipose 
tissue 




↑ expression in mice 
↔ in humans 
Increase secretion in murine model of diet 




Apelin ↑ circulating levels 
Central action on feeding behaviour in mice 
Infusions restores glucose tolerance in mice 
(Heinonen et al., 
2005) 
 
Adipokines involved in vtamin A metabolism 
Retinol binding 
protein (RBP)-4 
↑ expression and 
circulating levels 
Increase insulin resistance in mice {(Yang et al., 
2005) 
 




↑ secretion Oversecretion leads to decrease fibrinolysis 
and excessive thrombosis 
{Maury:2010fy} 
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Adipokines Change in obesity Functional effects References 
Angiotensino- 
gen 




↓ release of PGE2 by 
cultured adipose tissue 




Cytokines and chemokines 
TNFα ↑ circulating levels in 
obese animals  
↔ expression 
↑ released by cultured 
adipocytes 
Stimulates lipolysis 
Increase insulin resistance interfering with 
IRS1 downstream signaling 
Impairs pre-adipocytes differentiation 
(Hotamisligil et 
al., 1993; Kern et 






↑ expression in white 
adipose tissue 
Promotes monocyte recruitment in adipose 
tissue 
(Bruun et al., 
2005) 
 
IL6 ↑ circulating levels Secretion by adipose tissue leads to hepatic 
insulin resistance 
(Rotter et al., 
2003; Sabio et al., 
2008) 
 
IL8 ↑ circulating levels Chemoattractant and angiogenic factor (Straczkowski et 
al., 2002) 
 
IL1β ↑ expression Impairs insulin signaling by downregulation 
of IRS1 
Cytotoxic effect on pancreatic islet 
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1.2.8 Adipose tissue inflammation 
In the last 20 years, scientists highlighted that inflammation contributes to 
the development of obesity and also to the metabolic dysfunction 
associated with this pathology, in particular insulin resistance and type 2 
diabetes.  
 
1.2.8.1 Cytokines and chemokines 
The idea that inflammation plays a critical role in obesity, was first 
demonstrated  by Hotamisligil and colleagues who showed that obese mice 
had increased levels of tumor necrosis factor-α (TNFα), a pro-
inflammatory cytokine, in plasma and adipose tissue (Hotamisligil et al., 
1993) and that TNFα had a strong association with insulin resistance. 
Moreover, obese animals with TNFα-deficiency showed improved insulin 
sensitivity (Uysal et al., 1997). The critical role played by TNFα in obesity 
was also evident in morbidly obese humans: TNFα gene expression was 
observed to be increased in adipose tissue and its levels were found to be 
decreased after weight loss (Hotamisligil et al., 1995; Dandona et al., 
1998). 
Following the discovery that TNFα is produced in adipose tissue, other 
cytokines and chemokines were shown to be produced in this organ. 
Interleukin-6 (IL-6), another pro-inflammatory cytokine, was suggested to 
be involved in the development of obesity and insulin resistance (Bastard 
et al., 2002; Sabio et al., 2008): anti-IL-6 treatment in obesity rodent 
model showed to improve insulin sensitivity (Klover et al., 2005), and in 
humans circulating IL-6 levels were found decreased after weight loss. 
Adipocytes can also produce monocyte chemoattractant protein 1 (MCP1 
or CCL2) (Weisberg et al., 2006), which acts to recruit macrophages into 
adipose tissue (see section 1.2.8.2.1) and positively correlates with 
adiposity.  
Normal adipose tissue can also produce anti-inflammatory cytokines 
which maintain resident inflammatory cells in an anti-inflammatory state. 
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IL-10, IL-1 decoy receptor and IL8 are produced in the adipocyte and 
create a cross-talk between adipocytes and resident inflammatory cells.  
 
1.2.8.2 Inflammation in adipose tissue 
As already stated in the previous section, adipocytes and resident 
inflammatory cells in adipose tissue can produce pro-inflammatory 
cytokines and chemokines. When adipocytes expand in obesity, the 
balance between pro-inflammatory and anti-inflammatory proteins is 
disrupted with an increased production of molecules that can activate the 
host innate immune system. Inflammation itself is crucial to repair tissue 
and fight infections, however a prolonged inflammatory state can be 
detrimental and this appears to be the case in obesity and related metabolic 
diseases. Therefore obesity is associated with increased circulating levels 
of pro-inflammatory cytokines (Hotamisligil et al., 1993; 1995; Uysal et 
al., 1997; Dandona et al., 1998; Bastard et al., 2002), and with increased 
inflammatory cell influx and activation in adipose tissue itsself.  
 “Normal” adipose tissue is infiltrated by resident macrophages, which 
constitute approximately 10% of total adipose tissue cell numbers 
(Weisberg et al., 2006). Under basal (non-obese) conditions macrophages 
closely resemble the “alternatively activated” (M2) phenotype, secreting 
anti-inflammatory cytokines (IL-10 and IL-1 decoy receptor) and 
expressing arginase, which blocks inducible nitric oxide synthase (iNOS) 
activity, which is involved in generation of free radicals. However, these 
cells are also able to secrete pro-inflammatory cytokines upon stimulation 
with interferon-γ (IFNγ) (Zeyda and Stulnig, 2007) maintaining a balance 
between anti- and pro-inflammatory molecules.  
In obese subjects, adipose tissue is characterized by an increased number 
of “classically activated” (M1) macrophages, approximately 40% of total 
adipose tissue cells (Weisberg et al., 2006) that secrete pro-inflammatory 
cytokines TNF-α, IL-6, IL-12, and generate free radicals such as nitric 
oxide through activation of iNOS (Lumeng et al., 2007b).  
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Adipose Tissue Macrophages (ATMs) Recruitment 
MCP-1 seems to play a major role in the recruitment of macrophages. 
MCP-1 is produced by adipocytes and positively correlates with adiposity, 
so increasing adipocyte size and number will increase MCP-1 production, 
therefore increasing signals for macrophages recruitment. MCP-1 
knockout mice (MCP-1-/-) on a high fat diet have attenuated recruitment of 
macrophage infiltration in adipose tissue and improved insulin sensitivity 
(Inouye et al., 2007). ATMs recruited to the adipose tissue during high-fat 
diet feeding exhibit higher expression of the MCP-1 receptor CCR2 
compared with resident ATMs (Lumeng et al., 2007b). These data suggest 
that MCP-1 and CCR2 are important even though the may not be 
exclusively responsible for ATM recruitment (Zeyda et al., 2010). 
 
ATMs Characteristics and Activation 
In obese subjects, macrophages surround dying adipocytes in the inflamed 
adipose as “crown-like structures”, which are enriched with galactose N-
acetyl-galactosamine specific lectin 1 (MGL-1)-negative CD11c-positive 
cell surface markers, indicating an inflammatory phenotype (Lumeng et 
al., 2007b; Nguyen et al., 2007; Lumeng et al., 2008; Wu et al., 2010). As 
the complexities of ATM phenotype continue to unravel it has become 
apparent that CD11c positive ATMs have a mixed M1/M2 profile (Zeyda 
et al., 2010). Furthermore, a new ATM subpopulation has been found that 
are double negative for CD11c and mannose receptor (MR) and are 
involved largely in tissue repair (Zeyda et al., 2010). 
Recently it has been demonstrated that inflamed adipose tissue has an 
increased expression of toll-like-receptor (TLR) 4 (Song et al., 2006). 
TLRs are a family of receptors for pathogen-associated molecular patterns 
(PAMPs). TLR2 and 4, two member of this receptor family expressed in 
various cells among which by ATMs, were discovered through their ability 
to bind bacterial component (i.e. LPS) thereby activating macrophages. 
Interestingly, these receptors can bind saturated fatty acids indirectly, via 
fetuin-A interaction with both TLR4 and FFAs (Pal et al., 2012), providing 
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a mechanism by which diet and a lipid rich environment can activate 
inflammation in adipose tissue and promote metabolic disease.  This 
suggestion is also supported by studies on myeloid cell TLR4-/- animals 
which were protected form high-fat diet induced insulin resistance despite 
becoming obese when fed high fat diets(Suganami et al., 2007; Saberi et 
al., 2009).  
 
Other inflammatory cells presents in adipose tissue 
More recently, lymphocyte T cells of the adaptive immune system were 
shown to regulate adipose tissue macrophages (Lumeng et al., 2009). 
Elevated cytotoxic CD8+ T cells and helper CD4+ T cells as well as 
regulatory/anti- inflammatory Tregulatory cells were found in adipose 
tissue from obese subjects. CD8+T cells are necessary for the initiation 
and maintenance of adipose tissue macrophage infiltration and 
pathogenesis of the insulin resistance (Feuerer et al., 2009; Nishimura et 
al., 2009; Winer et al., 2009). Whilst the mechanisms leading to adipose 
tissue inflammation remain to be fully elucidated, elevated free fatty acid 
levels may initiate this inflammatory process inducing cellular stress and 
oxidative damage by activation of Toll like receptors (Schaeffler et al., 
2009) and adipocyte death (Rutkowski et al., 2009). 
 
1.2.9 Visceral obesity as an added risk factor in metabolic 
disease 
Obesity, particularly visceral obesity, plays an important role in the 
development of chronic disease, such as hypertension, type 2 diabetes, and 
cardiovascular disease. An increase of visceral adiposity is associated with an 
exaggerated lipolysis rate (from visceral adipocytes) and an excess of plasma 
free fatty acids (FFA). Higher FFAs are associated with increased glucose 
production and impaired muscle glucose uptake, oxidation, and storage 
(Kelley et al., 1993; Koutsari and Jensen, 2006).  FFAs have also an effect on 
insulin secretion (Paolisso et al., 1995): their intracellular metabolites trigger 
insulin release, but chronic exposure can promote β-cell dysfunction (Prentki 
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et al., 2002) with decreased insulin responses. Elevated FFA is a risk factor 
for ischemic heart disease (Pirro et al., 2002) and can directly cause vascular 
endothelial injury (Piro et al., 2008) or indirectly promote hypertension due to 
enthothelial dysfunction (Steinberg et al., 1997) or by phenylephrine, an α1-
adrenoceptor agonist, which is enhanced when plasma FFAs locally were 
raised in healthy volunteers to levels observed in obese patients (Stojiljkovic 
et al., 2001). It has been hypothesized that excessive visceral fat accumulation 
is more harmful compared to excess subcutaneous fat mass because fatty 
acids and deleterious adipokines released from this depot goes drain directly 
to the portal vein reaching the liver, where higher local levels of these 
substances contribute to suppression of liver function, they also go to other 
organs, and arteries, where they cause ectopic lipid deposition. 
 
1.2.10 Animals model of obesity 
A number of useful animal models have been developed by scientists to 
model aspects of this pathology. A commonly used animal model is the single 
gene loss-of- function mutations such as the leptin deficient obese 
(homozygous defective allele ob/ob) (Zhang et al., 1994) leptin receptor 
deficient diabetic (db/db) (Bahary et al., 1990)mice and Zucker) fatty rat 
(fa/fa (ZUCKER, 1961). 10 single gene loss-of-function defects that cause 
pronounced obesity are known (Speakman et al., 2008). However common or 
idiopathic obesity is normally multifactorial and of polygenic origin. 
Another strategy employed to understand obesity was to create a diet induced 
obesity (DIO) animal model. High-fat and high-fat high-sucrose-enriched 
diets increase body fatness in certain strains of mice that are genetically 
susceptible to obesity (e.g. C57BL/6 mouse; (Surwit et al., 1988)). Many 
studies have used this animal model to understand the regulation of food 
intake under conditions of high-fat intake as a model of human obesity, in an 
attempt to understand why some humans exposed to these diets also become 
obese (Speakman et al., 2008). The advantage of the DIO model is that it does 
not result from a single gene mutation and is therefore more comparable to 
human obesity. However, it is recognized that the diets used are somewhat 
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higher in fat content than most humans are exposed to (58% compared to 30-
40% in the average diet) and this is because rodents have a robust intrinsic 
obesity-resistance mechanism, thermogenesis from brown fat, that is 
quantitatively less important in humans in the overall regulation of energy 
balance. 
 
1.2.11 Liver complications in obese subjects 
Central obesity increases the risk of also developing also non alcoholic 
fatty liver disease (NAFLD). Bedogni and colleagues evaluated that 76% 
of obese subjects and 10-15% of normal individuals, not drinking alcohol 
in toxic amounts, are affected by NAFLD in the general population of the 
Dionysos study (Bedogni et al., 2005). They also observed that obese 
subjects, compared to healthy controls, showed a 4.6 fold increased in the 
risk of developing steatosis, that is defined as the process describing the 
abnormal retention of lipids within a cell (Bedogni et al., 2005). The term 
NAFLD includes various diseases, which also includes various degrees of 
simple steatosis: this pathology progress from simple steatosis (non 
alcoholic fatty liver, NAFL) to non alcoholic steatohepatitis (NASH: 
defined by steatohepatitis, the presence of Mallory bodies and fibrosis). 
Only approximately 10-25% of subjects, affected by NAFLD, develop 
NASH (Day, 2005; Harrison et al., 2003), the factors responsible to the 
switch from NAFLD to NASH are still unclear. Day and James proposed 
“two hit hypothesis” that provide a pathophysiological rational to the 
progression of liver damage (Day and James, 1998). This hypothesis 
suggests that the reversible intracellular accumulation of triglycerides in 
liver (NAFL, “first hit”) can lead to oxidative stress, mitochondrial 
dysfunction and inflammation induced liver injury (“second hit”) that 
cause steatohepatitis (NASH) (Day and James, 1998).  
 
1.3 Studies on obesity during pregnancy  
During pregnancy, changes in maternal metabolism occur in response to the 
growing fetus and placenta and their increasing metabolic needs (Butte, 2000; 
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Barbour et al., 2007). During early pregnancy, adipose tissue accretion is 
promoted (Butte, 2000; Barbour et al., 2007), glucose tolerance is normal or 
even slightly improved and muscle sensitivity to insulin and hepatic basal 
glucose production are normal (Catalano et al., 1993; 1999; Homko et al., 
1999; Butte, 2000; Barbour et al., 2007). On the other hand, late gestation is 
characterized by insulin resistance and facilitated lipolysis (Barbour et al., 
2007). In this period insulin has reduced ability to suppress lipolysis and this 
effect is further reduced in patients with gestational diabetes (Catalano et al., 
2002). As such, increased free fatty acids may contribute to increased hepatic 
glucose production and severe insulin resistance (Catalano et al., 1999; 
Friedman et al., 1999; Homko et al., 1999; Catalano et al., 2002; Barbour et 
al., 2007). Alterations in maternal glucose metabolism may be due to 
placental growth hormone, prolactin, cortisol, and progesterone which 
antagonize insulin action in particular during the 2nd and the 3rd trimesters 
(Catalano et al., 1993; Barbour et al., 2007). However the mechanisms that 
link pregnancy and maternal metabolic changes are still largely unknown 
(Barbour et al., 2007). 
The insulin resistance of normal pregnancy is multifactorial and involves a 
reduced ability of insulin to phosphorylate insulin receptor (IR), impaired 
expression of insulin receptor substrate (IRS)-1 and increased levels of p85α 
subunit of PI 3-kinase (Barbour et al., 2007). Impaired metabolism is 
exaggerated in gestational diabetes with clearly abnormal glucose tolerance. 
These patients also have lower levels of circulating adiponectin, a key insulin 
sensitizing hormone, that further declines with the progression of pregnancy 
(Barbour et al., 2007). The greater change in glucose and insulin metabolism 
in patients with gestational diabetes results in an abnormal oral glucose 
tolerance test. These patients also have lower levels of circulating 
adiponectin, a key insulin sensitizing hormone, that further declines with the 
progression of pregnancy (Barbour et al., 2007). 
In a study conducted within our group, Dr Sarah Barr assessed insulin 
sensitivity in lean and obese pregnant subjects using a hyperinsulinemic 
euglycaemic clamp protocol. In this study was observed that at 19 weeks, 
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lean pregnant patients were more insulin sensitive compared to obese 
subjects. During the course of pregnancy, the investigators observed an 
approximately 50% decrement in insulin sensitivity in lean patients by 36 
weeks of gestation, however there was no such decrement in obese pregnant 
patients throughout pregnancy. No difference in insulin sensitivity was 
detected between lean and obese pregnant patients at 36 weeks of gestation. 
These data suggests that pregnancy in obese patient is not associated with a 
further decrement in insulin resistance. In this study, serum fatty free acids 
were also measured: obese pregnant subjects showed to have increase NEFA 
levels compared to lean patient at 19 weeks, however similar to insulin 
sensitivity at 36 weeks no difference were observed between this 2 groups. 
These data highlight that the early exposure to high levels of NEFA and 
insulin resistance may be key in the development of adverse pregnancy 
outcomes. 
Insulin resistance in both adipose (free fatty acids and glycerol) and liver 
(HGP) results in greater, potentially abnormal provision of fuels to the fetus 
(Barbour et al., 2007). 
The effects of maternal obesity on the offspring are well studied, but little 
is known about the changes that occur in obese pregnant mothers. 
Increased serum levels of leptin, C-reactive protein (CRP) and IL-6 
(Ramsay et al., 2002) but lower PAI-1 and 2 and isobutyryl-CoA mutase, 
chain A (ICMA) expression (Stewart et al., 2007) are found in obese 
patients, compared with gestation, smoking and parity matched lean 
women. Critically, in pregnancy abdominal obesity is associated with 
glucose intolerance and insulin resistance (Ramsay et al., 2002; Martin et 
al., 2009), with the result that gestational diabetes is very common in this 
situation. TNFα has also been shown to be a predictor of insulin resistance 
in non- obese pregnant women in late gestation, however TNFα secretion 
from adipose tissue was not different when pregnant women with normal 
glucose tolerance were compared to lean women with gestational diabetes 
(Kirwan et al., 2002).Glucose intolerance (HAPO Study Cooperative 
Research Group, 2009) and insulin resistance (Boomsma et al., 2006) are 
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associated with adverse pregnancy outcome. Fat distribution during 
pregnancy was found associated with an increase in visceral fat deposition 
from preconception to postpartum compared to those not bearing children 
(Kinoshita and Itoh, 2006; Gunderson et al., 2008). A study conducted by 
Dr Sarah Barr investigated the fat distribution, using 3T Magnetic 
resonance imaging, in obese and lean pregnant subjects in the third 
trimester of pregnancy. Dr Barr observed that subcutaneous adipose tissue 
constitutes the largest adipose tissue depot in obese subjects. This study 
demonstrated also that obese pregnant women had significantly greater 
subcutaneous (2.3 vs 0.5 kg) and abdominal (0.5 vs 0.1kg) adipose tissue 
compared to lean pregnant patients.  
 
1.3.1 Study on maternal physiology during pregnancy in animal 
models 
A recent study on rats treated with a cafeteria diet (including biscuits, 
potato crisps, fruit and nut chocolate, Mars bars, cheddar cheese, golden 
syrup cake, pork pie, cocktail sausages, liver and bacon paté, strawberry 
jam and peanuts) showed an increase in gonadal fat and retroperitoneal fat 
weight, plasma cholesterol and plasma triglycerides at day 20 of gestation 
compared to day 5 (Akyol et al., 2009). This study also showed that 
animals treated with a cafeteria diet have similar energy intakes compared 
to animal treated with chow diet during pregnancy (Akyol et al., 2009). 
Furthermore a study using OF1 female rats, treated with standard diet, as 
control, or high fat diet prepared commercially and based on the standard 
diet with supplemented with beef tallow, chocolate and peanuts, showed 
that energy intake in high fat fed mice was similar to control animals by 
day 18 of pregnancy (Flint et al., 2005). Parametrial (equivalent to 
gonadal) adipose tissue was found expanded in high fat fed rats compared 
to controls by day 14 of pregnancy and its weight decreases after 
postpartum in particular at day 10 of lactation; mammary gland weights 
were also heavier in high fed pregnant rats at day 14 of gestation and day 1 
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of lactation becoming comparable to control mice by day 10 of lactation 
(Flint et al., 2005). 
A study using C57BL/6 mice treated using high fat diet (32% energy from 
fat, 52% from carbohydrate, and 16% from protein) or control diet (11% 
energy from fat, 73% from carbohydrate, and 16% from protein) for 8 
weeks prior to mating showed no statistically significant differences in 
maternal weight at the time of mating or at E18.5 (after removal of the 
pups) (Jones et al., 2009). Inguinal, parametrial, mesometrial and 
retroperitoneal fad pads (weighed all together) were increased by 7% in 
pregnant animals fed the high fat diet compared to controls; moreover 
serum total adiponectin levels were decreased and serum leptin increased 
in high fat fed pregnant mice at E18.5 compared to controls (Jones et al., 
2009). No differences were observed in maternal plasma levels of IL-6, 
TNF-α, glycated hemoglobin, fasting blood glucose, non-fasting insulin 
levels, furthermore blood glucose response to an intraperitoneal glucose 
load was similar in the control and HF-fed dams. Maternal lipid status was 
studied in both serum and red blood cells (Jones et al., 2009). High fat fed 
pregnant mice had 44% higher serum triglyceride levels and 19% lower 
serum concentrations of non-esterified fatty acids than control but similar 
cholesterol levels. Despite no change in total serum lipid levels, stearic 
acids were found increased, and oleic and linoleic acids decreased in red 
blood cells of high fat fed pregnant mice compared to controls (Jones et 
al., 2009). In this animal model up-regulation of placental nutrient 
transporters (GLUT1, SNAT2, SNAT4 and GLUT3) was observed (Jones 
et al., 2009).  
A study on female Sprague Dawley rats, showed that circulating and 
lumbar adipose tissue levels of adipokines, such as IL-1β, PAI 1, and TNF-
α, were increased at d 18 and 20 of gestation and this increased adipokines 
production correlate with enhanced activation of p38 MAPK in adipose 
tissue (de Castro et al., 2011). Treatment of pregnant rats with p38 MAPK 
inhibitor increased phosphorylation of insulin receptor IRS1 in adipose 
tissue, indicating that adipose tissue p38 MAPK activation contributes to 
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adipose tissue insulin resistance at late pregnancy(de Castro et al., 2011). 
A recent study in 2011 further investigates adipose tissue inflammation, in 
particular adipose tissue macrophage infiltration and activation, in normal 
pregnancy using C57BL/6 animals fed on normal chow diet. This study 
showed that pregnant mice were both glucose intolerance and insulin 
resistant compared to non pregnant animals at E17 of pregnancy (Zhang et 
al., 2011). The size of subcutaneous and parametrial adipocytes tissue was 
increased compared to non pregnant mice, indicating that pregnancy is 
associated with adipocyte hypertrophy at this gestational period (Zhang et 
al., 2011). Pregnant mice had increased macrophages infiltration in both 
subcutaneous and parametrial adipose tissue with an increase in the 
M1/M2 ratio, suggesting that the inflammatory changes occur in adipose 
tissue in late pregnancy (Zhang et al., 2011). Gene expression of pro-
inflammatory adipokines, such as TNF α, IL6, and PAI1, was also 
significantly increased in pregnant mice conpared to non pregnant (Zhang 
et al., 2011). This study therefore hypothesized that an imbalance between 
M1 and M2 macrophages induced by adipocyte hypertrophy changes the 
balance of pro and anti-inflammatory adipokines produced by adipose 
tissue which could be involved in insulin resistance as a physiological 
adaptation to maintain maternal and fetal metabolism in late pregnancy 
(Zhang et al., 2011). A recent study conducted in human pregnant subjects 
confirmed the changes in adipose tissue inflammation observed in the 
previous two articles (Resi et al., 2012). In this recent paper, adipose mass, 
obtained via liposuction, adipocyte and total cell numbers were increased 
in late pregnancy (36-38 weeks) in the subcutaneous gluteal depot 
compared to pre-gravid state (Resi et al., 2012). Using whole genome 
microarray analysis, the authors identified changes in pathways involved 
in immune responses, angiogenesis, 59 matrix remodeling and lipid 
biosynthesis in late pregnancy compared to pre-gravid state (Resi et al., 
2012). Furthermore, increased expression of macrophage markers (CD68, 
CD14, and the mannose-6 phosphate receptor) was observed highlighting 
increase recruitment of immune cells in both early (8-12 weeks) and late 
	   50	  
pregnancy suggesting that physiological adipose tissue inflammation is an 
early step preceding the development of insulin resistance which peaks in 
late pregnancy (Resi et al., 2012). 
A study using multiparous German Holstein cows showed that total HSL 
expression was lower in subcutaneous and retroperitoneal at 1 day after 
calving compared with prepartum samples (Locher et al., 2011). This study 
showed that phosphorylation at HSL phosphorylation on Ser660 was 
higher 21 day postpartum compared with 21 day prepartum in 
retroperitoneal adipose tissue, and phosphorylation at Ser563 was 
increased 21 day postpartum than 21 day prepartum in subcutaneous 
adipose tissue (Locher et al., 2011). At day 21 postpartum, cow treated 
with a low concentrated dry matter intake diet showed decreased of Ser 
563 phosphorylation retroperitoneal adipose tissue and a increased serum 
concentration of β-hydroxybutyrate than the cows did treated with high-
concentrate dry matter intake diet which could inhibits HSL 
phosphorilation (Locher et al., 2011). This study suggests that 
retroperitoneal adipose tissue could be more sensitive that subcutaneous 
tissues to the changes occuring peripartum in diary cow (Locher et al., 
2011). HSL phosphorylation is not the only molecule that changes during 
pregnancy in adipose tissue. A study conducted in rats highlight that LPL 
activity in the lumbar, perirenal and periuterine adipose tissues in Female 
Sprague-Dawley rats was higher at day 12 of pregnancy compared to day 
20, in particular in rats receiving linseed oil diet, compared to other 
animals receiving soybean, olive or fish oil diets (Fernandes et al., 2012). 
However free fatty acid profiles in maternal lumbar adipose tissue and 
colostrum was similar at both gestational timepoints considered and also 
comparable between diets, suggesting that specific dietary fatty acids in 
early pregnancy modulate adipose tissue lipid metabolism(Fernandes et al., 
2012). 
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1.4 Thesis hypothesis and aims 
The central thesis presented here is that obesity during pregnancy 
exacerbates adverse outcomes through worsening of adipose tissue insulin 
resistance and inflammation. 
To test this, the specific aims of this thesis were: 
• To determine adipose tissue distribution and insulin 
resistance in obese pregnant mice 
• To identify novel molecular pathways associated 
with adipose tissue expansion in obese mice during 
pregnancy and thereby generate new hypotheses. 
• To test these new hypotheses through validation and 
functional characterisation of the key pathways.   
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Chapter 2: Materials and Methods 
 
2.1 Animals 
2.1.1 Murine model of obesity in pregnancy  
All experiments conformed to local ethical guidelines of the University of 
Edinburgh and were licensed under the UK Home Office Animals (Scientific 
Procedures) Act (1986). We used 5 week old C57BL/6 female mice supplied 
by Charles River (Kent, London, UK). Obesity was established by allowing 
the mice ad libitum access to a defined high fat diet (Surwit et al., 1995) for 
12 weeks (HF) (D12331 supplied from Research Diet, New Brunswick, NJ) 
or a low fat control diet (Control) (D12328 supplied from Research Diet, New 
Brunswick, NJ). Table 2.1 summarizes the diet content for both the HF and 
control diet. After this period, male mice were presented to single-caged 
female mice whilst the diet exposure continued. Pregnancy was carefully 
monitored through plug checking and mice were taken for analysis at E14.5 
and E18.5 during pregnancy. Pregnant mice were compared to aged-matched 
non pregnant mice exposed to the appropriate diet. 
All mice were sacrificed by lethal exposure to CO2, blood was then 
collected into a EDTA-coated 1ml syringe by using a 28G needle though 
aortic puncture, tissues were harvested and immediately frozen in dry-ice 
and a small piece of mesenteric and subcutaneous fat was collected in 10% 
formalin. 
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Table 2.1: Details of HF and Control diet content 
 HF  Control 
Fat (% Kcal) 58 10.5 
Carbohydrate (% Kcal) 25.5 (sucrose) 73.1 (corn starch) 
Protein (% Kcal) 16.4 16.4 
Ingredients gm% (kcal%) gm% (kcal%) 
Casein, 80 Mesh 228 (912) 228 (912) 
DL-Methionine 2 (0) 2 (0) 
Maltodextrin 10 170 (680) 170 (680) 
Corn Starch 0 (0) 835 (3340) 
Sucrose 175 (700) 0 (0) 
Soybean Oil 25 (225) 25 (225) 
Coconut Oil, Hydrogenated 333.5 (3001.5) 40 (360) 
Mineral Mix S10001 40 (0) 40 (0) 
Sodium Bicarbonate 10.5 (0) 10.5 (0) 
Potassium Citrate, 1H2O 4 (0) 4 (0) 
Vitamin Mix V10001 10 (40) 10 (40) 
Choline Bitartrate 2 (0) 2 (0) 




2.1.2 Glucose Tolerance Test (GTT) 
The GTT was used to determine the efficiency of glucose clearance from the 
blood following a bolus administration of glucose.  A GTT can give an 
indication of whether glucose homeostasis is disturbed, as is expected in 
obesity, and is highly predictive of peripheral insulin sensitivity in the 
C57BL/6J mouse model.  
Mice were single-caged for several days to allow them to equilibrate to their 
environment and adapt to any stress of isolation. Mice were fasted for 6 hours 
to achieve blood glucose levels that reflect a physiological fast (basal). Blood 
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glucose level was measured using a glucometer by touching a drop of blood 
from a small scalpel venesection of the tail vein (OneTouch Ultra, LifeScan, 
USA). At baseline, prior to glucose administration, blood samples were 
collected in a Microvette CB 300 (Sarstedt, Leicester, UK) to determine 
insulin levels. A bolus of glucose solution (2g glucose/kg bodyweight using 
25% (w/v) D-glucose in distilled water) was delivered into the stomach by a 
gavage needle (20-gauge, 38 mm long curved, with a 21/4 mm ball end; Able 
Scientific, Canning Vale, Western Australia, Australia) or into the 
bloodstream using ip injection. Blood was collected at 15, 30, 60, and 90 or 
120 minutes after glucose administration. Ice-chilled whole-blood was 
fractionated into plasma by centrifugation at 6000g for 10 minutes in a 4°C 
eppendorf centrifuge and insulin levels determined, by ELISA (Crystalchem, 
Downers Grove, US) according to the manufacturers instructions. GTT in 
E18.5 pregnant mice was performed by Dr Vicky King. 
 
2.1.3 Intravenous Insulin Tolerance Test. 
Whole body insulin sensitivity was assessed by injecting insulin (1mU/g body 
weight of fast acting HumulinS, Novo Nordisk) into the tail vein of 
aneasthetized mice that had been fasted for 4 hours. Mice were culled 15 
minutes after injection and glucose levels used as an potential indicator of 
insulin efficacy (decrement in glucose level). Tissues (muscle, adipose tissue, 
liver) were collected for assessment of phosphorylated and unphosphorylated 
PKB, a key components of the insulin signalling pathway, using western blot 
techniques. 
In the case of the ITT, mice were fasted for 4 hour to achieve basal blood 
glucose and insulin levels. Blood glucose and insulin levels were measured as 
above. Thereafter, each mouse was anaesthetized by inhalation of Isoflurane 
(Merial, Harlow, Uk) and placed on a pre-warmed hot pad. After injection, 
mice were allowed to recover, and blood was collected 12 minutes and 30 
seconds to assess circulating glucose and insulin levels. Mice were then 
culled using CO2 15 after injection as decribed above, mesenteric and 
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subcutaneous fat and muscle were collected within 5 minutes and 
immediately frozen in dry-ice. 
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2.2 Human adipose tissues 
Patients were recruited according to the permissions granted by the 
Research Ethics Committee West of Scotland REC4 to the Edinburgh 
Reproductive Tissue Bio Bank (ERTBB-050). All patients gave informed 
written consent. Samples from visceral and subcutaneous fat were obtained 
from lean (20≥BMI≤25) and obese (BMI≥30) pregnant patients 
undergoing elective lower segment caesarean section. Exclusion criteria 
were:  
• Gestational diabetes (GDM) 
• Use of steroid medication 
• Hypertension 
• Twin pregnancy 
• Any pregnancy complication (i.e. intrauterine growth retardation). 
 
2.3 Adipocyte cell isolation 
2.3.1 Isolation of mature adipocytes   
Adipose tissue samples were collected in Krebs Ringer phosphate buffer 
(115mM NaCl, 5.9mM KCl, 1.2mM MgCl2, 1.2mM NaH2PO4, 12mM 
Na2HPO4, 2.5mM CaCl2) supplemented with 0.1%BSA and 1g/L D-glucose 
and maintained at 37°C in a Nalgene Bottle 30ml LDPE WM (Scientific 
Laboratory Supplier, Uk). Samples were minced into pieces using sterile 
scissors and digested with 2mg/ml Collagenase type 1 (LS004196-
Worthington Biochemical Corporation, Lakewood, US) in Krebs Ringer 
phosphate buffer (supplemented with 0.1%BSA and 1g/L D-glucose) for 
approximately 40 minutes at 37°C in a shaking water bath (15ml of 
collagenase was use for samples with weight ≤ 3g). Once digestion was 
completed, the reaction was stopped by adding 1v/v of Krebs Ringer 
phosphate buffer. Samples were passed through a sterile 250µm nylon mesh 
(PlastOK, Meshes and Filtration Ltd, Birkenhead, UK) into a 50mL Falcon 
Tube. Mature adipocytes were left to rest approximately 20 minutes in order 
to reach the top of the incubating culture media. The stromal vascular fraction 
(SVF) contained in the media underneaf the adipocyte layer was removed 
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using  a 10ml pipet. Mature adipocytes were washed using sterile warm 
DMEM (D2902-Sigma-Aldrich), and this process was repeated 3 times. After 
the last wash, 1 to 2 V/V cell suspension of DMEM was added to the mature 
adipocytes. Equal volumes of cell suspension (were distributed in Eppendorf 
tubes using gentle agitation using a magnetic stirrer. In every experiment an 
extra tube was put aside for determination of protein content in order to 
express the results of gene expression levels per µg of adipocyte protein. The 
adipocytes were allowed to rest an hour in an incubator at 37°C with 5%CO2.  
After this period mature adipocytes were treated according to the relevant 
experimental design (see 2.3.1.2). 
 
2.3.1.1 Basal lipolysis in mouse primary adipocytes  
Mature adipocytes from mouse tissue were incubated with fresh DMEM 
media for 6 hours in an incubator at 37°C with 5%CO2. The media was then 
collected and processed to assess fatty acid released from adipocytes as 
described in section 2.5.3 
 
2.3.1.2 Treatment of human adipocytes with an estrogen agonist 
Mature adipocytes from human adipose tissue were incubated with varying 
concentrations (1nM, 10nM, 100nM and 1µM) of 4,4',4''-(4-Propyl-[1H]-
pyrazole-1,3,5-triyl)trisphenol (PPT) [dissolved to 100mM using DMSO] 
(1426-Tocris, Brisol, UK) in DMEM media (D6046-Sigma-Aldrich). Vehicle 
DMSO control was included. Samples were incubated for 6 hours in a cell 
culture incubator at 37°C with 5%CO2 in Eppendorf tubes. The cells were 
then collected, after media aspiration, in QIAzol Lysis Buffer for qRT-PCR 
as described in section 2.9.  
 
2.3.2 Female clonal adipocyte Chub-S7 cell line 
An aliquot of immortalized primary human preadipocytes (subsequently 
termed Chub-S7 cell line) was obtained from Nestlé Research Centre, 
Lausanne, Switzerland (subject to MTA with Dr NM Morton). The Chub-S7 
cell line was derived from subcutaneous adipose tissue from a 33 year old 
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obese female patient and immortalized by infection with a recombinant virus 
carrying the papillomavirus-16 E7 gene {Darimont: 2003cf}. 
Cells were propagated up to passage 30, using 1v/v of DMEM (D6046-
Sigma-Aldrich) and nutrient mixture F-12 Ham (N6658-Sigma-Aldrich), 10% 
fetal calf serum (201F30-I-BioConcept AMIMED), 1% 
penicillin/streptomycin (P0781-Sigma-Aldrich) and 1% L-Glutamine 
(G7513-Sigma-Aldrich). Cells were maintained at 37°C, 5% CO2 and 90% 
humidity. 
For differentiation, cells were plated at a density of 20000 cells/cm2 on 
collagen-coated plates. Approximately four days after plating, cells reached 
confluence and were washed once with Hank’s Balance Salt Solution 
(H6648-Sigma-Aldrich) before using a serum free media for subsequent 
differentiation. 
Differentiation media (Darimont et al., 2006) was composed of 1v/v of 
DMEM (D6046-Sigma-Aldrich) and nutrient mixture F-12 Ham (N6658-
Sigma-Aldrich) supplemented with: 15mM NaHCO3 (6329-Merk,US),  
17µM D-Panthotenic acid (P6045-Sigma-Aldrich), 15mM Hepes (H0887-
Sigma-Aldrich), 33µM biotin (B4501-Sigma-Aldrich) and freshly added 
10µg/ml transferrin (T2252-Sigma-Aldrich), 1nM triiodothyronin (T2752-
Sigma-Aldrich), 850nM insulin (I5500-Sigma-Aldrich) and 500µg/ml fetuin 
(F3385-Sigma-Aldrich). 
From day 0 to day 3 of differentiation, the media was supplemented with 
1µM Dexamethasone (D1756-Sigma-Aldrich) and 500µM 3-isobutyl-1-
methyl-xanthine (I5879-Sigma-Aldrich). From day 3 to day 17 media was 
supplemented with 1µM Dexamethasone, 1µM Roziglitazone or (BRL49653 
71740-Cayman Chemical, Michigan, US) and 1 µM T09013017 (71810-
Cayman Chemical, Michigan, US). 
Fully differentiated Chub-S7 were then incubated with different 
concentrations of PPT (1nM, 10nM, 100nM and 1µM) of PPT desolved 
DMSO (1426-Tocris, Brisol, UK) in DMEM media. Vehicle DMSO DMEM-
only controls were included. Samples were left for 6 hours in an incubator at 
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37°C with 5% CO2. The cells were then collected using a syringe and a 19G 
needle in QIAzol Lysis Buffer for qRT-PCR as described in section 2.7.  
 
2.4 Enzyme-linked immunosorbent assay (ELISA) 
2.4.1 Mouse High Molecular Weight Adiponectin (Adiponectin 
HMW) 
Plasma adiponectin HMW was measured using an Adiponectin (Mouse) Total 
HMW (high molecular weight) ELISA (47-ADPMS-E01-Alpco, Salem, US) 
according to the manufacturer’s protocol. The sensitivity of the assay is 0.032 
ng/ml. We measured Adiponectin HMW because its levels are also more 
meaningful than the total adiponectin level in predicting insulin resistance 
and the development of metabolic syndrome (Hara et al., 2006).  To measure 
adiponectin HMW , 100µl of protease solution was added to 10µl of plasma, 
and incubated at 37°C for 20 minutes. Next 700µl of sample pretreatment 
buffer was added and stirred thoroughly (1:81 dilution). 10µl of pretreated 
sample was added to 1ml of dilution buffer (final dilution 1:8181). A standard 
curve (8, 4, 2, 1, 0.5, 0.25, 0.125, 0 ng/ml insulin) was created by diluting 
stock standard solution of 8 ng/ml mouse insulin provided in the kit. 50µl of 
sample diluents were dispensed in each well of a 96 well plate, and 50µl of 
sample or standard curves was added and incubated for one hour at room 
temperature. Contents were aspirated and washed twice with 350µl of 
washing buffer per well. 50µl of Biotin conjugated-PoAb per well was added 
and incubated for one hour at room temperature. Contents were aspirated and 
wells were washed 3 times using 350µl of washing buffer per well. 50µl per 
well of enzyme labeled streptavidin was added and the solution was allowed 
to react for 30mins at room temperature. Contents were aspirated and wells 
were washed three times using 350µl of washing buffer per well. Next, 50µl 
per well of substrate solution was added and the solution was allowed to react 
for 10mins at room temperature without exposure to light. The reaction was 
stopped by adding 50µl per well of stop reagent. Adiponectin HMW 
concentration of each sample was calculated with reference to the standard 
curve by measuring the absorbance within 30minutes using a 
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spectrophotometer at A492nm. Results were then multiplied for the dilution 
factor (8181). Background was accounted for by subtracting A600nm values.  
 
2.4.2 Measurement of mouse plasma estradiol 
Plasma estradiol level was measured using a Mouse/Rat Estradiol ELISA 
(ES180S-100-CalBiotech, Spring Valley, US) according to the 
manufacturer’s protocol. A recent paper has shown that this ELISA kit was 
reliable and correlate with mass spectrometry steroid analysis data 
(Haisenleder et al., 2011). Its sensitivity is 3pg/mL, and its specificity to 
detect other steroids is: progesterone 0.0002% of cross reaction, 
androstenedione 0.0001%, testosterone 0.0002%, cortisol 0.0001%.  
A standard curve (0, 3, 10, 30, 100, 300 pg/ml estradiol) was already 
provided in the kit. 25µl of sample or standard were dispensed in each well, 
and 100µl of working reagent of estradiol enzyme conjugated was added and 
incubated at room temperature for 2 hours. Contents were aspirated and 
washed three times with 300µl of washing buffer per well. 100µl of TMB 
Reagent were dispensed in each well and incubated at room temperature for 
30 minutes in the dark. The reaction was stopped by adding 50µl per well of 
enzyme reaction stop solution. Estradiol concentration of each sample was 
calculated with reference to the standard curve by measuring the absorbance 
within 15 minutes using a spectrophotometer at A450nm.  
 
2.4.3 Mouse Insulin 
Plasma insulin level was measured using a Mouse insulin ELISA kit (90080-
Crystal chem, Downers Grove, US) according to the manufacturer’s protocol. 
The sensitivity of this assay is 0.1 ng/ml using 5 µl of sample. A standard 
curve (0, 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8 ng/ml insulin) was created by 
diluting a stock standard solution of 25.6 ng/ml mouse insulin provided in the 
kit. 95µl of sample diluents were dispensed in each well of a 96 well plate, 
and 5µl of sample or the standard curve solutions were added and incubated 
for 2 hours at 4°C. Contents were aspirated and washed 5 times with 300µl of 
washing buffer per well. 100µl of anti-insulin enzyme conjugate per well was 
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added and incubated for 30mins at room temperature. Contents were aspirated 
and wells were washed 7 times using 300µl of washing buffer per well. 100µl 
per well of enzyme substrate solution was added and the solution was allowed 
to react for 40mins at room temperature without exposure to light. The 
reaction was stopped by adding 100µl per well of enzyme reaction stop 
solution. Insulin concentration of each sample was calculated with reference 
to the standard curve by measuring the absorbance within 30minutes using a 
spectrophotometer at A450nm. Background was accounted for by subtracting 
A630nm values. 
 
2.4.4 Mouse Leptin 
Plasma leptin level was measured using a Mouse insulin ELISA kit (90030-
Crystal chem, Downers Grove, US) according to the manufacturer’s protocol. 
The sensitivity of this kit is 200 pg/ml using 5µl sample. A standard curve (0, 
0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8 ng/ml leptin) was created by diluting 
stock standard solution of 25.6 ng/ml mouse leptin provided in the kit. Each 
well was washed twice using 300µl of washing buffer per well. 45µl per well 
of sample diluent were dispensed together with 50µl of guinea pig anti-mouse 
leptin serum per well and each of 5µl of sample or standard curve solutions – 
the resulting mixture was incubated overnight at 4°C. Contents were aspirated 
and washed 5 times with 300µl of washing buffer per well. 100µl of anti-
guinea pig IgG enzyme conjugate per well were dispensed and incubate for 3 
hours at 4°C. Contents were aspirated and wells were washed 7 times using 
300µl of washing buffer per well. 100µl per well of enzyme substrate solution 
was added and the solution was allowed to react for 30 mins at room 
temperature without exposure to light. The reaction was stopped by adding 
100µl per well of enzyme reaction stop solution. Leptin concentration of each 
sample was calculated with reference to the standard curve by measuring the 
absorbance within 30minutes using a spectrophotometer at A450nm. 
Background was accounted for by subtracting A630nm values. 
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2.4.5 Mouse Progesterone 
Plasma progesterone level was measured using a Progesterone Rat/Mouse 
ELISA (DEV9988-Demeditec, Kiel, Germany) according to the 
manufacturer’s protocol. The sensitivity of this kit is 0.04 ng/mL and its 
specificity to detect other steroids is: androsterone <0.1% cross reaction, 
androsterone <0.1%, corticosterone 0.3%, 11-desoxycorticosterone 1.8%, 5α-
dihydrotestosterone <0.1%, estradiol <0.1%, estriol <0.1%, 17α-
hydroxyprogesterone 0.6%, prednisolone <0.1%, prednisone <0.1%, 
pregnenolone 5.5% and testosterone 0.14%. 
A standard curve (0, 0.4, 1.5, 6.5, 25, 100 ng/ml progesterone) was already 
provided in the kit. 25µl of sample or standard were dispensed in each well, 
together with 50µl of incubation buffer and 100µl enzyme conjugate, and the 
mixture incubated at room temperature for one hour on a microplate mixer. 
The contents were aspirated and washed four times with 300µl of washing 
buffer per well. 200µl of substrate solution were dispensed in each well and 
incubated at room temperature for 30 minutes in the dark. The reaction was 
stopped by adding 50µl of stop solution per well. Progesterone concentration 
of each sample was calculated with reference to the standard curve by 
measuring the absorbance within 30 minutes using a spectrophotometer at 
A450nm. 
 
2.5 Enzymatic reaction 
2.5.1 Liver glycogen quantification 
Liver samples (~20-30mg) were placed in a capped 7ml glass bijou with 
500µl of 2N HCl and incubated at 95°C in a shaking water bath for 2 hours to 
break the branched glycogen superstructure into mono-saccharide subunits 
(glucose). 500µl of 2N NaOH  was added, and each sample was then adjusted 
at pH 7. Supernatant was then collected in a new Eppendorf tube and spun at 
1000g for 4 minutes at 4°C. The infranatant, below the lipid layer, was 
collected in a new tube avoiding any lipid floating. An aliquot of the 
supernatant was used for protein quantification as described in section 2.4.9. 
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To quantify glycogen the Thermo Infinity Glucose Reagent (TR15421-
Thermo Scientific, UK) was used.  The assay involved a series of reaction as 
follow: 
•Hexokinase catalysed the phosphorylation of glucose by ATP producing 
ADP and glucose-6-phosphate. 
•Glucose-6-phosphate is oxidised into 6-phosphogluconate (G-6-PDH) with 
the reduction of NAD+ to NADH by G-6-PDH. The amount of NADH 
formed is proportional to the concentration of glucose in the sample and can 
be measured by by absorbance at 340 nm. 
A standard curve of glucose was created (0, 1, 2, 4, 10, 20, 30 and 40 mg/ml 
of glucose) and 50µl of standards and 5µl of each sample were added into a 
96 well plate. 200µl hexokinase reagent was added and the plate incubated at 
37°C in the plate reader for 3 minutes. Glucose concentration and the inferred 
quantity of glycogen of each sample was calculated with reference to the 
standard by measuring the absorbance using a spectrophotometer at A340nm.  
 
2.5.2 Liver triglyceride quantification 
Liver samples (~100-200mg of frozen tissue) were homogenised in 10 
volumes (v/w) of isopropanol in glass 15ml culture tubes using a tissue 
homogenizer at full speed. This step fractionates hydrophobic moieties such 
as neutral lipids. Tubes were then placed on a shaker at maximum speed for 
45 minutes, with additional vortexing of each tube every 10 minutes. After 
this period, tubes were centrifuged at 1500g (Eppendorf Centrifuge 5414R) at 
room temperature for 10 minutes; supernatant was removed and placed in 7ml 
glass bijou on ice. To quantify triglycerides, Thermo Infinity Triglycerides 
Reagent (TR22421-Thermo Scientific, UK). The assay involve s a series of 
reaction as follow: 
•Triglycerides are enzymatically hydrolysed by lipase to free fatty acids and 
glycerol.  
•The glycerol is phosphorylated by adenosine triphosphate (ATP) with 
glycerol kinase (GK) to produce glycerol-3-phosphate and adenosine 
diphosphate.  
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•Glycerol-3-phosphate is oxidised by dihydroxyacetone phosphate (DAP) by 
glycerolphosphate oxidase producing hydrogen peroxide (H2O2).  
•In a Trinder5 type colour reaction catalyzed by peroxidase, the H2O2 reacts 
with 4-aminoantipyrine (4-AAP) and 3,5-dichloro-2-hydroxybenzene 
sulfonate (DHBS) to produce a red coloured dye. The absorbance of this dye 
is proportional to the concentration of triglycerides present in the sample. 
A 96 well plate was placed on ice and 2µl of isopropanol (blank), standard 
(2.5mmol/L) and samples were added. 200µl reagent was added and the plate 
was incubated at 37°C in the plate reader for 5 minutes. 
Triglyceride concentrations in each sample were calculated as a ratio to the 
standard by measuring the absorbance using a spectrophotometer at A500nm. 
 
2.5.3 Quantification of free fatty acid levels in adipocyte cell 
infranatants 
The NEFA-C kit (Wako Diagnostics, Richmond, US) was used to measure 
free fatty acids. This is an enzymatic method that relies upon the acylation 
of coenzyme A (CoA) by the fatty acids in the presence of added acyl-CoA 
synthetase (ACS). The acyl-CoA thus produced is oxidized by added acyl-
CoA oxidase (ACOD) with generation of hydrogen peroxide, in the 
presence of peroxidase (POD) permits the oxidative condensation of 3-
methy-N-ethyl-N(β-hydroxyethyl)-aniline (MEFA) with 4-
aminoantipyrine to form a purple colored adduct which can be measured 
colorimetrically at 550 nm. 
20µl media from subcutaneous adipocytes cultured in DMEM media for 
6hours (see 2.3.1.1) and 5 µl standard (1mmol.L), water was used in order 
to have the same volume in all wells, were added into a 96 well plate. 
150µl of reagent A was added and the plate incubated at 37˚C x 3mins. 
Next, 75µl of reagent B was added and incubated at 37˚C for 4.5mins. 
Free fatty acids concentration of each sample was calculated with 
reference to the standard by measuring the absorbance using a 
spectrophotometer at A546nm. Background was accounted for by subtracting 
absorbance values in the wells at A660nm. 
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2.6 Determination of cellular and tissue protein levels 
using BCA assay 
To quantify proteins, the RC DC Protein Assay Reagents Package (500-
0120-BioRad, UK) and standard were used. A standard curve of bovine 
serum albumin was created (0, 5, 7.5, 10, 15 and 20 mg/ml of bovine 
serum albumin). 2 µl of standards or 2µl of each sample were added into a 
96 well plate. 25µl reagent A were added and subsequently 200µl reagent 
B were added. Plates were incubated at room temperature for 15 minutes. 
Protein concentration of each sample was calculated with reference to the 
standard curve by measuring the absorbance using a spectrophotometer at 
A750nm. 
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2.7 Quantification of gene mRNA levels  
2.7.1 Total RNA extraction from adipose tissue, adipocytes and 
fully differentiated Chub-S7 cells 
Adipose tissues (~80-100mg frozen sample) were homogenized in 1ml 
QIAzol Lysis Buffer using one metal bead per sample and shaking the 
samples twice for 4 minutes at 25Hz in TissueLyser (QIAGEN, Crawley-
West Sussex, UK). Mature CHUB-S7 cells and adipocytes were 
homogenized with 1mL QIAzol Lysis Buffer using a 1mL syringe and 
19G needle, aspirating the liquid 10 times. Adipose tissues lysate or cell 
homogenates were incubated at room temperature for 5min. 200µl of 
chloroform was added and tubes were shaken for 15 seconds before 
subsequent incubation at room temperature for 3 minutes. Samples were 
then centrifuged at 10000g (Eppendorf Centrifuge 5414R) for 15min at 
4°C to separate RNA into the aqueous phase. The upper aqueous phase 
was transferred to a fresh Eppendorf tube and 1v/v of 70% ethanol was 
added to the upper phase and vortexed. Up to 700µl of sample was applied 
to an RNeasy mini column (QIAGEN, Crawley-West Sussex, UK) and 
placed in a 2ml collection tube. The mini-column was centrifuged for 
15seconds at 8000g (Eppendorf Centrifuge 5414R) and the flow-through 
discarded. This step was repeated twice. 350µl BW1 buffer was added in 
the column before centrifuging for 15 seconds at 8000g and discarding the 
flow-through. 80µl of DNase 1 solution (79254-QIAGEN, Crawley-West 
Sussex, UK) was added to the column and incubated at room temperature 
for 15 minutes. 350µl BW1 buffer was added in the column and it was 
centrifuged for 15seconds at 8000g (Eppendorf Centrifuge 5414R) and 
flow-through was discarded. 500µl RPE buffer was added in each column 
and it was centrifuged for 15seconds at 8000g and flow-through was 
discarded. 500µl RPE buffer was added to each column and the column 
spun for 2 minutes at 8000g (Eppendorf Centrifuge 5414R) to wash the 
column. The column was placed in a new 2ml collection tube and 
centrifuged at 8000g (Eppendorf Centrifuge 5414R) for 1min. The RNeasy 
column was then placed in a new 1.5ml collection tube. 30µl RNase-free 
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water (provided in the RNeasy mini kit) was directly added to the spin 
column membrane, incubated for 1min, and then centrifuged at 8000g 
(Eppendorf Centrifuge 5414R) for 1min to elute the total RNA. The eluate 
was then put back into the column, incubated for 1min, and then 
centrifuged for 1min to elute. The RNA concentration was measured using 
a Nanodrop spectrophotometer (Thermo, Wilmington, USA) and RNA 
quality and integrity/purity was verified using RNA 6000 Labkit chip on 
the 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA) RNA was 
preserved in -80°C. 
 
2.7.2 RNA extraction: liver  
Liver samples ~20-30mg, cut from frozen liver with a chilled scalpel on 
dry ice, were homogenised in 350µl RTL Buffer supplemented with β-
mercaptoethanol (QIAGEN, Crawley-West Sussex, UK) using a 
TissueLyser (QIAGEN, Crawley-West Sussex, UK). 1v/v of 70% ethanol 
was then added to the cleared lysate and vortex. Up to 700µl of sample 
was applied to an RNeasy mini column (QIAGEN, Crawley-West Sussex, 
UK) and placed in a 2ml collection tube. RNA was then processed as 
above  
 
2.7.3 2100 BioAnalyzer 
500µl of RNA 6000 Nano gel matrix (Agilent Technologies, Palo Alto, 
CA) was centrifuged in a spin filter at 1500g (Eppendorf Centrifuge 
5414R) for 10 minutes, and a 65µl aliquot of filtered gel placed into 0.5ml 
RNase-free tubes (gel stable for 4 weeks). We then added 1µl of RNA 
6000 Nano dye concentrate into a 65µl filtered gel. The solution was 
vortexed and spun at 13000g for 10 minutes. 9µl of gel-dye was added in a 
RNA 6000 Nano chip in the well marked with (G), the chip was then 
positioned in a priming station with a plunger, the priming station closed 
and the plunger pressed until it was held by a clip. After 30 seconds, the 
clip was released and left to travel back to the starting position. 9µl of gel-
dye was added in a RNA 6000 Nano chip in the well marked with G, and 
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5µl of RNA 6000 Nano marker was added in all the 13 remaining wells. 
1µl of ladder was added in the bottom right well (marked with a ladder 
symbol), and 1µl of RNA was added in the remaining 12 wells. The chip 
was then vortexed for 1 minute at 2400rpm on an IKA vortexer and then 
run on the Agilent 2100 bioanalyzer within 5 minutes. Samples that 
demonstrated high quality [i.e ratio of integrity or RIN (ratio of 28S rRNA 
to 18s rRNA) greater then 8.6, Figure 2.1] were used for microarray 
analysis or qRT-PCR.  
 
 
Figure 2.1 Example of electropherogram of RNA from 
mesenteric fat mRNA a HF pregnant animal  
 
2.7.4 cDNA synthesis 
For this procedure a cDNA the Synthesis Kit (4368813-Applied Biosystems, 
Carlsbad, US) was used. 
A mastermix was prepared for each sample and RT negative control (Table 
2.2). 600ng of DNase treated RNA was adjusted to a 10 µl volume using 
RNase-free water; 10 µl of mastermix was added to each sample and mixed 
by pipetting. Samples were then incubated on a Thermal Cycler (GRI G-
Storm 1) at 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes. 
cDNA was then stored at -20°C for later qRT-PCR analysis. 




Table 2.2 cDNA synthesis mastermix 
 
 RT+ve (x1 sample) RT-ve (x1 sample) 
10x RT Buffer 2µl 2µl 
25x DNTP’s 0.8µl 0.8µl 
10x Random Primers 2µl 2µl 
Reverse Transcriptase (RT) 1µl Nil 
Rnase inhibitors (1 U/µl) 1µl 1µl 
Rnase-free wather 3.2µl 4.2µl 
 
2.8 Microarray and microarray data analysis 
2.8.1 Microarray 
For this analysis 500ng of mesenteric adipose tissue RNA was used. RNA 
was processed for hybridisation through standard Affymetrix protocols, 
with one round of cDNA amplification using the GeneChip® 3’ IVT 
Express Kit. Processed RNA was hybridised to Affymetrix Mouse 
Genome 430 2.0 GeneChips. RNA processing and microarray analyses 
were carried out by Ark Genomics, Roslin, Edinburgh. 
 
2.8.2 Microarray data: extraction and normalization 
Data were extracted by the microarray team through the Genechip 
Operating System (GCOS) software and CEL (probe intensity data) files 
along with an experimental description file were used for further data 
processing. CEL files were imported into Bioconductor (Gentleman et al., 
2004), and normalised by RMA in the Affy (Gautier et al., 2004) module 
by the CVS Bioinformatics Team 
 
2.8.3 Microarray data analysis 
The experimental design and analysis approach of microarray data will be 
extensively explained in Chapter 4 section 4.2.2. 
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2.9 qRT-PCR using standard curve methods 
qRT-PCR was performed using a ABI 7900HT (Applied Biosystems, 
Carlsbad, US), using the Taqman mastermix (H4440040-Applied 
Biosystems, Carlsbad, US) on a 384 well plate with inventoried gene-
specific Taqman primer/probes (Table 2.4): all probes marked with m1 
were designed across exons, skipping therefore intronic part, and those 
marked with g1 were design across exon-intron junction, being therefore 
able to detect genomic DNA. 
The standard curve was obtained by diluting a pool composed by equal 
volume of all the samples (dilution 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 
1:512 of cDNA pool). All samples and RT-ve controls were diluted 1:20 
using RNase-free water with the aim of having the samples in the linear 
part of the standard curve for more accurate comparison of relative values. 
Standard, RT-ve, water control were assayed in triplicate for each gene 
while samples were measured in duplicate. Table 2.4 summarizes the 
primer/probe set used in our experiments. 
The mastermix containing primers/probe and the enzyme was prepared 
accordingly to table 2.3.  
8µl of mastermix was dispensed in each well and 2µl of standard, RT-ve, 
water control or samples were added.  
The reaction was composed of 3 stages, the third of which was repeated 40 
times: 
- Stage 1: incubation at 50°C for 2 minutes 
- Stage 2: incubation at 95°C for 15 seconds 
- Stage 3: 95°C for 15 seconds and 60°C for 1minute 
 
Mean Ct (cycle threshold) of each standard was plotted against log10 dilution 
factor and linear regression was used to fit a standard curve to the data. 
Acceptable standard curves had a slope between -3.3 and -3.7, with R2 >0.99. 
Mean Cts of unknowns were normalised against expression of a 
housekeeping gene, cyclophilin A. 
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Table 2.3 qRT-PCR mastermix 
 x1 sample 
Mastermix 5μl 
Rnase-free water 2.5μl 
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Table 2.4 Taqman primer/probe ID 
Gene Assay ID 
Mouse Cyclophilin A Mm02342429_g1 
Mouse FASN  Mm00662319_m1 
Mouse Rbp4  Mm00803266_m1 
Mouse ERα  Mm00433149_m1 
Mouse ERβ Mm00599821_m1 
Mouse SCD1 Mm00772290_m1 
Mouse ME1  Mm00782380_s1 
Mouse Dgat2  Mm01273905_m1 
Mouse Hsd17b12  Mm00479916_m1 
Mouse PPARα  Mm00440939_m1 
Mouse Leptin  Mm00434759_m1 
Mouse IGF1  Mm00439560_m1 
Mouse IGFBP3 Mm00515156_m1 
Mouse TNFα  Mm00443258_m1 
Mouse MCP1  Mm00441242_m1 
Mouse Pepck  Mm01247058_m1 
Mouse GPAT  Mm00833328_m1 
Mouse CPT1a  Mm00550438_m1 
Mouse APO CIII  Mm00445670_m1 
Mouse Rdh11 Mm00458129_m1 
Human ERα Hs00174860_m1 
Human ERβ Hs01100353_m1 
Human FASN  Hs01005622_m1 
Human Rbp4  Hs00924047_m1 
Human SCD1  Hs01682761_m1 
Human ME1 Hs00159110_m1 
Human Dgat2  Hs01045913_m1 
Human Hsd17b12  Hs00275054_m1 
Human PPARα  Hs00947537_m1 
Human Cyclophilin A  Hs04194521_s1 




2.10 Fluorescence-activated cell sorting (FACS) 
Adipose tissue samples were collected in Krebs Ringer phosphate buffer 
(115mM NaCl, 5.9mM KCl, 1.2mM MgCl2, 1.2mM NaH2PO4, 12mM 
Na2HPO4, 2.5mM CaCl2) supplemented with 0.1%BSA and 1g/L D-
glucose and maintained at 37°C in a Nalgene Bottle 30ml LDPE WM 
(Scientific Laboratory Supplier, Uk). Samples were minced into pieces 
using sterile scissors and digested with 2mg/ml Collagenase type 1 
(LS004196-Worthington Biochemical Corporation, Lakewood, US) in 
Krebs Ringer phosphate buffer (supplemented with 0.1%BSA and 1g/L D-
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glucose) for approximately 40 minutes at 37°C in a shaking water bath 
(15ml of collagenase was use for samples with weight ≤ 3g). Once 
digestion was completed, the reaction was stopped by adding 1v/v of 
Krebs Ringer phosphate buffer. Samples were passed through a sterile 
250µm nylon mesh (PlastOK, Meshes and Filtration Ltd, Birkenhead, UK) 
into a 50mL Falcon Tube. Samples were then spun at 600g (Eppendorf 
Centrifuge 5414R) for 12 minutes at room temperature. The supernatant  
(composed by mature adipocytes and media) was removed and the pellet 
was resuspended in 10 mL of Krebs Ringer phosphate. Samples were then 
filtered using 100µm and 40µm (BD Bioscience, Oxford, UK), and were 
subsequently spun 600xg for 12 minutes at room temperature. The 
supernatant was removed and the pellet was resuspended in 2ml of red 
blood cell lysis buffer (R7757-Sigma-Aldrich) and incubated at room 
temperature for 10 minutes. After this incubation, 10mL of PBS was added 
to stop the reaction and samples were spun at 600g for 12 minutes at room 
temperature. The supernatant was removed and the pellet was resuspended 
in 100µL of PBS and stored on ice. Cell number was estimated using an 
haemacytometer in XµL cell suspension diluted ½ in trypan blue, a vital 
staining that selectively color dead cells in blue. 
For FACS analysis we used a minimum of 0.5 million and a maximum of 
1 million cells for each of the conditions. After quantification cells were 
divided in different FACS tubes and resuspended to 100µL of volume 
using PBS. 10µL of affinity purified anti-mouse CD16/32 - blocks 
Fragment crystallizable region (Fc) binding: this product reacts with an 
epitope shared by mouse CD16 and CD32; CD16 (Fcγ III Receptor) and 
CD32 (Fcγ II Receptor) are the low affinity receptors for the mouse IgG Fc 
portion and are expressed by B cells, monocyte/macrophages, NK cells, 
and neutrophils, avoiding therefore a-specific binding (14-0161-82-
eBioscience, San Diego, US) diluted 1:10 in PBS was added to each tube 
and incubated on ice for 10 minutes. Antibodies were diluted in 10% 
mouse serum (Sigma, Uk) as described in table 2.5 to obtain a final 
volume of 50µL. A single stain for both the general myeloid cell marker 
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CD11b and the inflammatory macrophage marker CD11c was used, as 
well as isotype control staining (isotype controls need to be matched to the 
specific primary Abs -species and isotype, including heavy and light 
chains-, they were used in order to determine the level of specific staining 
by the primary Ab). Unstained samples were routinely used in order to 
check the specificity of our antibodies and to obtain basal fluorescence 
levels from each samples. 
50µL of diluted antibodies were added to each sample and incubated on ice 
for 30 minutes. After this period 1mL of PBS was added and samples were 
spun at 300g for 5 minutes (Eppendorf Centrifuge 5804R). The 
supernatant was removed and 100µL 10% formalin was added to each 
tube, samples were then vortexed vigorously for 10 seconds and stored in 
the fridge at 4°C. FACS analysis was performed within 2days from the 
staining. 
FACS analysis was performed using FACSCalibur machine (BD 
Bioscience, Oxford, UK), and data were analyzed using FlowJo software 
(Tree Star, Ashland, US). Figure 2.1A represent an example of SSC-H vs 
FSC-H in SVFs; Figure 2.2B represent an example of histogram of CD11b 
single positive cells with the relatives controls (unstained cells and 
isotype). Figure 2.2C represent an example of histogram of CD11c single 
positive cells with the relatives controls (unstained cells and isotype). 
Figure 2.2D is representative plot of CD11b+CD11c+ cells, the same gate 
was used in all our analysis. 
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Table 2.5 List of antibody and their dilutions for FACS analysis 
Antibodies Catalog Number/Manufacturer Dilution 

























Figure 2.2: FACs analysis. A. SSC-H vs FSC-H in SVCs; B. CD11b+ in black, 
unstained in blue and isotype in orange; C. CD11c+ in black, unstained in blue and 
isotype in orange; D. plot of CD11b+CD11c+ cells 
 
	   76	  
2.11 Immunohistochemistry 
Adipose tissue has been processed for immunohistochemistry by the 
hystology core facility (in partcular Garry Menzies embedded the tissue, Bob 
Morries cut the tissue, Nancy Evans and Mike Millar processed slides for 
immunohistochemistry and performed bond run). 
 
2.11.1 Paraffin embedding 
The tissues were fixed for 24 hours in 10% formalin, after which they were 
transferred into 70% ethanol.  Processing of the tissues was automated in a 
Leica TP1050 processor (Leica Microsystems, Milton Keynes, UK).  They 
were then hand embedded in liquid paraffin wax and allowed to cool prior to 
being stored at room temperature until required.   
 
2.11.2 Slide cutting 
10µm sections were cut using the microtome RM2135 (Leica Instruments, 
GmbH Germany).  The sections were then placed in a water bath set to 45°C 
and floated onto charged slides.  The slides were then incubated at 50°C 
overnight. 
 
2.11.3 Dewaxing and rehydratation 
Sections were deparaffinised in xylene (VWR) for 5 minutes twice at room 
temperature.  The tissue sections were then rehydrated by placing them in two 
baths of 100% ethanol (VWR), 95% ethanol, 75% ethanol each for 30 
seconds, followed by washing in water. 
 
2.11.4 Automated immunohistochemistry 
Sections were placed on to a bond staining robot and perilipin antibody, a 
kind gift from Dr Andrew Greenberg -TUFTS University, Boston, 
USA(Souza et al., 1998), at 1:400 dilution was incubated on sections for 2 
hours at room temperature, following 3x 4 min washes in TBS-0.1% Tween 
20 (TBS-T) sections were incubated with a goat anti Rabbit alkaline 
phosphatase conjugated polymer, following further TBS washes sections 
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were removed from the robot and incubated with vector Blue as per 
manufacturers instructions and washed in water.  
Sections were subjected to heat induced epitope retrieval (HEIR) in 
Novocastra pH 6 retrieval solution by heating to 125 C for 30 seconds and 
cooling to 90C for 10 seconds in a decloaking chamber, sections were cooled 
further in running tap water before loading onto robot. Following washing in 
buffer and blocking in hydrogen peroxide, sections were further blocked 
using rodent block M for 30 mins at RT, following 2 x 5 min washes sections 
were incubated with ERα (VP-614, Vector, Peterborough, Uk) at 1:50 
dilution for 2 hours, sections were further washed in TBS-T for 2 x 5 mins 
then incubated with Mouse on Mouse Polymer for 30 mins before further 
buffer washes and DAB incubation. Sections were cover slipped using 
permafluor. 
 
2.11.5 Adipocytes counts: stereologer 
To determine adipocytes cells number -as an indirect measurement of fat cell 
size, stereology was conducted on mesenteric and subcutaneous fat samples 
(n=6 in each groups) using perilipin as a adipocyte cell surface marker of 
adipocytes. For this purpose ImageProPlus software and Leitz DM RB 
(Leica, Uk) was used. In order to measure adipocytes dimension, adipocytes 
number was quantified in 10 random area of equal dimension 
(1243375.5µm2) in our section were used and analysed using manual tag 
stereology. The marker was blind to conditions and a 40x objective was used 
for this purpose.  
 
2.11.6 Imaging 
Rapresentative images of adipocytes size and of adipocytes expressing ERα 
were captured using the Provis AX70 (Olympus Optical, UK) using 
AxioVision Rel. 4.8.0.0 Software (Carl Zeiss Imaging Solutions, GmbH 
Germany). 
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2.12 Western Blot analysis of protein levels 
2.12.1 Western Blot for plasma Rbp4 or ERα/ERβ quantification 
1µ of plasma was mixed with 9µl loading buffer (see table 2.8) and incubated 
at 90°C for 10 minutes. 10ul of the denatured samples and 10µl of a 
denatured commercially prepared molecular weight marker cocktail (See 
Blue, LC5925- Invitrogen, UK) were loaded onto SDS-PAGE gels (see table 
2.8) and run at 100 Volts for 2 hours to separate proteins. Proteins were 
electrotransfered from the gel to a PVDF membrane (Immobilon-FL, 
Millipore) in transfer buffer (1x, table 2.7) at 200mA for two hours. After 
transfer, the membrane was washed in TBS-0.1% Tween 20 (TBS-T see table 
2.8) for 5mins and then incubated in TBS-T with 5% dry skimmed milk 
(Marvel) for 1 hour at room temperature to block non-specific binding. The 
membrane was rinsed three times for five mins each with TBS-T and 
incubated with the appropriate primary antibodies (see table 2.6) in TBS-T 
5% BSA overnight at 4°C. Next, the membrane was washed three times for 
5mins with TBS-T, then incubated with a goat anti-rabbit secondary anti-
body diluted 1:10000 in TBS-T 5% BSA. The membranes were then washed 
twice in TBS-T and then in PBS. The membranes were then scanned using 
the Odyssey system (Li-Cor), and the quantification was performed using 
Image Studio Analysis Software provided with this machine. 
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Table 2.6: List of  primary antibody for western blot used with Odyssey 
detection system 
Antibody Dilution 
polyclonal rabbit anti-human retinol binding protein primary 
antibody (A0040-Dako, UK) 
1:1000 
monoclonal mouse anti-human estrogen receptor (ER) α (VP-614, 
Vector, Uk) 
1:200 
monoclonal rabbit anti-human ER β (Sc8974, Santa Cruz, Usa)  1:200 
monoclonal rabbit anti-human β-tubulin (Sc9104, Santa Cruz, Usa) 
1:600 




2.12.2 Western Blot for analysis of tissue insulin signalling 
0.5ml lysis buffer (see table 2.8) was added to each frozen adipose tissues or 
muscle sample and they were homogenized at full speed for 3 minutes using a 
motorized homogenizer (IKA, Uk). The homogenates were centrifuged at 
8000g for 10 minutes at 4°C (Eppendorf Centrifuge 5414R). The aqueous 
solution, underneath the lipid layer, was carefully transferred into new tubes, 
this step was repeated if the aqueous solution was not clear. A protein assay 
was used to measure protein concentration using 2µL each homogenate (as 
described in 2.4.9).  50µg of proteins was mixed with 5µl of 6x loading buffer 
(see table 2.8) and lysis buffer was used to adjust the final volume to 10µl. 
Samples were heated at 95°C for five minutes, cooled on ice, quickly spun (at 
13000g in Eppendorf Centrifuge 5414R). Samples and 10µl molecular weight 
marker (See Blue, LC5925- Invitrogen, UK) were loaded onto NuPAGE 
Novex 4%-12% Bis-Tris Mini Gels 1.0mm 15 wells (NP0323BOX-
Invitrogen, UK) using MOPS buffer (NP0050-Invitrogen, UK) and run at 100 
Volts for 2 hours to separate proteins. Proteins were electrotransfered from 
the gel to a PVDF transfer membrane 0.45µm (GE Healthcare) in transfer 
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buffer (see table 2.8) at 200mA for 2 hours. The transfer system was kept 
cool during electrotransfer with an inset ice-block. After transfer, the 
membrane was washed in TBST for 5mins and then incubated in TBS-T with 
5% dry skimmed milk (Marvel) for 1 hour at room temperature to block non-
specific binding. The membrane was rinsed 3 times 5 mins with TBS-T and 
incubated with the appropriate primary antibody (see table 2.7) in TBS-T 5% 
BSA overnight at 4°C. Next, the membrane was washed three times for 5mins 
with TBS-T, then incubated with an anti-rabbit HRP-conjugated secondary 
antibody (1:1000, Cell signaling) in TBS-T with 5% skimmed milk with 
gentle agitation for 2 hours at room temperature. The membrane was then 
washed 3 times 5 mins in TBS-T. The membrane was incubated with 1ml 
developing solution (ECL Western Blot Analysis System, RPN2109-GE 
Healthcare Chalfont St Giles, Uk) for one minute. Excess developing solution 
was drained; the membrane was wrapped in saran wrap in a cassette and then 
exposed to X-Ray film (28906836-GE Healthcare, Chalfont St Giles, Uk) for 
10 seconds to 1 minute in a cassette in the dark room under red-light, 
depending on the strength of the signal. The signal was revealed by exposing 
the film through a Konica X-Ray developer (Konica, FL, US). 
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Table 2.7: list of  primary antibody for western blot used with ECL detection 
system 
Antibody Dilution 
Akt (pan) (11E7) Rabbit mAb (4685S-Cell Signaling) 1:2000 
Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb (4060S-Cell Signaling) 1:4000 
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Table 2.8: Solutions for western blot 
Buffer Receipt 
Lysis Buffer 50mmol/l Tris, pH 7.4, 0.27 mol/l sucrose, 1mmol/l sodium orthovanadate, 
pH 10, 1mmol/l EDTA, 1mmol/l EGTA, 10mmol/l sodium β-
glycerophosphate, 50mmol/l NaF, 5mmol/l sodium pyrophosphate, 
1%[wt/vol] Triton X-100, 0.1% [vol/vol] 2-mercaptoethanol, and protease 
inhibitors—EDTA free tablets (Roche) 
SDS-PAGE gel 
12% separating gel: 3.35ml dH2O, 2.5ml 1.5M Tris (pH8.8),0.1ml 10%SDS, 4ml 30%Acrylamide, 0.75ml 
10%APS, 0.01ml Temed; 
Stacking gel: 2.85ml dH2O, 1.25ml 0.5M Tris (PH 6.8), 0.05ml 10%SDS, 
0.85ml 30%Acrylamide, 0.025ml 10%APS, 0.005ml Temed. 
Running buffer (10x) 
30g Tris, 144g Glycine, 10g SDS, made to 1L dH2O. 
Loading buffer (6x) 1.8ml 2M Tris (PH 6.8), 3ml Glycerol, 0.3ml 0.5% Bromophenol Blue, 1.8g 
SDS, 925mg DTT, made up to 10ml with dH2O. 
Loading buffer for 
plasma 3.55mL dH2O, 1.25 0.5M Tris-HCl pH6.8, 2.5 ml glycerol, 2ml 10% SDS, 0.2ml 0.5% bromophenol blue and 0.5ml β-mercaptoethanol 
Transfer buffer (10x) 24.2g Tris, 112.3g Glycine made to 1L dH2O. 
Transfer buffer (1x) 100ml transfer buffer (10x), 800ml dH2O, 100ml Methanol  
TBS (10x) 12.11g TRIS HCl, 87.66g NaCl, made up to 1L dH2O, pH 7.6 
TBS-T  1L TBS, 1ml Tween-20 
 
 
2.13 Data analysis and statistics 
Unless otherwise stated, data are presented as the mean ± standard error of 
the mean (S.E.M). Statistical analysis was performed using SigmaStat 3.5 and 
graphs were created using Graph Pad (GraphPad Prism 4 Demo). The groups 
were compared using one-way ANOVA (Tukey comparison all groups) or 
Kruskal-Wallis Test (Dunns: comparison of pairs of columns) for the CHUB-
S7 cells and primary adipocytes treatment with PPT and DPN; or two-way 
ANOVA (Holm-Sidak, pairwise multiple comparison) for whole animal 
studies comparing different states of pregnancy and diet. A P value of <0.05 
was considered to show a statistically significant difference between groups. 
Normality of data was calculated using D’Agostino and Pearson omnibus 
normality test (when n≥8) or Kolmogorv-Smirnov test (when n≥5). 
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Chapter 3: Characterisation of the HF-diet 
induced obesity mouse model during pregnancy 
 
3.1 Introduction 
During pregnancy, changes in maternal metabolism occur in response to 
the growing fetus and placenta and their increasing metabolic needs. 
During early pregnancy, adipose tissue accretion is promoted (reviewed by 
(Barbour et al., 2007)) and glucose tolerance is normal or even slightly 
improved (Catalano et al., 1993; 1999). On the other hand, late gestation is 
characterized by insulin resistance and increased lipolysis. In this period 
insulin has reduced ability to suppress lipolysis and this effect is further 
amplified in patients with gestational diabetes (Catalano et al., 2002). As 
such, increased free fatty acids may contribute to increased hepatic glucose 
production and severe insulin resistance (Friedman et al., 1999; Catalano 
et al., 1999; 2002). Alterations in maternal glucose metabolism may be due 
to any or all of placental growth hormone, prolactin, cortisol, and 
progesterone which antagonize insulin action in particular during the 2nd 
and the 3rd trimesters (Catalano et al., 1993). However, the mechanisms 
that link pregnancy and maternal metabolic changes are still largely 
unknown. Critically, in pregnancy, abdominal obesity is associated with 
glucose intolerance and insulin resistance (Ramsay et al., 2002; Martin et 
al., 2009), with the result that gestational diabetes is very common in this 
situation. Both glucose intolerance (HAPO Study Cooperative Research 
Group, 2009) and insulin resistance (Boomsma et al., 2006) are associated 
with adverse pregnancy outcome. Fat distribution during pregnancy was 
found to be associated with an increase in visceral fat deposition from 
preconception to postpartum compared to non pregnant women 
(Gunderson et al., 2008); however, published results on fat gain during 
pregnancy show considerable variations due to different methodology 
used, variation in the design of the studies and inter-subject variation.  
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Little is known about the molecular mechanisms linking insulin resistance, 




The aims for the current chapter were 
1) To investigate the effect of HF diet on fat distribution during 
pregnancy in mouse 
2) To determine the impact of HF diet-induced obesity and 
pregnancy on circulating levels of adipokines and sex 
steroids 
3) To investigate the effect of HF diet-induced obesity and 
pregnancy on insulin resistance  
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3.2 Experimental design 
Five week old C57BL/6 female mice were fed either with a HF diet (30) or 
a control diet (19) for 12 weeks (see section 2.1.1). After this period 
females were single-caged and mated with male mice whilst continuing the 
diet. Mice were weighed weekly during the 12 weeks of treatment and at 
E10.5, E14.5 and E18.5 during pregnancy. At E14.5 and E18.5, pregnant 
mice were culled and compared with age-matched non-pregnant animals. 
Maternal weight without pups was used as the correction for organ weight 
ratios throughout.  Mesenteric, subcutaneous fat and liver weight was 
measured at cull, tissues were then frozen on dry ice and stored at -80°C. 
Blood was also collected at this stage. Adipocyte size was determined 
using immunohistochemistry (see 2.11). Basal lipolysis was quantified in 
subcutaneous primary adipocytes (see 2.3.1 and 2.3.1.1) Leptin, 
adiponectin, estradiol and progesterone were measured using ELISA 
methods (see section 2.4.1, 2.4.2, 2.4.4, 2.4.5). A GTT was also performed 
in E14.5 and E18.5 (performed by Dr Vicky King) pregnant mice (see 
section 2.1.2). To investigate tissue insulin sensitivity, 4 hour fasted E14.5, 
E18.5 and non-pregnant mice were injected with 1mU/g BW insulin 
(estimated using an algorithm generated from maternal bodyweight minus 
pup weights in separate experiments) and animals were culled after 15 
minutes (see section 2.1.3). Protein kinase B (AKT) phosphorylation (a 
marker of activation in response to insulin; reviewed by (Taha and Klip, 
1999)) and total PKB was measured using western blot, β-tubulin levels 
was also measured in this blot as an internal control (see section 2.12.2). 
Due to the large number of samples analysed, in order to account for 
differences between different western blot a positive control (samples 
previously obtained by Dr N Morton) was run in each western blot and the 
results for the samples investigated in this thesis were normalised against 
this positive control. 
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3.3 Results 
3.3.1 The effect of HF diet on weight gain after 12 weeks of 
treatment and during pregnancy 
Starting from the fourth week of treatment, animals undergoing HF diet 
were heavier (Fig 3.1 A) compared to control mice.  
Weight during pregnancy remained higher at all the time point 
considered (E10.5, E14.5 and E18.5) in HF pregnant mice compared to 
controls pregnant mice. However the body weight gain throughout 
pregnancy was higher in control pregnant mice (59.6% of body weight) 
compared to HF pregnant animals (41.7% of body weight) (Fig 3.1 B). 
 
 
Figure 3.1 Effect of HF diet on weight gain: A after 12 weeks of diet (n=19 HF 
mice, n=30 control mice) and B during pregnancy (n=8 HF mice, n=16 Control 
mice); Data analysed using Two-Way ANOVA **=P≤0.01, ***=P≤0.001 
 
3.3.2 Effect of HF diet and pregnancy on mesenteric, 
subcutaneous fat and liver weight  
HF feeding increased mesenteric fat weight (per gram of body weight) in 
non pregnant mice (Figure 3.2 A). Pregnancy did not alter mesenteric fat 
mass in control diet-fed mice (Figure 3.2 A). Mesenteric fat mass was 
drastically lowered in HF pregnant mice compared with HF non-pregnant 
mice at all the stage of pregnancy considered (Figure 3.2 A). 
Subcutaneous fat weight (per gram of body weight) was increased with HF 
diet in pregnant and non-pregnant mice compared to gestation matched 
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control diet-fed mice (Figure 3.2 B). Moreover, HF-fed pregnant mice had 
decreased subcutaneous fat mass compared with HF-fed non pregnant 
animals (Figure 3.2 B), although this effect was milder compared to the 
one observed in mesenteric fat (Figure 3.2 A). Pregnancy did not show any 
statistically significant effect on subcutaneous fat weight in control 
animals. 
Pregnancy increased liver weight (per gram of body weight) in both HF- 
and control diet-fed pregnant mice. In contrast to the E14.5 stage of 
pregnancy, liver mass was higher in HF-fed mice compared to control diet-
fed mice at E18.5. 
 
 
Figure 3.2 The effect of HF diet and pregnancy on organ weight: A 
mesenteric fat (n=19 HF mice, n=30 control mice), B subcutaneous fat (n=8 HF 
mice, n=16 Control mice) and C liver; n=11-15; Data analysed using Two-Way 
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3.3.3 The effect of HF diet and pregnancy on leptin and high 
molecular weight adiponectin (AdiponectinHMW) plasma levels 
As expected, HF diet increased plasma leptin levels in non-pregnant mice 
(Figure 3.3A). Pregnancy increased leptin levels in control and HF 
animals. In control mice plasma leptin concentration increased gradually 
during pregnancy reaching its highest level at E18.5 (Figure 3.3A). In 
contrast, in HF-fed pregnant animals leptin levels reached an earlier 
plateau at E14.5 and leptin levels converged in HF diet fed and control 
diet-fed pregnant mice by E18.5 (Figure 3.3A).  
HF diet decreased circulating adiponectin high molecular weight (HMW) 
levels in non pregnant mice compared to control diet-fed non-pregnant 
mice (Figure 3.3B). Pregnancy decreased plasma adiponectinHMW levels in 
control pregnant mice, but did not further decrease adiponectin 




Figure 3.3 The effect of HF diet and pregnancy adipokines plasma levels: A 
Leptin (n=8-15), B AdiponectinHMW (n=8 in each group); Data analysed using 
Two-Way ANOVA *=P≤0.05, **=P≤0.01, ***=P≤0.001 
 
3.3.4 The effect of HF diet and pregnancy on estradiol and 
progesterone plasma levels 
Plasma estradiol levels rose during pregnancy, achieving a maximum at 
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a slight increase in estradiol levels were observed by E14.5 compared to 
non-pregnant animals (Figure 3.4A). 
Plasma progesterone levels were higher in pregnant animals compared to 
non pregnant animals (Figure 3.4B). Progesterone circulating levels were 
similar at E14.5 in HF and control pregnant mice, however, by the end of 
pregnancy progesterone levels in HF mice were higher compared to 




Figure 3.4 Effect of HF diet and pregnancy hormones plasma levels: A 
Estradiol (n=7 in each group), B Progesterone (n=7 in each group); Data analysed 
using Two-Way ANOVA **=P≤0.01, ***=P≤0.001 
 
3.3.5 Effect of HF diet and pregnancy on lipolysis and adipocyte 
dimension 
In order to assess the basal lipolysis rate, primary adipocytes were isolated 
from subcutaneous fat and cultured to quantify the release of free fatty 
acids into the media after 6 hours. We found no difference in lipolysis 
between HF or control non-pregnant mice (Figure 3.5) However, 
subcutaneous primary adipocytes of HF-fed pregnant mice released more 
free fatty acids compared to control diet-fed pregnant mice (Figure 3.5). 
To determine if the increased basal fatty acids released had an effect on 
adipocyte hypertrophy, adipocyte size was determined using an indirect 
method wherein adipocyte number in 10 randomly selected areas of equal 
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the 6 groups of mice. Cells per unit area (cpu) decreased as fat cell size 
increases. Stereology was conducted on mesenteric and subcutaneous fat 
samples using perilipin (blue staining) as a lipid droplet surface marker of 
adipocytes. HF non-pregnant mice had decreased adipocyte number 
compared to control non pregnant animals in both mesenteric and 
subcutaneous fat (Figure 3.6A and 3.7A), indicating that HF non-pregnant 
mice had larger adipocytes compared to control diet-fed non-pregnant 
animals, as expected. Pregnancy per se increased adipocyte size in control 
mice in subcutaneous and mesenteric fat depots. No difference was 
observed in adipocyte size of HF pregnant animals compared to HF non-
pregnant mice (Figure 3.6A and 3.7A). At E14.5, however HF pregnant 
mice has still larger adipocytes compared to control pregnant mice (Figure 
3.6A and 3.7A). Figure 3.6B and 3.7B show a representative image of 
adipocytes dimension in both mesenteric fat (Figure 3.6B) and 
subcutaneous fat (Figure 3.7B) in our 6 experimental groups. 
 
Figure 3.5 Effect of HF diet and pregnancy on lipolysis from subcutaneous fat 
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Figure 3.6 Effect of HF diet and pregnancy on mesenteric fat adipocytes A 
cell per unit  (n=6 in each group, 10 random area quantified per slides) and B 
representative images for adipocytes blu staining perilipin (brown staining ERα; 
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Figure 3.7 Effect of HF diet and pregnancy on subcutaneous fat adipocytes A 
cell per unit  (n=6 in each group, 10 random area quantified per slides) and B 
representative images for adipocytes blue staining perilipin (brown staining ERα; 
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3.3.6 Effect of HF diet and pregnancy on glucose homeostasis 
To evaluate the effect of HF diet and pregnancy on glucose homeostasis 
we performed glucose tolerance tests (GTT) at E14.5 and E18.5.  At 
E14.5, HF pregnant mice were hyperglycaemic, and exhibited 
hyperinsulinaemia (higher insulin at 15 and 30 minutes after glucose bolus 
compared to control pregnant mice (Figure 3.8A and B). However during a 
GTT at the latest stage of pregnancy considered (E18.5) no differences 
were found in HF pregnant mice compared with controls (Figure 3.8C and 
D).   
 
 
Figure 3.8 Effect of HF diet and pregnancy on insulin resistance: A Glucose 
plasma levels E14.5 (n=5-12), B Insulin plasma levels at E14.5 (n=5-12), C 
Glucose plasma levels E18.5 (n=6-7), D Insulin plasma levels at E18.5 (n=6-7), 
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3.3.7 The effect of HF diet in pregnancy on tissue insulin 
signalling 
To investigate tissue insulin sensitivity, a single time-point insulin 
tolerance test was performed in our experimental groups. Protein Kinase B 
(PKB) phosphorylation and total PKB levels were measured using western 
blot as an indicator or tissue insulin sensitivity. 
Figure 3.9A shows plasma insulin levels after insulin injection. Insulin 
injection produced higher insulin levels and reduced glucose level 
compared with saline treated animals. (Figure 3.9B). 
Mesenteric fat PKB phosphorylation was comparable across groups; a part 
an increase observed in 14.5 control pregnant mice compared to the others 
control groups (Figure 3.9C).  
In non-pregnant mice, subcutaneous fat PKB phosphorylation level was 
comparable between control or HF diet-fed groups. By E14.5 of 
pregnancy, control diet and high fat diet-fed mice exhibited a marked 
reduction in PKB phosphorylation, an effect that was accentuated in the 
HF-fed pregnant mice (Figure 3.9D). By late pregnancy (E18.5), PKB 
phoshorylation levels had returned to levels found in non-pregnant control 
diet fed mice. In contrast, PKB phosphorylation increased in HF-fed 
pregnant mice by E18.5 but remained lower than the control diet fed 
pregnant mice (Figure 3.9D).  
Muscle phospo-PKB was comparable across the groups, a part from a 
reduction observed in HF 14.5 pregnant mice compared to HF non 
pregnant animals (Figure 3.9E). Figure 3.10 is a representative image of 
the western blot performed in mesenteric fat (1), subcutaneous fat (2) and 
muscle (3). 




Figure 3.9 Effect of HF diet and pregnancy on PKB phosphorylation. A. 
Insulin levels after insulin injection, B glucose levels after insulin injection In y-
axe ratio between phosporylated PKB (Ppkb) and un-phosphorylated PKB (pkb) 
is presented: C Mesenteric fat  (n=6 in each group), D Subcutaneous Fat (n=6 in 





































































































Figure 3.10 Effect of HF diet and pregnancy on Ppkb after insulin injection. 
Representative images of western blot performed on Ppkb, pkb and β tubulin. 1 
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3.4 Discussion 
The data presented in this chapter show that pregnancy is unexpectedly 
associated with a reduction in visceral fat mass accumulation.  
Whilst absolute body weight remains higher in HF-fed mice during 
pregnancy compared to HF non pregnant mice and control mice; 
pregnancy significantly reduced mesenteric fat weight in HF mice. This 
effect is specific to this fat depot as no differences in weight were observed 
in subcutaneous fat of HF pregnant mice compared to HF non pregnant 
animals. These data contrast with the increase in adipose tissue expansion 
observed in pregnant rats treated with diet rich in calories (see 1.3, (Akyol 
et al., 2009), (Flint et al., 2005)) and with the increase general adiposity in 
a non obese mouse model treated with a high fat diet (see 1.3 (Jones et al., 
2009)). 
Circulating leptin was found to be increased in HF diet in non pregnant 
mice as expected (Zhang et al., 1994). In both HF and control pregnant 
groups, at E14.5 and E18.5 of pregnancy, we observed a higher 
concentration of this protein in plasma compared to the non pregnant 
groups. Leptin circulating levels increased gradually in control pregnant 
mice throughout pregnancy, however in HF pregnant mice there was no 
further increase in plasma levels of this protein at E18.5 compared to the 
middle of pregnancy; suggesting an interaction between diet and 
pregnancy at E14.5 but not at E18.5 in the production of this protein. A 
possible explanation of the increased leptin plasma levels in pregnant mice 
could be due to the production of this protein by the placenta (Hoggard et 
al., 1997). However must be also considered that estradiol can stimulate an 
increase in leptin production in adipocytes (Piermaría et al., 2003; Yi et al., 
2008). Furthermore, hyperinsulinemia increased leptin production in 
adipocytes (Boden et al., 1997), therefore it is plausible that in control 
animals the worsening in insulin resistance, that reaches its peak at the last 
stage of pregnancy, is responsible for the gradual increase in circulating 
leptin levels during pregnancy. Moreover the lack of difference in leptin 
plasma levels between E14.5 and E18.5 in HF mice could be due to the 
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lack of worsening in insulin resistance in HF mice between these time 
points. 
AdiponectinHMW was decreased in HF non pregnant mice, as expected 
(reviewed by (Arita et al., 1999)). Pregnancy decreased plasma levels of 
this protein in control mice. Surprisingly no difference was found in the 
plasma levels of this protein in HF pregnant group, at E14.5 and E18.5, 
compared with HF pregnant mice. These data suggest that the decreased 
mesenteric and subcutaneous fat mass do not translate to an increase in 
circulating AdiponectinHMW levels. However, because no difference was 
found between HF pregnant and control pregnant animals at the different 
stages of pregnancy considered, this suggests that the combination of 
pregnancy and HF diet in this animal model does not create a worse 
adiponectinemia. 
Estradiol levels increase as expected during pregnancy reaching their 
maximum circulating levels by the end of pregnancy (McCormack and 
Greenwald, 1974). No difference were observed between HF and control 
groups at both time points during pregnancy considered, suggesting that 
obesity has no effect on this hormone concentration in plasma.  
We also analyzed progesterone concentration in plasma. In mouse plasma 
progesterone increased starting from E3 of gestation and remain high until 
E16 when its starts to decline (progesterone withdrawal) (McCormack and 
Greenwald, 1974) preparing for labour. We observed that as expected, 
both HF and control E14.5 control mice have increased plasma 
progesterone levels compared to non pregnant, however at E18.5 HF 
pregnant mice do not display progesterone withdrawal. However we could 
not detect progesterone receptor in mesenteric adipose tissue suggesting 
that this hormone does not play a direct role in the reduction in mesenteric 
fat expansion.  
The reduced visceral fat mass in HF pregnant mice, correlates with an 
increase in lipolysis assessed in primary adipocytes. However despite the 
increased release of free fatty acid by the end of pregnancy in HF mice, 
adipocyte size remained constant in HF pregnant animals suggesting 
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therefore a balance in storage/release of fatty acids in adipocytes during 
pregnancy in HF mice. Moreover we observed that pregnancy in control 
animals is responsible for the increased in adipocyte size, as already shown 
(Zhang et al., 2011), indicating that adipocyte enlargement is not directly 
responsible for increased fat mass and that probably the compartment 
mostly involved in this process is the SVF. 
Glucose tolerance test at E14.5 showed that HF pregnant mice were both 
hyperglycemic and hyperinsulinemic, however at E18.5 no difference was 
found in obese and control pregnant mice. This observation suggests a 
normalization in insulin resistance in HF mice by the end of pregnancy 
compared to controls. The use of two different routes of administration of 
glucose bolus (oral at E14.5 and injection at E18.5), and the different way 
to test plasma glucose levels (glucometer at E14.5 and colorimetric assay 
at E18.5) meant that a direct comparison between results in E14.5 and 
E18.5 animals could not be made, however these data still allow us to see 
the differences between HF-fed and control fed mice at each time 
considered.  
However, the test on tissue insulin sensitivity (by PKB phosphorylation) 
were  comparable between the 6 groups considered in the adipose tissue 
and therefore insulin-mediated effects such as lipogenesis and suppression 
of lipolysis do not contribute to the reduced visceral fat mass. It cannot be 
excluded that the collection of tissue after 15 minutes post injection was 
not ideal to detect altered PKB phosphorylation and that the activation of 
other proteins (downstream [glycogen synthase kinase 3 -GSK3-, forkhead 
box O -FOXO- or tuberous sclerosis 2 -TCS 2] or upstream [insulin 
receptor substrate 1 -IRS1] of pkb) is differentially affected by HF diet and 
pregnancy in these mice. 
 
A significant increase in liver weight was observed in HF- and control 
diet-fed pregnant groups, at E14.5 and E18.5, compared to non pregnant 
animals, suggesting that pregnancy mediates expansion of this organ. At 
E18.5 HF pregnant mice were shown to have increased liver weight 
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compared to control pregnant mice, this difference was not present at 
E14.5 suggesting an additive effect of pregnancy and HF diet at E18.5 but 
not at E14.5. Liver changes and its implication in our animal model will be 
further investigated in Chapter 6, the following chapter will focus mainly 
on changes occurring in mesenteric and subcutaneous fat. 
 
In summary, HF feeding during pregnancy unexpectedly decreases 
mesenteric fat expansion and metabolic impairment converges at the end 
of pregnancy with the worsening profile of control diet-fed pregnant mice. 
These effects appear to be independent of direct insulin action in the 
adipose tissue, at least as measured by the current methods. The next 
chapter takes an open question as to what the underlying molecular 
mechanisms contributing to the reduced mesenteric fat might be.  
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Chapter 4: The mesenteric adipose tissue 
transcriptome profile of HF pregnant mice.   
 
4.1 Introduction 
Microarray analysis of global gene expression is a powerful method that 
provides an unbiased overview of all differentially expressed genes. 
Combined with extensively curated software analysis tools linked to public 
databases, a broad view of linked gene pathways can be used to gain 
insight into the transcriptional mechanisms underlying altered phenotypes. 
In this case, microarray technology was applied to the adipose depot that 
showed the most striking change in animals that were made obese with 
high fat diet before and during pregnancy up until day 18.5 (late 
pregnancy). By asking the open question: “What are the changes at the 
gene expression level in HF E18.5 pregnant mice that are responsible for 
the decrease visceral fat mass and the brake in expected increase 
worsening of insulin resistance observed in Chapter 3?” we aimed to 
generate new testable hypotheses on the underlying molecular mechanism 
for the unexpectedly reduced mesenteric fat accumulation.  
 
Aims 
1) To profile the transcriptome of mesenteric fat in HF 
pregnant mice compared to both control pregnant and HF 
non pregnant mice 
2) To use qRT_PCR to validate some selected changes in gene 
expression arising from the microarray data. 
3) To determine if these changes in gene expression are 
specific to a particular fat depot by comparing expression of 
selected genes in mesenteric and subcutaneous fat 
4) To determine if these changes in gene expression are 
restricted to the end of pregnancy by comparing expression 
of selected genes at E14.5 and E18.5. 
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4.2 Experimental design  
Five week old C57BL/6 female mice were fed either with a HF diet (8) or 
a Control diet (8) for 12 weeks (see section 2.1.1). After this period 
females were single-caged and mated with male mice whilst continuing the 
diet. The transcriptome of mesenteric fat was profiled in HF fed E18.5 
pregnant and non pregnant mice and compared with aged-matched non 
pregnant mice and with control fed pregnant at E18.5 (Figure 4.1) using 
microarray (see 2.8). Microarray data analysis and pathways analysis will 
be extensively explained in the following paragraphs.  
Selected genes from the top ‘hits’ generated from the analysis strategies 
described below were validated using qRT-PCR in a larger sample size of 
animals (n=8 in each group of non pregnant mice, E14.5 pregnant animals 
and E18.5 pregnant mice as described in Chapter 2 section 2.9). Leptin and 
ERβ expression was also measured by qRT-PCR in each group.  
In order to validate gene expression levels beyond altered transcript levels, 
one key gene, Rbp4 was measured at the protein level in plasma using 
western blot as described in 2.12.1 (n=7 in each group of in non pregnant 
mice and E18.5 pregnant mice as described).  
A strong feature of the microarray analysis was altered expression of genes 
in inflammatory pathways. To identify whether these differences were 
paralleled by functional changes (cell number), FACS analysis of cells 
isolated from the stromal vascular fraction of an additional visceral 
adipose depot (gonadal) was performed. %CD11b+CD11c+ pro-
inflammatory macrophages were quantified as described in 2.10 (n=5 in 
each group of non pregnant mice, n=6 control E18.5 mice and n=11 HF 
E18.5 mice). 
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Figure 4.1 Schematic representation of the microarray experiment and the 
comparisons between groups that were made: each box represents an 
experimental group and the arrow indicates the possible comparisons to other 
experimental groups. 
 
4.2.1. Microarray data analysis 
4.2.1.1 Microarray data: statistical analysis 
Data were statistically analyzed with the Limma (Smyth, 2004) package 
and the Rank Products (RankProd) package (Breitling et al., 2004) with the 
help of the CVS Bioinformatics Team. Rather than use the numerical 
values of fold changes, RP uses the ranks of the fold changes, which is 
relatively insensitive to outliers, and hence more specific. The RP score is 
calculated by multiplying the ranks of all the pairwise fold changes 
between sample groups (eg high fat fed pregnant v control fed pregnant). 
The lower the RP score, the more likely a fold change is real and 
potentially interesting. A permutation step (100 rounds) included in RP 
allows a data distribution to be built and a significance value (p-value) to 
be assigned to each gene. The p-value or ‘percent false positives: pfp’ 
indicates the probability that a gene will have that rank or higher by 
chance. In contrast to Limma and many other analysis tools, Rank 
Products is non-parametric and does not assume a particular distribution 
for the gene expression data, although it does require that the genes have 
broadly similar variance. Rank products works well with biologically 
noisy data. It is more likely to detect real gene expression differences 
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whereas Limma or other t-test based analysis strategies often fail in this 
scenario because of noise. 
 
4.2.1.2 Microarray data: database creation 
Following analysis, microarray data, along with gene annotations were 
exported from Bioconductor to a tab-delimited text file. The data were 
then loaded into a custom built MySQL database (www.mysql.com) with a 
web-based query interface built in PHP (php.net) by the CVS 
Bioinformatics Team (Dr Donald Dunbar). The query interface allows 
searching by gene annotation and gene expression statistics. For example, 
fold change and p-value thresholds can be set to identify genes that are 
differentially expressed between one or more of pairs of samples. Once the 
query has been performed, the selected genes are returned along with 
expression data (intensities, fold changes and p-values) and annotation 
information. The annotations are linked where applicable to external 
databases like NetAffx, Entrez Gene, the Mouse Genome Database and 
Pubmed. The database is available to registered users at 
(www.bioinf.mvm.ed.ac.uk/projects/silvia/). Microarray data are archived 
in the ArrayExpress data repository (www.ebi.ac.uk/arrayexpress) before 
publication. 
 
4.2.1.3 Microarray data: data mining 
For pathway analysis only genes with a Rank Product P-value of <0.05, 
expression level >100 and fold change ±1.5 were considered. We excluded 
from our analysis genes where at all five replicates had expression levels 
below 100, (ie corresponding to background level), in order to avoid 
analyzing genes whose signal was comparable to that from background 
noise.  We decide to use a ±1.5 fold change difference as the threshold in 
our study in order to minimize false positives and ensure that only robust 
changes would be highlighted for further analysis. 
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4.2.1.4 Microarray data: pathway analysis 
Microarray data were analyzed using three different methods ([i] Database 
for Annotation, Visualization and Integrated Discovery [DAVID], [ii] 
WebGestalt and [iii] Metacore) and a consensus achieved between them. 
For pathway analysis, only genes with Rank Product P-value <0.05, 
expression level >100 and fold change ±1.5 were considered. This allowed 
increased confidence in the generation of gene lists with likely functional 
relevance.  
 
[i] Database for Annotation, Visualization and Integrated Discovery (DAVID) 
v6.7 
DAVID aims to distill biological meaning from a given large gene list. It 
allows the user to perform Gene Ontology (GO) analysis, discover 
enriched functionally related gene groups and it provides an initial insight 
on the major biological functions associated with the gene list and also 
possible link with diseases (Dennis et al., 2003; Huang da et al., 2009). GO 
is a collaborative project to standardize the description of gene expression 
between different databases (http://www.geneontology.org/). Gene set 
enrichment analysis “is a computational method that determines whether 
an a priori defined set of genes shows statistically significant” 
(http://www.broadinstitute.org/gsea/index.jsp) Enrichment analysis 
increased therefore, the likelihood of identifying biological processes most 
pertinent to the disease or biological system studied. Moreover DAVID 
allows users to visualize genes on the BioCarta and KEGG pathway maps 
(these are collections of manually drawn pathways maps based on 
literature knowledge on molecular interaction and reaction networks), and 
to highlight gene-disease association (Dennis et al., 2003; Huang da et al., 
2009). In addition to the basic Gene Set Enrichment, DAVID clusters 
similar functional groupings to give more confidence that a finding is real. 
For example, if cholesterol metabolism GO category and its KEGG 
pathway are both enriched in a dataset, it is more likely that cholesterol 
metabolism is of interest. The major limitation of this method is the 
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inability to submit gene lists and their fold changes, so the analysis is 
focused on the link of different genes by their function and does not 
consider the different levels of expression.  However, DAVID provided us 
with a list of pathways that were different in our gene set of significantly 
up-regulated or down-regulated genes in each our comparisons, giving us 
the first insight on the pathways changed in the HF pregnant mice. 
 
 
Figure 4.2 Example of DAVID analysis results: Annotation cluster indicate the 
GO terms: BP=biological process; MF=molecular function; CC=cellular 
component. FAT represents the filter algorithm applied by DAVID. The 
enrichment analysis score is also reported as well the localisation/broad function 
for that group of genes.  The green and black symbol allow the user to visualize 
the common and difference of annotations cross the group gene members. The 
number of genes, P value as well as Benjamini test result (statistical test to 
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[ii] WEB-based GEne SeT AnaLysis Toolkit (Webgestalt)  
Webgestalt is “an integrated data mining system for the management, 
information retrieval, organization, visualization and statistical analysis of 
large sets of genes.” (Duncan, 2010) (Zhang et al., 2005). For this analysis 
we have used the 2010 version; this version supports eight organisms 
(including human, mouse, rat, worm, fly, yeast, dog and zebrafish). Once 
the user has inputted the list of genes (in our case Affymetrix probe set 
IDs) with the fold change on an excel file, WebGestalt allows the user to 
visualize the genes in different biological contexts (Duncan, 2010) (Zhang 
et al., 2005): 
• GO Tree: organises genes on a GO Directed Acyclic Graph 
(DAG) creating a visual tree linking and creating a hierarchy 
between different GO categories with enriched gene number 
(Figure 4.3)  
• KEGG and BioCarta tables and maps: WebGestalt organizes 
genes based on the KEGG pathways in a KEGG table (as does 
DAVID). This type of table shows KEGG pathways associated 
with the gene set, the number of genes involved in each 
pathway and provides a P-value indicating the significance of 
the enrichment for each KEGG pathway (Duncan, 2010) 
(Zhang et al., 2005). With the WebGestalt enrichment analysis, 
a Benjamini & Hochberg multiple correction testing is 
performed, however due to the structure of Gene Ontology and 
KEGG terms, this the analysis and correction should be 
regarded as a “guide” rather than a statistically rigorous 
procedure. This however is not a problem when interpreted 
correctly, and many useful discoveries have been made by this 
method.	  WebGestalt can also organize in a gene sets using a 
BioCarta table that has a similar structure to a KEGG table 
(Duncan, 2010) (Zhang et al., 2005). 
The major advantage of WebGestalt, compared to the DAVID system, is 
the possibility of submitting a gene list of associated fold-change 
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differences. Hence the programme can establish a link between different 
GO categories not only in relation to the gene function but also in relation 
to expression levels detected performing the microarray analysis (Duncan, 
2010) (Zhang et al., 2005). WebGestalt also allows the user to visualize the 
link and the hierarchy between these categorizes, creating an easier and 
quicker method of understanding the hierarchy of the differently expressed 
gene set (Duncan, 2010; Zhang et al., 2005). 
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Figure 4.3 Example of GO Directed Acyclic Graph in red gene set change, 
black not changed  
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[iii] MetaCore 
MetaCore is an “integrated knowledge database and software suite for 
pathway analysis of experimental data and gene lists”; it is based on a 
database of human protein-protein, protein-DNA, protein compound 
interactions and metabolic and signaling pathways for human, mouse and 
rat. MetaCore software (from GeneGo Inc., St. Joseph, MI, USA) includes 
tools for data visualization, mapping, biological networks and an 
interactome  (interaction among genes).  
MetaCore analysis of large gene sets consists of an enrichment analysis of 
matching gene IDs with their functional ontologies. The ontologies include 
GeneGo Pathways Maps, GO Processes, GeneGo Process Networks and 
GeneGo Diseases and the relevance to different categories is defined by P-
values.  
GeneGo Pathway Maps (Figure 4.5) represent a set of consecutive signals 
confirmed by experimental data or inferred relationships from the 
literature. The main goal of this analysis is to determine the 
interconnectivity between the different genes present in the given data set 
and how this is biologically relevant. About 70000 pathways are available 
in MetaCore software, more than those present in KEGG (±10000) and 
BioCarta (±5000); this is one of the major advantage of this system. 
The GO Process organizes networks (graphical representation showing 
nodes connected by edges) in a hierarchical structure according to gene 
ontology (Figure 4.6).  The GeneGo Process Network is a network model 
of the main cellular processes created on the base of GO Processes and 
GeneGo Pathway Maps. 
GeneGo Diseases is based on the classification of Medical Subject 
Headings (MeSH) and allows the researcher to identify in biomarkers 
corresponding to different diseases in any gene set. 




Figure 4.4  References for figure 4.6 and 4.7




Figure 4.5 Example of GeneGo Pathways Maps 
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Figure 4.6 Example of GeneGo Process networks: Green arrow indicate 
positive activation, red arrow negative activation, gray arrow unspecified link. A 
Red dot indicates that that gene is down-regulated
	   114	  
 
4.2.1.5 Microarray data visualization: Spotfire DecisionSite 
Spotfire DecisionSite (http://spotfire.tibco.com/) was used by the CVS 
Bioinformatics Team (Dr Donald Dunbar) to plot gene expression data. 
Data were plotted on log (base 2) intensity and log (base 2) ratio levels. 
Genes were coloured by significance in the Rank Products statistical test: 
genes with a P-value less than the 0.05 threshold were coloured red. In 
addition, several genes of interest were marked by their gene symbol. 
Genes below the general expression threshold (ie those expressed in less 
than 100 intensity units throughout the experiment) were excluded from 
the plots. 
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4.3 Results 
4.2.1 Effect of HF diet and pregnancy on the mesenteric fat 
transcriptome. 
Microarray analysis using the Affymetrix Mouse Genome 430 2.0 
GeneChip revealed that a large number of genes with a Rank Product P-
value <0.05 expression level >100 and fold change > ±1.5, were 
differentially up-regulated or down-regulated in adipose tissue of HF 
pregnant mice compared with HF non pregnant or control pregnant mice. 
In general in our microarray study we observed significant variability in 
gene expression levels within each  group of mice, however we were able 
to identify 112 up-regulated and 184 down-regulated genes in HF pregnant 
compared with HF non pregnant, and 89 up-regulated genes and 437 
down-regulated genes in HF pregnant compared with control pregnant 
mice(Table 4.1). Some of these genes were up-regulated or down-
regulated in more than one comparison, the number of genes with similar 
direction of change in any two comparisons are shown in Table 4. 2. These 
finding suggest that some of the genes changes identified in our study were 
not uniquely due to pregnancy and/or to a high fat diet (Table 4.2).  
Spotfire DecisionSite was used to plot gene expression values by the CVS 
Bioinformatics Team (Dr Donald Dunbar). Figure 4.7A represents Log 
(base 2) ratios of gene expression intensities in pregnant and non-pregnant 
mice on the high fat and control diets. The y-axis shows the comparison of 
pregnant and non-pregnant strains, regardless of diet. The x-axis compares 
high fat and control diets regardless of pregnancy status. Red spots 
represent genes that are significantly differentially expressed in pregnant 
mice on high fat diet compared to control diet. Several genes of interest 
with higher expression in pregnant mice (compared to non pregnant) and 
on a high fat diet (compared to control diet) are marked and labelled. 
Figure 4.7B and C, shows Log (base 2) gene expression intensities in (B) 
Pregnant mice and (C) Non-pregnant mice on the high fat and control 
diets. For each strain, the y-axis shows the log2 expression in high fat fed 
mice. The x-axis is for control diet. Red spots represent genes that are 
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significantly differentially expressed in high fat diet compared to control 
diet for each pregnancy status. Several genes of interest discussed in the 
text are marked and labelled on graphs. Genes expressed below the 
arbitrary threshold (100) throughout the experiment were removed for 
clarity. 
 
Table 4.1 Number of up-regulated and down-regulated genes in our 
comparisons 
 
Groups Up-regulated Down-regulated 
HF non pregnant vs control non pregnant ↑ 526 genes ↓ 274 genes 
Control pregnant vs Control non pregnant ↑ 62 genes ↓ 85 genes 
HF pregnant vs HF non pregnant ↑ 112 genes ↓ 184 genes 
HF pregnant vs control pregnant ↑ 89 genes ↓ 437 genes 
 
 
Table 4.2 Number of up-regulated and down-regulated genes in more than 
one comparison 
 
Groups Up-regulated overlapping genes  
Down-regulated 
overlapping genes 
HF non pregnant vs control non pregnant  
and  
Control pregnant vs Control non pregnant 
38 31 
HF non pregnant vs control non pregnant  
and  
HF pregnant vs HF non pregnant 
13 61 
HF non pregnant vs control non pregnant  
and  
HF pregnant vs control pregnant 
26 165 
Control pregnant vs Control non pregnant  
and  
HF pregnant vs HF non pregnant 
15 12 
Control pregnant vs Control non pregnant  
and  
HF pregnant vs control pregnant 
10 15 
HF pregnant vs HF non pregnant  
and  





	   117	  
 
 
Figure 4.7 Spotfire DecisionSite: A. Log (base 2) ratios of gene expression 
intensities in pregnant and non-pregnant mice on the high fat and control diets. 
The y-axis shows the comparison of pregnant and non-pregnant strains regardless 
of diet. The x-axis compares high fat and control diets regardless of pregnancy 
status. Red spots represent genes that are significantly differentially expressed in 
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pregnant mice on high fat diet compared to control diet. Several genes of interest 
with higher expression in pregnant mice and on a high fat diet are marked and 
labelled. B. and C. Log (base 2) gene expression intensities in (B) Pregnant mice 
and (C) Non-pregnant mice on the high fat and control diets. For each strain, the 
y-axis shows the log2 expression in high fat fed mice. The x-axis is for control 
diet. Red spots represent genes that are significantly differentially expressed in 
high fat diet compared to control diet for each pregnancy status. Several genes of 
interest discussed in the text are marked and labelled on graphs. Genes expressed 




4.2.1.1. Broad gene expression changes 
When the altered genes were analysed with DAVID, WebGestalt and 
Metacore, the most significantly up-regulated genes (Table 4.3), in HF 
E18.5 pregnant mice compared to HF non pregnant animals, were those 
associated with changes in adipose tissue morphology, in particular 
vascular remodelling (Thbs1, Thbs2, MMP11), production of secreted 
proteins (IGF1 and IGFBP3) and estrogenic signalling (ERα and 
HSD17β12). The most significantly down-regulated transcripts (Table 
4.3), in HF E18.5 pregnant mice compared to HF non pregnant animals, 
included genes involved in de novo lipogenesis and lipid storage (ME1, 
FASN, SCD1 and Dgat2), cholesterol biosynthesis (Dhcr24, Dhcr7 and 
ApoA1), inflammation (MCP1, TNFα, Ccl8, Igh and Orm1) and retinol 















Pathway Gene symbol Gene name Mean fold difference 
Igf1 Insulin growth factor 1 1.6 Secreted protein 
Igfbp3 Insulin growth factor binding protein 3 3.1 
Thbs1 Thrombospondin 1 1.5 
Thbs2 Thrombospondin 2 1.9 
Vascular 
remodelling 
Mmp 11 Matrix metalloproteinase 11 1.8 
Esr1 (ERα) Estrogen receptor α 1.4 Estrogenic 
signalling 




Pathway Gene symbol Gene name Mean fold difference 
ME1 Malic enzyme 1 -2.9 
FASN Fatty acid synthase -2.3 
SCD1 stearoyl-CoA desaturase 1 -1.4 
de novo lipogenesis 
and lipid storage 
Dgat2 diacylglycerol O-acyltransferase 2 -2.2 
Dhcr 24 24-dehydrocholesterol reductase -1.9 
Dhcr 7 7-dehydrocholesterol reductase -2.7 
Cholesterol 
Biosynthesis 
ApoA1 Apolipoprotein A1 -5.9 
Mcp1 Monocyte chemotactic protein1 -1.3 
TNFα Tumor necrosis factor α -1.1 
Ccl8 Chemokine (C-C motif) ligand 8 -1.8 
Igh immunoglobulin heavy locus -2.8 
Inflammation 
Orm1 orosomucoid 1 -8 
Rbp4 Retinol binding protein 4 -2.7 Retinol metabolism 
Taldo transaldolase 1 -1.2 
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Up-regulated genes 
Rdh11 retinol dehydrogenase 11 -1.6  
Retsat retinol saturase -1.2 
 
Table 4.3 Selected differentially expressed genes in visceral adipose tissue 
from HF E18.5 pregnant compared to HF non pregnant animals. Highly up 
or down-regulated pathways are listed along with individual genes. Fold changes 
between these two groups are shown for clarity. Pathways/fold changes were 
analysed with David, Websgestalt and Metacore.
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4.2.2 qRT-PCR validation 
We performed qRT-PCR on the some of the genes shown in Table 4.3 to validate 
the differences observed by micro-array. Overall there was a high level of 
congruency between microarray data and qRT-PCR measurement of transcript 
levels. We performed qRT-PCR in both mesenteric and subcutaneous fat to 
determine whether pathways that were different in the different groups of the 
microarray were specific to the mesenteric depot, or also changed in the 
subcutaneous fat. Microarray validation was conducted in our four experimental 
groups, non pregnant and E18.5 pregnant both control and HF animals; 
additionally mRNA levels of selected genes were measured also at E14.5 to 
determine whether the changes happened at an earlier stage of pregnancy where 
the reduction in mesenteric fat expansion was also observed. We observed that 
some of the genes validated as differentially expressed had increased expression 
levels at E14.5 compared to non pregnant and E18.5 groups reducing the power of 
statistical analysis. In case of statistical significance differences between the 
analysis performed with or without the E14.5 groups, we will present also the 
results of the two-way ANOVA performed comparing only non pregnant and 
E18.5 pregnant both control and HF mice.  
Ten of thirteen selected differentially expressed genes were found to be 
significantly differentially expressed by qRT-PCR.  
In the following paragraphs the results of microarray validation will be presented 
dividing our results depending on the function/pathways in which the genes 
presented belong. 
 
4.2.2.1 Secreted Protein 
The increased mesenteric adipose tissue IGFBP3 mRNA levels by E18.5 in HF 
pregnant mice, was confirmed by qRT-PCR (Figure 4.8.A). Furthermore, IGFBP3 
mRNA levels were elevated by E14.5 in HF pregnant mice compared to control 
pregnant mice at the same gestational age (Figure 4.8.A). IGFBP3 was also 
elevated in the subcutaneous fat depot of E14.5 HF pregnant mice compared to 
both the other HF fed group and E14.5 control pregnant mice (Figure 4.8.D), 
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moreover it was also increased in HF E18.5 pregnant mice compared to control 
mice at the same gestational age.  
The up-regulation of IGF1 gene expression in mesenteric fat in E18.5 HF 
pregnant mice compared to HF non pregnant mice was confirmed by qRT-PCR 
(Figure 4.8B). Furthermore, IGF1 gene expression levels were observed to be 
increased by E14.5 in HF pregnant mice compared to other HF groups and 
compared with E14.5 control pregnant animals (Figure 4.8B). IGF1 mRNA was 
lower in subcutaneous fat depot of both control and HF pregnant mice compared 
to the respective non pregnant group; however this decrease was gradual in HF 
pregnant animals compared to control pregnant mice (Figure 4.8E). 
We also quantified adipose leptin mRNA in order to correlate gene expression 
with circulating levels presented in 3.3.3. Leptin was up-regulated in mesenteric 
fat in HF pregnant mice at E14.5 compared with control mice at the same 
gestational stage and E18.5 HF pregnant mice (Figure 4.8C). Mesenteric fat leptin 
gene expression was also found to be decreased in HF E18.5 pregnant mice 
compared to HF non pregnant animals. In subcutaneous fat, leptin mRNA levels 
were greater in HF non pregnant mice compared to controls; pregnancy gradually 
decreased expression levels of this gene in HF animals at E14.5 and further down-






Figure 4.8 mRNA levels of IGFBP3, IGF1 and Leptin: A, B and C mRNA expression 
levels in mesenteric fat; C, D and F mRNA expression levels in subcutaneous fat. Data 
analysed using two-way ANOVA *=P<0.05, **P≤0.01, ***P≤0.001; c =comparison 
between HF E18.5 pregnant mice and HF non pregnant mice [c=P<0.05, ccc=P<0.001], d 
=comparison between HF18.5 pregnant mice and control E18.5 pregnant animals 






4.2.2.2 Estrogenic signalling  
The increased ERα mRNA level in E18.5 HF pregnant mice highlighted in our 
microarray was confirmed by qRT-PCR. ERα mRNA levels was higher in 
mesenteric fat of HF fed E18.5 pregnant mice compared with HF non pregnant 
animals (Figure 4.9A). However no difference was found between  E14.5 HF 
pregnant and other HF groups  (Figure 4.9A).  ERα mRNA levels were down-
regulated in subcutaneous fat of HF non pregnant mice compared with control non 
pregnant, and by pregnancy in both HF fed and control fed animals (Figure 4.9D). 
ERα was detected in the nucleus of adipocytes (Figure 4.9G). 
Additionally we investigated mRNA expression levels of ERβ, another estrogen 
receptor isoform, in order to understand if the changes in estrogen receptor gene 
expression were specific only for the α isoform or affected the estrogen receptor 
pathway at a broad level. ERβ transcript levels were higher in HF mice at E14.5 
compared with control pregnant at the same gestational stage (Figure 4.9B) and 
lower at E18.5 in control pregnant animals compared to control non pregnant 
animals (Figure 4.9B). Furthermore subcutaneous fat ERβ mRNA levels were 
greater at E14.5 in HF pregnant mice compared to HF non pregnant and E18.5 
pregnant mice (Figure 4.9E) and by E18.5 in control pregnant mice compared to 
control non pregnant animals (Figure 4.9E). Moreover ERβ gene expression levels 
were decreased in  HF E18.5 pregnant mice compared to control pregnant animals 
at the same gestational age (Figure 4.9E) 
The increased HSD17β12 mRNA levels by E18.5 in HF pregnant mice observed 
in our microarray were not confirmed by qRT-PCR (Figure 4.9C). Furthermore at 
E14.5 we observed greater up-regulation of the transcript levels of this genes in 
both HF and control pregnant mice compared with non pregnant and E18.5 HF 
pregnant animals (Figure 4.9C).  HSD17β12 mRNA levels were decreased in both 
non pregnant and E18.5 pregnant HF mice compared to respective control groups; 
and increased in E18.5 control pregnant animals compared to control non 
pregnant mice (Figure 4.9C). HSD17β12 mRNA levels were down-regulated in 
subcutaneous fat of HF non pregnant mice compared with control non pregnant, 
and by pregnancy in both control fed, starting from E14.5, and HF fed animals at 
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E18.5 (Figure 4.9F). By E18.5 we observed a decreased expression levels of this 







Figure 4.9 mRNA levels of ERα, ERβ and HSD17b12: A, B and C mRNA expression 
levels in mesenteric fat; D, E and F mRNA expression levels in subcutaneous fat. Data 
analysed using two-way ANOVA *=P<0.05, **P≤0.01, ***P≤0.001; ∞ =effect of diet in 
two way ANOVA statistical analysis [∞ =P<0.05],  a =comparison between HF non  

















































































































































































pregnant mice and control non pregnant mice [a=P<0.05], b =comparison between E18.5 
control pregnant mice and control non pregnant mice [b=P<0.05], c =comparison 
between E18.5 HF pregnant mice and HF non pregnant mice [c=P<0.05], d =comparison 
between HF18.5 pregnant mice and control E18.5 pregnant animals [d=P<0.05, 
dd=P<0.01]  (n=8 in each group). G representative image of ERα  (in brown) expression 
in adipocytes (marked with blue) nucleus 
 
4.2.2.3 de novo lipogenesis and lipid storage  
The decreased mesenteric adipose tissue ME1 mRNA levels in HF mice compared 
with control mice suggested by micro-array was confirmed by qRT-PCR (Figure 
4.10A). Furthermore, ME1 mRNA levels were increased in control pregnant mice 
at E14.5 compared to the others control groups (non pregnant and E18.5) (Figure 
4.10A). ME1 was lower in the subcutaneous fat depot of HF non pregnant mice 
compared to control mice at all time points. Additionally, in both control and HF 
fed mice ME1 levels were lower in pregnancy compared with the non pregnant 
group (Figure 4.10F). 
Similar to ME1, the lower mesenteric adipose tissue FASN mRNA levels in HF 
mice compared to control was confirmed by qRT-PCR (Figure 4.10B). These 
differences were maintained in pregnancy compared with gestation matched 
controls. Furthermore, FASN mRNA levels were greater in control pregnant mice 
at E14.5 compared to the others control groups (non pregnant and E18.5) (Figure 
4.10B). FASN was also lower in the subcutaneous fat depot of HF fed mice 
compared to control mice and further decreased by pregnancy in control fed mice 
(Figure 4.10G). 
The lower mesenteric adipose tissue SCD1 mRNA levels in HF fed mice 
compared controls was confirmed by qRT-PCR (Figure 4.10C). Furthermore, 
SCD1 mRNA levels were increased in control pregnant mice at E14.5 compared 
to the others control time points (Figure 4.10C).  SCD1 mRNA levels were lower 
in HF E14.5 pregnant mice compared to E18.5 HF pregnant animals. SCD1 gene 
expression levels were also lower in the subcutaneous fat depot of pregnant mice 
compared to diet matched non pregnant controls, with a further decrease between 
E14.5 and E18.5 in the HF group (Figure 4.10H). 
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The lower mesenteric adipose tissue Dgat2 mRNA levels by E18.5 in HF 
pregnant mice compared to HF non pregnant and E18.5 control pregnant animals 
was confirmed by qRT-PCR (Figure 4.10D). Furthermore, Dgat2 mRNA levels 
were down-regulated also by E14.5 in HF pregnant mice compared to control 
pregnant mice, and increased in control pregnant mice at E14.5 compared to the 
others control groups (Figure 4.10D). Dgat2 was also decreased in the 
subcutaneous fat depot of pregnant mice treated with both control and HF diet 
compared to the non pregnant animals, with a further decline from E14.5 to E18.5 
in HF mice (Figure 4.10I). 
The elevated PPARα mRNA levels in HF compared with control mice were not 
validated by RT-PCR. (Figure 4.10E) in fact no statistical significant changes 
were observed within our groups in either mesenteric fat or subcutaneous fat 






Figure 4.10 mRNA levels of ME1, FANS, SCD1, Dgat2 and PPARα: A, B, C, D and E 
mRNA expression levels in mesenteric fat; F, G, H, I and L mRNA expression levels in 
subcutaneous fat. Data analysed using two-way ANOVA *=P<0.05, **P≤0.01, 
***P≤0.001; a =comparison between HF non  pregnant mice and control non pregnant 
mice [a=P<0.05], c =comparison between HF E18.5 pregnant mice and HF non pregnant 
mice [c=P<0.05, ccc=P<0.001], d =comparison between HF18.5 pregnant mice and 
control E18.5 pregnant animals [d=P<0.05] (n=8 in each group) 
 
4.2.2.4 Retinol metabolism 
One of the pathways that we observed changing in our microarray analysis was 
that of retinol metabolism. In order to validate the changes in the expression of 
genes involved in this signal pathways we performed qRT-PCR for the two genes 
that showed the highest fold change difference in HF pregnant mice by E18.5, 
namely Rbp4 and Rdh11. Additionally, we determined plasma concentration of 
Rbp4 using western bloting (section 4.2.3). 
The decreased mesenteric adipose tissue Rbp4 mRNA levels in E18.5 pregnant 
both control and HF fed compared with the respective non pregnant groups was 
confirmed by qRT-PCR (Figure 4.11A). Furthermore Rbp4 mRNA was increased 
in by E14.5 in HF pregnant mice (Figure 4.11A) compared to non pregnant and 
E18.5 HF mice. Rbp4 was also decreased in the subcutaneous fat depot of 
pregnant mice treated with both control and HF diet with a further fall between 
E14.5 and E18.5 in HF pregnant mice (Figure 4.11C).  
The lower mesenteric adipose tissue Rdh11 mRNA levels in HF fed mice 
compared to control fed animals was confirmed by qRT-PCR (Figure 4.11B). 
However no difference were observed in subcutaneous fat Rdh11 gene expression 





Figure 4.11 mRNA levels of Rbp4 and Rdh11: A and B mRNA expression levels in 
mesenteric fat; C and D mRNA expression levels in subcutaneous fat. Data analysed 
using two-way ANOVA *=P<0.05, **P≤0.01, ***P≤0.001; b =comparison between 
E18.5 control pregnant mice and control non pregnant mice [b=P<0.05], c =comparison 





Some of the major changes highlighted by the microarray analysis were in 
inflammatory pathways. In order to validate the changes in the expression of 
inflammatory genes we performed qRT-PCR for MCP1 and TNFα transcript 
levels (see 1.2.5.5). Additionally, we determined the percentage of pro-
inflammatory macrophages in adipose tissue using flow cytometry (section 4.2.4). 
The lower mesenteric adipose tissue MCP1 mRNA levels in HF pregnant mice 
compared with non pregnant was confirmed by qRT-PCR (Figure 4.12A). 
Furthermore we observed a trend of decreased MCP1 mRNA by E14.5 in HF 
pregnant mice compared to HF non pregnant (Figure 4.12B), however this was 
not statistically significant (Figure 4.12A). In contrast, subcutaneous fat MCP1 
mRNA was increased by E14.5 in HF pregnant mice compared with HF non 
pregnant and E14.5 control pregnant mice, but decreased in E18.5 HF pregnant 
mice compared with HF non pregnant mice (Figure 4.12C). 
The decreased mesenteric adipose tissue TNFα mRNA levels in HF pregnant mice 
was suggested by qRT-PCR, however it did not reach statistical significance 
(Figure 4.12B).  In contrast, pregnancy increase subcutaneous fat TNFα mRNA in 





Figure 4.12 mRNA levels of MCP1 and TNFα: A and B mRNA expression levels in 
mesenteric fat; C and D mRNA expression levels in subcutaneous fat. Data analysed 
using two-way ANOVA *=P<0.05, **P≤0.01, ***P≤0.001 (n=8 in each group) 
 
4.2.3 Effect of HF diet and pregnancy on insulin resistance  
To further validate at protein levels the reduction in Rbp4 mRNA levels in E18.5 HF 
pregnant mice (compared to non pregnant HF controls) highlighted by our 
microarray and confirmed with qRT-PCR, we performed Rbp4 quantification in 
plasma using western blot. 
In agreement with our micro-array and qRT-PCR, plasma levels of this protein were 
found decreased in E18.5 HF pregnant mice compared to HF non pregnant animals 
(Figure 4.13A). However, in contrast with the qRT-PCR data we observed that 
plasma Rbp4 levels were greater in HF non pregnant mice compared to control non 






Figure 4.13 Plasma Rbp4 quantification A. quantification Rbp4 plasma levels, B. 
Representative image of Rbp4 western blot. Data analysed using two-way ANOVA 
*=P<0.05 (n=7 in each groups) 
 
 
4.2.4 Effect of HF diet and pregnancy on levels of pro-inflammatory 
adipose tissue macrophages 
To further validate and characterise the putative reduction in inflammatory gene 
mRNA levels we quantified the number of pro-inflammatory macrophages in 
adipose tissue.  We compared the percentage of cells expressing CD11b and CD11c 
(a marker of an M1-type proinflammatory macrophage, (Lumeng et al., 2007b; a) 
(Nguyen et al., 2007; Wu et al., 2010) (Zeyda et al., 2010; Zeyda and Stulnig, 2007)) 
present in gonadal fat in E18.5 pregnant and non pregnant mice both control fed and 
HF fed.  HF diet increased the number of stromal vascular fraction (SVF) cells in 
adipose tissue (Figure 4.14A) in both non pregnant and pregnant mice. We quantified 
the percentage of pro-inflammatory macrophages (CD11b+CD11c+) in gonadal fat as 
a surrogate marker for inflammation. HF diet increased the percentage of pro-
inflammatory macrophages in adipose tissue of non pregnant mice, as expected 
(Figure 4.10B) (Lumeng et al., 2007b; a) (Nguyen et al., 2007; Wu et al., 2010) 
(Zeyda et al., 2010; Zeyda and Stulnig, 2007). However, whilst pregnancy alone had 



















































































mice exhibited a significant decrease in adipose tissue macrophages compared to the 
non pregnant state (Figure 4.14B).  
 
Figure 4.14 Proinflammatory adipose tissue macrophages quantification A. SVF 
number and B. percentage CD11b+CD11c+ ATMs. Data analysed using two-way ANOVA 




We performed a microarray analysis of the transcriptome in mesenteric fat in 
order to understand the molecular mechanisms responsible for the decrease in 
mesenteric fat mass observed in HF pregnant animals, with this approach we 
aimed to generate a new testable hypothesis of the molecular mechanisms 
underlying the pregnancy effects on fat distribution.    
Microarray analysis of transcriptome levels in mesenteric fat allowed us a more 
extensive understanding of the gene changes responsible for the decreased 
mesenteric fat weight observed in HF pregnant animals. In HF pregnant mice, 
pathways analysis highlighted up-regulation of mRNA of genes associated with 
changes in adipose tissue morphology, in particular vascular remodelling, 
production of secreted proteins and estrogenic signalling; and down-regulation of 
transcripts of proteins involved in in de novo lipogenesis and lipid storage, 
inflammation and retinol metabolism, compared with HF non pregnant and 
control pregnant animals. We performed microarray validation with qRT-PCR on 
mesenteric fat transcript levels.  Moreover we also investigated the gene 
expression levels of selected genes in another time point during pregnancy, E14.5, 
in order to understand which of these changes where occurring by the end of 
pregnancy and which were already present at E14.5. We subsequently validated 
our microarray using qRT-PCR in both mesenteric and subcutaneous fat in order 
to understand if the changes in gene expression levels, observed with this 
approach, were depot specific. Subcutaneous fat showed a different gene 
expression profile, for all the genes considered, compared to mesenteric fat. In 
general pregnancy decreased mRNA levels for the majority of genes considered in 
both controls and HF pregnant mice in the subcutaneous fat depot. This finding 
suggests tissue specificity for the changes highlighted in mesenteric fat and it 
underlies the importance of mesenteric fat changes, in terms of fat weight and 
gene expression, for the metabolic effect already presented in Chapter 3. 
 
4.4.1 Secreted Protein 
The increase in IGF1 mRNA an important protein involved in adipogenesis 
(Christoffersen et al., 1998; Smith et al., 1988), in mesenteric fat of HF fed 
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animals at E14.5 compared with controls and other HF fed groups, suggests an 
increase in adipogenic stimuli in HF pregnant mice at E14.5. IGF1 can be bound 
by different IGF-binding proteins, such as IGFBP3: mesenteric fat IGFBP3 
mRNA was increased in HF mice at the two stages of pregnancy considered, 
suggesting that the quantity of free IGF1 protein change during pregnancy, with a 
peak at E14.5. The comparison between changes in mesenteric and subcutaneous 
expression levels of these genes, highlights the tissue specific importance of the 
pathways revealed by the microarray study, as the changes in temporal expression 
of IGFBP3 and IGF1 mRNA were different the two depots. In mesenteric fat we 
observed an greater availability of IGF1 mRNA, and possibly its free protein, in 
non pregnant HF mice and at E18.5 of pregnancy, in subcutaneous fat the 
expression level of this gene is decreased by pregnancy. 
We also investigated leptin mRNA levels in order to understand if the increased 
plasma leptin levels observed in pregnant mice was mainly due to an increase 
transcription of this gene in adipose tissue (either mesenteric or subcutaneous) or 
to other possible sources of this protein, such as placenta (Hoggard et al., 1997). 
In mesenteric fat, leptin mRNAs in HF mice were greater at E14.5 pregnant mice 
compared to both HF non pregnant and E18.5, and was decreased at the last stage 
of pregnancy considered compared to non pregnant mice. Although in 
subcutaneous fat, leptin mRNA levels were higher in HF compared with control 
animals, in non pregnant and E14.5 pregnant mice, expression levels of this gene 
decreased as pregnancy advanced. Adipose tissue expression of leptin mRNA did 
not correlate with circulating protein level (chapter 3), suggesting that other sites 
such as the placenta could contribute to plasma level of this protein in pregnancy 
(Hoggard et al., 1997). 
 
4.4.2 Estrogenic signalling 
One of the pathways that was highlighted in our microarray analysis is estrogenic 
signalling. 
ERα mRNA expression levels were higher (Ct 26.2±0.1) compared to ERβ mRNA 
levels (Ct 36.2±0.1) suggesting a likely involvement of ERα but not ERβ in the fat 
redistribution observed in HF pregnant mice (see Chapter 1). ERα gene expression 
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was increased by the end of pregnancy in HF mice (Figure 4.5A), however no 
differences were identified on mesenteric fat ERα gene expression between E14.5 
pregnant mice and the other HF groups. Estradiol plasma levels in C57BL/6 mice 
were higher at E18.5 compared with E14.5 (Chapter3), suggesting a possible 
increase in ligands for this receptor (and hence receptor activation) by the end of 
pregnancy. We were able to detect ERα at protein levels in adipocytes nucleus, 
however the quantification of this protein in our six groups still needs to be done. 
In addition to ERα, we found changes in HSD17b12 expression; this protein has 
been shown to be the major isoform for the HSD17b family in the conversion of 
estrone to estradiol in adipose tissue (Bellemare et al., 2009). The increase in gene 
expression of HSD17b12 at E14.5 could be important in increasing local estradiol 
generation at this stage of pregnancy increasing the quantity of ERα ligand at 
E14.5.  
 
4.4.3 de novo lipogenesis and lipid storage 
One of the major pathways affected in our microarray in HF fed mice and in 
particular in HF pregnant animals was de novo lipogenesis and lipid storage. 
Dgat2 expression levels were down-regulated in E18.5 HF pregnant mice in 
mesenteric fat compared to E18.5 control pregnant mcie, suggesting that HF 
pregnant animals would have a decreased ability to store triglycerides by this 
gestation. In subcutaneous fat, pregnancy decreased Dgat2 gene expression levels 
in both control fed and HF fed mice. Adipocyte primary culture, presented in 
Chapter 3 (see 3.3.3), revealed an increase in lipolysis rate in adipocytes from 
obese pregnant mice compared with control animals: suggesting that not only is 
lipid formation and storage inhibited in our HF-pregnancy model but also that HF 
pregnant mice are releasing more lipids compared with controls.  These data are 
consistent with insulin resistance in the adipose tissue, observed using Phospho-
PKB levels after insulin stimulation (see 3.3.7). Decreased triglyceride storage, 
suggested by decreased Dgat2 mRNA levels in HF pregnant mice, may explain 
the decreased fat mass expansion, in particular the decreased mesenteric fat, in HF 
pregnancy described in chapter 3. Unchanged ME1 and FASN mRNA levels 
between non pregnant and pregnant HF mice supports the idea that insulin 
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resistance observed in HF pregnant and non pregnant mice is responsible for the 
decrease in de novo lipogenesis in obese animals. However SCD1 transcription 
levels showed decreased gene expression at the late stage of pregnancy suggesting 
a contribution of pregnancy in the down-regulation of this pathway. However, 
adipocyte size (see 3.3.3) does not change between HF non pregnant and pregnant 
mice, indicating a balance between fat accumulation and release in adipocytes 
from subcutaneous fat. 
 
4.4.4 Retinol metabolism 
Adipose tissue Rbp4 induce insulin resistance reducing PI3K signaling in muscle 
and increasing transcription of gluconeogenic enzyme phosphoenolpyruvate 
carboxykinase in liver via a retinol dependent mechanism (Yang et al., 2005). 
Genes involved in retinol biosynthesis were found by microarray analysis to be 
downregulated in HF animals in late pregnancy. These findings, together with 
decreased circulating insulin levels in HF animals in pregnancy (compared to the 
non pregnant state) would lead to a relative increase in insulin sensitivity in obese 
by E18.5 (or a decrease in the difference in insulin resistance between obese and 
lean) (Yang et al., 2005). This hypothesis is consistent with the lack of difference 
observed in oGTT between control pregnant and HF pregnant mice by E18.5 (see 
3.3.6).     
 
4.4.5 Inflammation 
Furthermore, microarray analysis highlighted decreases in inflammatory 
pathways: overall pregnancy suppresses adipose tissue inflammation otherwise 
typical of obesity. We confirmed the decreased inflammatory state of mesenteric 
fat in obese pregnant mice using qRT-PCR on MCP1 and TNFα transcription 
levels. Despite increased in subcutaneous fat mRNA levels of these two genes at 
E14.5, gene expression was found to be back to non pregnant levels by E18.5: 
suggesting a tissue specific temporary increase in these two inflammatory marker 
in subcutaneous fat. We have also investigated percentages of pro-inflammatory 
macrophage (CD11b+CD11c+) in gonadal fat (as a percentage of all SVF cells) – 
the decrease also confirmed at a cellular levels the attenuated adipose tissue 
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inflammation in pregnancy. Thus the decrease in adipose pro-inflammatory 
cytokine synthesis was mirrored (and perhaps caused) by decreased pro-
inflammatory macrophage content of gonadal fat in HF pregnant (versus non 
pregnant) animals. Reduced visceral fat accumulation of pro-inflammatory 
macrophages would be expected to improve whole body insulin sensitivity ((Xu et 
al., 2003)). 
 
Our current hypothesis, driven by the microarray analysis and validation, is that 
altered ERα activation/increased estradiol presence in mesenteric fat may be the 
underlying reason for the reduced fat mass, lipogenesis and improved 
inflammatory profile, and ultimately, effect a brake in expected increase 
worsening of insulin resistance in HF pregnant mice. Numerous studies suggest a 
crosstalk between IGF1 and ERα: Klotz et al indicated that IGF1 could mimic 
estradiol-independent ERα activation (Klotz et al., 2002), another study showed 
that E2-induced growth of endometrial carcinoma cells is mediated by IGF1 
autocrine stimulation (Kashima et al., 2009). These data taken together suggest 
that IGF1-ERα crosstalk is important in the phenotype that we discovered: during 
pregnancy the increased free IGF1 by the end of pregnancy and the increased 
HSD17b12 production at E14.5 could therefore contribute to increased activation 
of ERα throughout pregnancy in mesenteric fat. Moreover ERα in vitro up-
regulates also leptin expression levels (Yi et al., 2008): as we observed in our 
model mesenteric fat leptin mRNA was increased by E14.5 in HF pregnant mice 
and increased at plasma protein levels in all our pregnant groups in particular in 
HF E14.5 mice, suggesting a contribution from ERα activation in the production 
of these protein (Piermaría et al., 2003). Furthermore, it has been shown that ERα 
plays an important role decreasing triglycerides accumulation in vitro in 3T3-L1 
adipocytes (Homma et al., 2000) and in vivo estrodial treatment decreased 
lipogenesis and triglycerides storage in mice(Bryzgalova et al., 2008), suggesting 
that decreased in mesenteric fat Dgat2 in HF pregnant mice and the other genes 
involved in de novo lipogenesis in HF mice can be due to augmented ERα 
activation. To support our hypothesis, liver mRNA analysis in ERα deficient mice 
showed increased expression of lipogenic genes and decreased transcription levels 
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of genes involved in lipid transport (Bryzgalova et al., 2006). Furthermore, in 
another study estradiol treatment decreases transcription of FASN and Scd1 in 
liver of leptin deficient mice (Gao et al., 2006). ERα, has also effects on 
decreasing inflammation (extensively reviewed by (Brown et al., 2010)).  
Moreover, ERα knock-out mice are diabetogenic and obese with severe hepatic 
insulin resistance. Our animal model showed (3.3.7) no differences in the level of 
insulin resistance, measured using Ppkb as a marker of insulin signal pathway 
activation, between HF non pregnant mice and E18.5 HF pregnant animals, 
furthermore our GTT study (see 3.3.6) indicates that at by E18.5 HF animals have 
the same degree of insulin resistance compared to control mice suggesting 
therefore that the levels of insulin resistance at this stage of pregnancy are not 
abnormally high in HF mice. Moreover plasma AdiponectinHMW and leptin (3.3.4) 
levels in HF E18.5 pregnant mice were comparable with those of control mice at 
the same gestation, indicating that HF mice by the end of pregnancy do not have 
gestational diabetes (López-Tinoco et al., 2012). It should be considered that the 
increased ERα mRNA observed in HF pregnant mice is modest and there could be 
a contribution of ERα co-regulators in the observed phenotype, however no 
diffencences were observed in these in our microarray.   
In the next chapter we will focus on testing our hypothesis, that altered ERα 
activation/increased estradiol presence in mesenteric fat may be the underlying 
reason for the reduced fat mass, lipogenesis and improved inflammatory profile, 
and ultimately, effect a brake in expected increase worsening of insulin resistance 
in HF pregnant mice, and try to understand the molecular pathways which link the 
increased activation of ERα and the reduced fat mass, lipogenesis and improved 
inflammatory profile, and ultimately, attenuates the expected increase in insulin 
resistance in pregnancy. 
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Estrogen and its receptors (ER) play an important role in fat distribution and body 
weight. ERα knock-out mice are diabetic and obese, with severe hepatic insulin 
resistance in the absence of any difference in energy intake (Heine et al., 2000). In 
contrast, ERβ deficient mice display improved glucose tolerance and insulin 
sensitivity and no change in body fat content (Foryst-Ludwig et al., 2008), 
suggesting that ERα plays an important role in regulating metabolic homeostasis 
through adipose tissue biology. ERα and β are expressed in both subcutaneous and 
visceral fat tissues; however, ERβ appears to be preferentially present in 
subcutaneous adipose (Pedersen et al., 2001). ERs are predominantly expressed in 
adipocytes rather than SVF ((Price and O'Brien, 1993; Mizutani et al., 1994)). 
However the major changes on adipocyte metabolism are principally due to ERα 
activation, examples of this are fully differentiated 3T3-L1 adipocytes stably 
transfected with ERα which show decreased triglyceride accumulation and 
reduced lipoprotein lipase LPL (fatty acid uptake into adipocytes) expression 
(Homma et al., 2000). 
The microarray pathway analysis data presented in chapter 4 highlighted the 
potential involvement of ERα in the phenotype of decreased mesenteric fat 
expansion, decreased lipogenesis, amelioration of adipose tissue inflammatory 
profile and constraint of glucose intolerance observed in HF pregnant animals. 
This led to the generation of the following hypothesis: that ERα activation in 
adipocytes is the underlying mechanism for the reduced fat mass and decreased 
lipogenesis, improved inflammatory profile in HF pregnant mice, and that ERα 
activation ultimately effects a brake on the worsening of insulin resistance in these 





• To investigate the effect of ERα activation on mRNA expression of 
key genes of de novo lipogenesis, IGF pathway, retinol metabolism 
and estrogenic signaling in fully differentiated Chub-S7 adipocytes. 
• To investigate the effect of ERα activation on mRNA expression of 
key genes of de novo lipogenesis, IGF pathway, retinol metabolism 





5.2 Experimental design 
Chub-S7 cells were propagated and differentiated (see section 2.3.2).  We treated 
fully differentiated cells with increasing concentrations of a selective ERα agonist, 
PPT (see section 2.3.2). Levels of mRNA for genes identified as altered in the 
microarray study (chapter 4) involved in estrogenic signaling, IGF pathway, 
retinol metabolism and de novo lipogenesis were quantified using qRT-PCR 
(n=6). Expression of ERα and β protein was investigated using western-blot in 
Chub-S7 cells (see section 2.12.1). Primary adipocytes from obese and lean 
pregnant women (see section 2.2) were treated with increasing concentrations of 
PPT (see section 2.3.1 and 2.3.1.2). mRNA expression of genes involved in 
estrogenic signaling, IGF pathways, retinol metabolism and de novo lipogenesis 






5.3.1 ERα and ERβ protein levels in fully differentiated Chub-S7  
ERα and ERβ protein levels were investigated in fully differentiated Chub-S7 
cells to demonstrate the presence of the receptors in question. Both ERα and ERβ 
proteins were present. ERβ protein was more readily detectable compared to ERα 
(Figure 5.1) when corrected for the internal control suggesting that ERβ is more 
abundant in the fully differentiated Chub-S7 adipocyte. However, it needs to be 
considered that the Chub-S7 cell line is derived from subcutaneous fat (Darimont 
et al., 2003) where ERβ is preferentially expressed (Pedersen et al., 2001). To 
account for this issue an extremely selective ERα agonist (PPT; (Stauffer et al., 




Figure 5.1 ERα and ERβ protein levels in fully differentiated Chub-S7, ***P≤0.001 
(n=6 in each groups) 
 
5.3.2 Effect of PPT treatment on fully differentiated Chub-S7  
Fully differentiated Chub-S7 were treated with 1nM, 10nM, 100 nM or 1µM of 
the selective ERα agonist PPT or a vehicle control (0.4% DMSO). Expression 
levels of various genes involved in estrogenic signalling, retinol metabolism, IGF 
signalling, triglyceride storage and de novo lipogenesis was quantified. PPT 
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down-regulated the majority genes with maximal effects observed at the lowest 
concentration (Figures 5.2-5.4). 
 
 
5.3.2.1 Effect of PPT treatment on estrogenic signalling in fully 
differentiated Chub-S7 cells 
PPT treatment suppressed mRNA levels of the ERα gene maximally at 1nM 
(Figure 5.2A), but had no effect at the highest concentration. PPT did not have 
any effects on mRNA levels of the ERβ gene (Figure 5.2B). The effect of PPT on 
HSD17b12 mRNA levels was inconsistent, showing suppression at 1nM and 
0.1uM, but having no effect at 10nM and 1uM (Figure 5.2C).  
 
Figure 5.2 Effect of PPT treatment on mRNA levels of genes involved in estrogenic 
signalling in fully differentiated Chub-S7 (n=6 in each groups). A. ERα, B. ERβ and C. 
HSD17b12 (n=6 in each groups). Normality of data was calculated using Kolmogorv-
Smirnov test and statistical analysis was performed Kruskal-Wallis Test (Dunns: 




5.3.2.2 Effect of PPT treatment on IGF signalling in fully differentiated 
Chub-S7cells 
PPT suppressed mRNA levels of IGF1 and IGFBP3 gene comparably across the 
entire concentration range (Figure 5.3A and B).  
 
 
Figure 5.3 Effect of PPT treatment on mRNA levels of genes involved in IGF 
signalling in fully differentiated Chub-S7 (n=6 in each groups). A. IGF1 and B. 
IGFBP3 (n=6 in each groups). Normality of data was calculated using Kolmogorv-
Smirnov test and statistical analysis was performed Kruskal-Wallis Test (Dunns: 
comparison of pairs of columns). *=P<0.05 
 
5.3.2.3 Effect of PPT treatment on retinol metabolism gene mRNAs in 
fully differentiated Chub-S7 cells 
PPT treatment selectively suppressed RDH11 mRNA levels (Figure 5.4A) and 




Figure 5.4 Effect of PPT treatment on expression levels of genes involved in retinol 
metabolism in fully differentiated Chub-S7 (n=6 in each groups). A. Rdh11 and B. 
Rbp4 (n=6 in each groups). Normality of data was calculated using Kolmogorv-Smirnov 
test and statistical analysis was performed Kruskal-Wallis Test (Dunns: comparison of 
pairs of columns). *=P<0.05  
 
5.3.2.4 Effect of PPT treatment on genes for lipogenesis in fully 
differentiated Chub-S7 
PPT treatment decreased gene expression levels of ME1, FASN, SCD1 and Dgat2 





Figure 5.5 Effect of PPT treatment on mRNA levels of genes involved in lipogenesis 
in fully differentiated Chub-S7 (n=6 in each groups). A. Me1, B. FASN, C. SCD1 and 
D. Dgat2 (n=6 in each groups). Normality of data was calculated using Kolmogorv-
Smirnov test and statistical analysis was performed Kruskal-Wallis Test (Dunns: 
comparison of pairs of columns). *=P<0.05, **=P<0.01 and ***=P<0.001 
 
5.3.3 Effect of PPT treatment on visceral and subcutaneous adipocytes 
from lean and obese pregnant women 
To test the ERα hypothesis in the most relevant possible system, primary 
adipocytes were isolated from visceral and subcutaneous fat of obese and lean 
pregnant women (see 2.2) and treated with 1nM, 10nM, 100 nM and 1µM PPT or 
vehicle control. As before, levels of mRNA for genes involved in estrogenic 
signalling, retinol metabolism, IGF signalling, triglyceride storage and de novo 
lipogenesis were measured. PPT significantly suppressed SCD1 mRNA levels 
(Figure 5.6 A) in visceral adipocytes from lean pregnant women. Notably, 
differences in mRNA levels were observed between the lean and obese and 
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between visceral and subcutaneous adipocytes. No statistically significant effect 
of PPT was observed in any group for SCD1, FASN, Dgat2 and Rbp4 (Figure 
5.6B-H and Figure 5.8 A-H), ERα, HSD17b12, IGF1 and IGFBP3 (Figure 5.7 A-






Figure 5.6 Effect of PPT treatment on mRNA levels of genes in primary visceral 
adipocytes collected from lean (left graphs) and obese (right graphs) pregnant patient 
(n=5 in each groups). A and B SCD1, C and D FASN, E and F Dgat2, G and H Rbp4. 
Normality of data was calculated using Kolmogorv-Smirnov test and statistical analysis 





Figure 5.7 Effect of PPT treatment on mRNA levels of visceral primary adipocytes 
collected from lean (left graphs) and obese (right graphs) pregnant patient (n=5 in 
each groups). A and B  ERα, C and D HSD17b12, E and F IGF1, G and H IGFBP3. 
Normality of data was calculated using Kolmogorv-Smirnov test and statistical analysis 





Figure 5.8 Effect of PPT treatment mRNA levels of genes in primary subcutaneous 
adipocytes collected from lean (left graphs) and obese (right graphs) pregnant women 
(n=5 in each groups). A and B  SCD1, C and D FASN, E and F Dgat2, G and H Rbp4. 
Normality of data was calculated using Kolmogorv-Smirnov test and statistical analysis 




Figure 5.9 Effect of PPT treatment on gene expression levels of subcutaneous 
primary adipocytes collected from lean (left graphs) and obese (right graphs) 
pregnant patient (n=5 in each groups). A and B ERα, C and D HSD17b12, E and F 
IGF1, G and H IGFBP3. Normality of data was calculated using Kolmogorv-Smirnov 
test and statistical analysis was performed Kruskal-Wallis Test (Dunns: comparison of 






To test the hypothesis that ERα activation in adipocytes is the underlying 
mechanism for the reduced fat mass and decreased lipogenesis, improved 
inflammatory profile, and thereby ultimately effects a brake on the worsening of 
insulin resistance in HF pregnant mice, Chub-S7 cells were used.  
Treatment of Chub-S7 adipocytes with PPT suppressed ERα mRNA levels but not 
ERβ levels indicating that the activation of ERα has a selective negative feedback 
on its own mRNA expression levels, confirming that PPT is activating ERα but 
not ERβ. PPT decreased HSD17b12 (an enzyme involved in the conversion from 
estrone to estradiol (Bellemare et al., 2009)in adipocytes) at two of the four 
concentrations used in this study, supporting a negative feedback from ERα 
activation to estrogenic signaling in adipocytes.  
PPT treatment decreased mRNA levels of IGF1 and IGFBP3 in ChubS7 
adipocytes.  This refutes that hypothesis that ERα drives increased expression of 
this gene pathway in adipocytes, as indicated by the elevated IGFBP3 found by 
microarray in visceral (mesenteric) adipose tissue of HF-fed pregnant mice. 
However, it is likely that the IGF1 and IGFBP3 signaling system is more highly 
involved with the process of early preadipocyte differentiation (see 1.2.3, (Smith 
et al., 1988; Boney et al., 1994; Scavo et al., 2004; Grohmann et al., 2005; 
Holzenberger et al., 2001; Chan et al., 2009)). The increased IGFBP3/IGF1 
mRNA levels in the mesenteric fat of HF pregnant mice may reflect changes in 
cells of the SVFs, likely preadipocytes. Future studies using PPT treatment of 
differentiating Chub-S7 cells would address this possibility.  
PPT treatment down-regulated gene expression levels of RDH11 in fully 
differentiated Chub-S7, (with a trend to down-regulation of Rbp4) suggesting that 
selective ERα action has negative impact on retinol metabolism. RDH11 is a 
retinol dehydrogenase which converts retinol into retinal and vice versa, limiting 
therefore the intracellular concentration of retinol. Retinol can be then converted 
in adipose tissue into retinoic acids, a potent stimulator of the nuclear receptor 
RXR, which plays an important role in adipogenesis (see 1.2.3). In addition, 
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Rdh11 may play a major role in preadipocyte differentiation (Haeseleer et al., 
2002; Hamza et al., 2009) therefore future studies using PPT treatment of 
differentiating Chub-S7 cells would address the role of ERα activation on 
preadipocyte differentiation and also its effects on the relationship between   
IGF1/IGFBP3 and retinol metabolism in this condition.  
The trend of PPT treatment to down-regulate Rbp4 mRNA production is 
reminiscent of the reduction in Rbp4 mRNA and the decreased plasma Rbp4 
levels observed in mesenteric adipose tissue and plasma of HF E18.5 pregnant 
mice (see 4.2.2.4). This could contribute to the constraint of glucose intolerance in 
HF pregnant mice as Rbp4 can negatively affect glucose homeostasis (Yang et al., 
2005). However, changes in Rbp4 mRNA and protein levels do not correlate with 
PKB phosphorylation (see 3.3.7) suggesting that the effect of ERα activation on 
Rbp4 production in adipocytes has a paracrine effect on insulin resistance of other 
organs, but does not affect adipose tissue insulin resistance directly. Although it 
must be considered that the effect of PPT treatment on Rbp4 mRNA expression 
levels observed was non statistical significant, therefore the link between ERα 
activation and the repression of Rbp4 gene expression levels must be further 
proved with future experiments. 
PPT suppressed mRNA levels of genes in the lipogenic pathway, consistent with 
the reduced visceral fat mass in HF E18.5 pregnant mice.  These results are 
mechanistically consistent with suppression of hepatic lipogenesis by estradiol 
treatment (Gao et al., 2006). 
Although expected to be informative because they are derived from subcutaneous 
fat of a 33 years old obese female (Darimont et al., 2003)), Chub-S7 adipocytes 
expressed more ERβ protein levels than ERα, although in mesenteric fat  mRNA 
levels of ERα are much higher [ERα mRNA expression levels were higher (Ct 
26.2±0.1)] compared to ERβ mRNA levels (Ct 36.2±0.1) (see 4.2.2.2). It must be 
considered that ERβ is more highly expressed in subcutaneous fat (Pedersen et al., 
2001) compared to mesenteric (visceral) fat. Chub-S7 cells are derived from 
subcutaneous fat (Darimont et al., 2003) and therefore they could maintain the 
characteristic of the tissue of origin. In addition, Chub-S7 adipocytes failed to 
respond to the lipolytic agonist isoprenaline, despite their clear lipid droplet laden 
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morphology (NM Morton, unpublished). This suggests that Chub-S7 cells exhibit 
only partial, lipogenic characteristics of mature fat cells and results should 
therefore be interpreted cautiously. Another limitation of this approached is the 
lack of a known adipocytes specific genes which is transcribed following ERα 
activation; to overcome this problem transfection of cells with a estrogen 
responsive element (ERE) linked with luciferase will be useful to demonstrate that 
the changes in gene expression following PPT treatment, observed in this chapter 
are mediated by ERα activation and not by aspecific action of PPT. 
 
Due to the limitations of the Chub-S7 cells, the effect of PPT was subsequently 
tested in primary adipocytes collected from visceral and subcutaneous fat of lean 
and obese pregnant women. In visceral primary adipocytes from lean patients, 
PPT decreased SCD1 gene expression levels, confirming the result observed in 
Chub-S7 adipocytes. No statistically significant effect was observed for any other 
gene in any condition.  This may be primarily due to the lack of study power and 
the high variability found in gene mRNA levels in primary fat cells.  A power 
calculation, performed using Stata software, indicated that increasing the number 
of patient recruited for this study will give us a better chance to reach statistical 
significance for some of the genes considered (i.e. Rbp4 mRNA). Notably, 
primary adipocyte gene expression profiles differ between lean and obese, 
visceral and subcutaneous fat, suggesting tissue specific differences between 
visceral and subcutaneous fat and between lean and obese subjects.    
 
In summary the evidence presented in this chapter support to our hypothesis that 
altered ERα activation directly drives suppression of genes involved in 
lipogenesis and triglyceride storage. However to finally confirmed our hypothesis 
functional and in vivo study (see 7.2.1) must be performed. Moreover the 
experiments presented in this chapter were performed in mature adipocytes 
because the majority of the genes highlighted in our microarray are important in 
the metabolism of mature fat cells and it cannot be excluded that ERα activation 




Chapter 6: Effect of high fat diet in pregnancy on 
hepatic function and lipid content 
 
6.1 Introduction 
The liver undergoes dynamic physiological changes during pregnancy and can 
manifest pathological changes with obesity. Some liver abnormalities arise 
specifically in pregnancy. Obstetric cholestasis (or intrahepatic cholestasis of 
pregnancy) occurs in about 1 in 100 women, when bile acid excretion by the liver is 
reduced, leading to increased concentrations in the serum.  A rare condition is acute 
fatty liver of pregnancy (AFLP). It presents during the third trimester and post 
partum, and affects about 1/13,000–16,000 pregnant women (Pockros et al., 1984; 
Reyes et al., 1994). AFLP in contrast with non alcoholic fatty liver disease (NAFLD 
– see Chapter 1.2.11) has been linked to deficiencies in enzymes of fatty acid-
oxidation in the fetus that affect maternal fatty acid metabolism (Hepburn and 
Schade, 2008). 
 
6.1.1. The impact of visceral adiposity on hepatic function 
Excessive visceral adipose tissue plays an important role in the development of 
NAFLD. Increased delivery of free fatty acids, adipokines and hormones from the 
central fat depots via the portal vein directly to the liver (“portal theory”) (Nielsen et 
al., 2004) has a more immediate impact upon liver function than factors released 
from the peripheral fat depots. Stable isotope studies have shown that serum fatty 
acids released by adipose tissue are the main source of hepatic triglycerides in 
NAFLD (Donnelly et al., 2005) rather than hepatic de novo synthesis or direct uptake 
and storage from the diet. A recent study showed that intrahepatic lipids increased by 
104% for every 1% increase in intra-abdominal adipose tissue, but only by 21% for 
any 1% increase in subcutaneous fat (Thomas et al., 2005); underlining the close link 
between visceral adiposity and NAFLD. It has been suggested that increased fatty 
acid delivery from visceral fat to liver results in increased hepatic gluconeogenesis, 
triglyceride synthesis, very low density lipoprotein (VLDL) synthesis and release (a 
metabolic risk factor (Windler and Havel, 1985; Ginsberg et al., 1986)), elevated 
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hepatic glucose output through impairment of insulin signaling via PKC pathway, 
and oxidative stress with activation of NF-kB and subsequent production of 
cytokines (Cai et al., 2005). Another important source of triglycerides in liver is 
increased de novo lipogenesis. De novo lipogenesis is increased in the liver of 
subjects with NAFLD (Donnelly et al., 2005), although it accounts for a lower 
proportion of the accumulated lipid. This results from increased expression of the 
sterol regulatory element-binding protein (SREBP) 1c transcription factor that 
activates lipogenic genes such as acetyl-CoA carboxylase (ACC), FASN and SCD1 
(Higuchi et al., 2008; Kotronen et al., 2009). Subjects with increased liver fat content 
also present with increased adipose tissue inflammation (Makkonen et al., 2007) and 
increased adipose tissue ceramides (Kolak et al., 2007) (sphingolipids with metabolic 
functions, such as inflammation and insulin resistance). However the mechanisms 
that link NAFLD to increased adipose tissue inflammation, independent of obesity, 
are still unclear.  NAFLD is not the only condition that creates an enlargement in 
liver (hepatomegalia), other potential reasons for hepatomegalia are increased 
glycogen storage, hepatitis, iron deposition in liver, liver cancer or leukemia and 
infections, such as tuberculosis and mononucleosis.   
In parallel with decreased visceral fat mass and the possible increased delivery of 
free fatty acids released from visceral fat into the blood stream, we observed that our 
animal model of obesity in pregnancy exhibited increased liver weight that reached 
statistical significance  by E18.5 (see 3.3.2). In this chapter we aimed to investigate 
the underlying molecular basis of this phenomenon. 
 
Aims 
• To investigate the functional impact of high fat diet and pregnancy on liver 
metabolism 
• To determine the underlying molecular basis of altered liver function induced 





6.2 Experimental design 
Five week old C57BL/6 female mice were fed either with a HF diet (7) or a Control 
diet (8) for 12 weeks (see section 2.1.1). After this period, females were single-caged 
and mated with male mice whilst continuing the diet. To investigate the basis of the 
increased liver weight observed in section 3.3.2, liver triglycerides (see section 2.5.2) 
and liver glycogen (see section 2.5.1) content were quantified in pregnant mice at both 
E14.5 and E18.5 during pregnancy and compared with age-matched non-pregnant 
mice. In the same group of animals, mRNA expression of genes (Table 7.1) either 
involved in hepatic lipid and carbohydrate metabolism or related to the altered 
hormonal milieu and metabolic changes implicated in our adipose tissue microarray 










6.3.1 The effect of diet and pregnancy on liver triglyceride and 
glycogen content 
An increased liver weight was observed in pregnant animals, in particular in HF E18.5 
pregnant mice compared to HF non pregnant mice and control E18.5 pregnant animals 
(see 3.3.2). To investigate the possibility that this was due to altered hepatic lipid or 
carbohydrate metabolism indicative of NAFLD or GDM-like processes, we measured 
hepatic glycogen and triglyceride content. 
Maternal liver triglyceride content was increased at E14.5 and E18.5 in HF pregnant 
mice compared to HF-fed non pregnant and control diet-fed gestation-matched 
pregnant animals. In contrast, there was no significant difference in liver triglyceride 
levels between HF non -pregnant and control non-pregnant animals (Figure 6.1A).  
Liver glycogen content was lower in HF-fed E18.5 pregnant mice compared to 
control-fed E18.5 pregnant mice. No statistically significant differences were observed 
between non pregnant and pregnant mice within either the HF or the control group 




Figure 6.1 Liver triglyceride and glycogen A. liver triglyceride levels and B. liver 
glycogen. Data analysed using two-way ANOVA *=P<0.05, **P≤0.01, ***P≤0.001 (n=6 


















































6.3.2 The effect of diet and pregnancy on metabolic gene expression 
levels in liver. 
To determine possible molecular mechanisms underlying increased liver weight 
during pregnancy we performed qRT-PCR gene expression analyses of key genes 
(Table 6.1) either involved in hepatic lipid and carbohydrate metabolism or related to 
the altered hormonal milieu and metabolic changes implicated in our adipose tissue 





Table 6.1: List of genes analyzed in liver 
Pathway Gene Function Reference 
Component of very low 
density lipoprotein 
ApoCIII Triglyceride uptake in liver (Eckardstein and 
Holz, 1991) 
 
Gluconeogenesis Pepck converts oxaloacetate into 
phosphoenolpyruvate and 
carbon dioxide, a limiting step 





GPAT Catalyzes the first step during 
de novo synthesis of 
triacylglycerol 
(Cao et al., 2006) 
 
Cpt1a Regulatory enzyme in liver 
mitochondrial ß-oxidation 
of long-chain fatty acids 
(Akkaoui et al., 
2009) 
 
Me1 Converts malate into pyruvate (Shrago et al., 
1963) 
Fasn Converts Malonyl CoA into 
18:0 acids 
See 1.2.4 
Lipid biogenesis  
Dgat2 Responsible to store 
triglycerides  
See 1.2.4 
Erα Regulate glucose homeostasis 
in liver 
(Bryzgalova et al., 
2006) 
Erβ Other estrogen receptor  
Estrogen signaling  
Hsd17b12 Converts estone to estrodial (Bellemare et al., 
2009) 
Tnfα Drives steatohepatitis formation (Henao-Mejia et al., 
2012) 
Inflammation 
Mcp1 Upregulated in patients with 
steatohepatitis 









6.3.2.1 The effect of diet and pregnancy on gene of hepatic lipid 
metabolism 
Liver ApoCIII mRNA levels were greater in pregnant compared to the non pregnant 
control mice, however no difference was detected in HF mice at difference gestational 
ages compared to HF non pregnant controls (Figure 6.2A). By the end of pregnancy, 
ApoCIII mRNA levels were lower in HF E18.5 mice compare to control E18.5 animals 
(Figure 6.2A).  
No statistical significant differences were identified in Pepck gene expression levels in 
any of our groups (Figure 6.2B). Similarly, GPAT mRNA levels were comparable 
throughout pregnancy in both HF and control animals. However at E14.5 GPAT 
expression was lower in HF pregnant mice compared to controls (Figure 6.2C).  
CPT1a was elevated at E14.5 and E18.5 in HF pregnant mice compared to non pregnant  
HF control mice. In addition mRNA levels for this gene were increased in control 
pregnant mice at E14.5 compared to both control non pregnant and control E18.5 
pregnant mice (Figure 6.2D). During pregnancy CPT1a mRNA levels were greater in 
HF pregnant animals compared to controls at both E14.5 and E18.5 (Figure 6.2D). ME1 
mRNA levels were decreased in control pregnant mice at E18.5 compared to non 
pregnant animals. In addition MEI mRNA was lower in HF pregnant mice at both E14.5 
and E18.5 compared to non pregnant animals (Figure 6.2E). No differences in MEI 
mRNA were identified between HF and control animals in any state considered (Figure 
6.2E). FASN was lower in HF E14.5 pregnant animals compared to control mice at the 
same gestational stage (Figure 6.2F). We did not observe any significant difference in 
any other comparisons (Figure 6.2F).  
No statistical significant differences were identified in Dgat2 gene expression levels in 





Figure 6.2 Liver expression levels of genes involved in hepatic lipid metabolism A. 
ApoCIII, B. CPT1a, C. Pepck, D. Gpat, E. Me1, F Fasn, G Dgat2, Data analysed using 






























































































































































































6.3.2.2 The effect of diet and pregnancy on genes involved in estrogen 
signaling and inflammation in liver 
To investigate the possible role of altered ERα activation, as a mechanism not only 
underlying adipose tissue changes, but also in liver physiology ERα, ERβ and 
HSD17b12 gene expression levels were measured. No differences were seen in ERα 
and HSD17b12 mRNA levels between our groups (Figure 6.3 A and B). ERβ and 
MCP1 mRNA were undetectable. Liver TNFα mRNA transcription levels were greater 
in HF E14.5 pregnant mice compared to control E14.5 pregnant animals and HF non 
pregnant and HF E18.5 pregnant mice (Figure 6.3 C).  
 
 
Figure 6.3 Liver expression levels of genes involved in estrogenic signaling and 




















































































In contrast to the reduction in visceral fat weight, we observed an increased liver 
weight (described in Chapter 3 section 3.1) when pregnant HF animals were compared 
to non pregnant controls.  Liver triglyceride content showed a profound increase as 
pregnancy progressed in HF mice compared to gestation-matched control diet-fed 
animals. These data are consistent with an increase in liver weight in HF pregnant 
mice. This could suggest that the increase in liver weight of HF pregnant mice relates 
to increased triglyceride, perhaps induced by increased portal delivery of NEFA from 
the visceral adipose tissue (based on evidence from chapter 1), thereby mimicking the 
process of NAFLD. The reduced glycogen content of the HF-fed pregnant mice at this 
point (E18.5) is also consistent with heptic insulin insensitivity and increased glucose 
output. In contrast to HF pregnant mice, no pregnancy related differences were 
observed in liver triglycerides between control groups, so liver lipid accumulation is 
not consistent with the increased liver weight observed in control pregnant groups. 
However, in control pregnant mice the greater liver weight compared to control non-
pregnant mice was associated with a higher glycogen content at E18.5 but not at 
E14.5.   
 
ApoCIII is a component of VLDL that inhibits lipoprotein lipase and hepatic lipase, 
thus inhibiting hepatic glucose uptake (Eckardstein and Holz, 1991). We observed that 
ApoCIII mRNA, was increased through pregnancy in control but not in HF mice. Thus 
in control-pregnant mice there is presumably a growing inhibition of hepatic lipid 
uptake, whereas the inhibition of serum lipid uptake is unaltered in HF pregnant mice 
as pregnancy progresses.  
In addition Pepck (which converts oxaloacetate into phosphoenolpyruvate and carbon 
dioxide, the first step of gluconeogenesis) mRNA levels were unaffected by diet and 
pregnancy, suggesting this major rate-limiting step in gluconeogenesis is not 
responsible for altered flux of glucose into glycogen storage in pregnancy or obese 
animals, suggesting that glycogen sythesis/breakdown may be the rate-limiting 
reacting responsible of the observed phenotype.  
The regulation of lipid metabolism was complex throughout pregnancy and did not 
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reflect the final differences in lipid levels. This is underlined by the reduced mRNA 
levels for the enzyme that regulates the final step of glyerolipid biosynthesis (GPAT) 
and a concomitant increase in mRNA for the rate-limiting enzyme of β-oxidation 
(Cpt1a) in HF-fed pregnant mice that should predict reduced liver lipid levels rather 
than the increased levels observed in figure 6.1.  However on of the major limits of our 
approach consists in the fact that we only looked at transcript levels of a small number 
of genes involved in these pathways and not to the entire signalling cascade and their 
enzyme activity. However, in patients with NAFLD, β-oxidation is increased and due 
to enhanced CPT1a expression leading to increased entry of long chain fatty acids into 
the mitochondria (Paterson et al., 2004). These data suggest that, in our model, even if 
there is an increase stimulus to oxidize triglycerides (as suggested by CPT1a mRNA 
levels) thereby counteracting triglyceride accumulation, this is not enough to 
compensate for increased triglyceride accumulation in HF pregnant animals. 
Genes involved in de novo lipogenesis were down regulated in obese pregnant mice 
(ME1) or unchanged (FASN and Dgat2), suggesting that changes in transcription of 
genes involved in de novo lipogenesis are not contributing to the increased 
triglycerides storage observed in HF pregnant mice.  
An alternative explanation for increased triglyceride storage in HF pregnant mice 
could be an excessive influx of fatty acids from mesenteric fat through the portal vein. 
Another possibility could be an impairment of liver triglycerides export due to insulin 
resistance and subsequent PI3-k activation (Björnsson et al., 1992; Phung et al., 1997).  
We also looked at estrogen signaling in liver in order to determine if estrogens play a 
role in the increased liver weight during pregnancy, because, in particular ERα, has 
been shown to regulate liver lipid metabolism. No changes were observed in 
expression levels of genes involved in this signal pathway cascade (ERα and 
HSD17b12); notably, however, plasma estrogen levels remained higher during 
pregnancy in both HF and control mice (see 3.3.4). The changes in gene expression of 
FASN and GPAT we observed are not consistent with altered ERα/E2 action 
highlighted by Bryzgalova and Gao ((Bryzgalova et al., 2006; Gao et al., 2006)). 
Bryzgalova and collegues demonstrated that ERα deficient mice display hepatic 
insulin resistance (Bryzgalova et al., 2006), furthermore treatment of ob/ob mice with 
estrodial for 30 days improved insulin sensitivity mediated by the specific down-
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regulation of liver transcription levels of genes involved in lipid metabolism, such as 
FASN and mitochondrial isoform of GPAT (Gao et al., 2006). We observed that ME1 
gene expression levels, but not FASN mRNA levels, can be linked with increase E2 
present in pregnant mice (Chapter 3.3.4) and subsequent activation of its own receptor. 
In contrast with Gao and collegues (Gao et al., 2006), this evidence suggests that at 
physiological levels E2 may regulate some aspects of gene expression for genes of de 
novo lipogenesis in liver but not the entire process. However neither our or Gao and 
collegues study characterised the effect of altered ERα activation on enzyme activity, 
so we cannot totally exclude that ERα plays an important role in this process. 
Furthermore in the Gao study the levels of E2 administered to the animals (100 µg/kg 
body weight) were higher compared to the plasma levels that we detected (see chapter 
3.3.4) and prolonged for 30 days, while the hormonal changes that we observed relate 
to a shorter period. 
 
Given the association of fatty liver with steatohepatitis (NASH), we also examined 
expression levels of genes of inflammation. Specifically, we investigated MCP1, 
which is a marker of steatohepatitis (Bertola et al., 2010), and TNFα, which has 
recently been reported to drive steatohepatitis (Henao-Mejia et al., 2012). Mcp1 
mRNA was undetectable and Tnfα mRNA was increased in HF E14.5 pregnant mice 
compared with HF non pregnant and E18.5, and E14.5 control pregnant mice. By the 
end of pregnancy no differences were identified between HF and control mice. These 
data suggest that HF pregnant mice do not have increased risk of developing NASH 
compared with controls. 
 
In summary we observed that pregnancy is associated with increased liver triglyceride 
content, in particular in E18.5 HF pregnant mice. The liver of HF pregnant mice is 
unexpectedly not associated with the increased transcriptional regulation of genes 







Chapter 7: Discussion 
The original hypothesis presented in this thesis was that obesity during pregnancy 
exacerbates adverse outcomes through worsening of adipose tissue insulin 
resistance and inflammation. The work described in this thesis was designed to 
examine the effect of pregnancy and obesity on adipose tissue mass expansion, 
insulin resistance and inflammation. To address these aims an animal model of 
obesity (HF-fed mice) during pregnancy was generated.   
 
7.1 Effects of Obesity in pregnancy adipose tissue biology 
Surprisingly, obesity combined with pregnancy was not associated with 
exaggerated adipose tissue (mesenteric fat) expansion but with a specific 
curtailment of expansion of this fat depot. Additionally, no significant differences 
were observed in subcutaneous fat mass between pregnant and non pregnant mice.  
The reduced mesenteric fat mass, the maintained subcutaneous fat expansion in 
HF pregnant mice and the maintained adiposity in control pregnant mice 
contrasted with previous reports both of an increase in adipose tissue expansion in 
pregnant rats treated with a diet rich in calories (see 1.3, (Akyol et al., 2009), 
(Flint et al., 2005)) and with the increase in general adiposity in a high fat fed 
mouse model treated with a lower calories content (32%) compared to the ones 
used in this thesis (58%) (see 1.3 (Jones et al., 2009)). However the differences in 
term of diet composition, animals and strain used by these studies and the animal 
model presented in this thesis require consideration. Akyol and collegues used 
female Wistar rats and a complex diet prepared in house composed of four out of 
the following elements which were rotated daily (biscuits, potato crisps, fruit and 
nut chocolate, Mars bars, cheddar cheese, golden syrup cake, pork pie, cocktail 
sausages, liver and bacon pâté, strawberry jam and peanuts) (Akyol et al., 2009). 
Animals treated with this cafeteria diet were then compared with animals treated 
with standard chow diet (Akyol et al., 2009). The major limitation of this 
approach consists in the lack of standardization of the content of the cafeteria diet 
over different days of the treatment; and, perhaps more importantly, the inability 
to have the same protein and carbohydrate content in cafeteria fed mice and chow 
fed animals. To avoid this problem, Flint and colleagues have treated OF1 female 
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mice with a commercially prepared high fat diet; however there is a discrepancy 
in term of protein and carbohydrate content between high fat diet and control diet 
in this secenario (Flint et al., 2005). This discrepancy does not allow analysis of 
whether the observed phenotype observed resulted from an increase in fat 
consumption or from modification of carbohydrate and protein ingestion. Jones 
and colleagues used a similar approach to the one presented in this thesis: they 
treated C57BL/6 mice with a high fat diet, albeit lower in term of fat content 
compared to the one that was used in this work, and compared animals treated 
with this high fat diet with mice treated with a control diet matched in terms of 
protein and carbohydrate content (Jones et al., 2009). However after 8 weeks of 
treatment animals treated with this high fat diet were not heavier compared with 
animals treated with control diet (Jones et al., 2009).   
The reduced visceral fat expansion of high fat fed (pre-gravidly obese) pregnant 
mice observed in this thesis correlated with an increase in basal lipolysis rate 
assessed in subcutaneous primary adipocytes. However, despite the increased rate 
of adipocyte fatty acid release by the end of pregnancy in HF mice, adipocyte size 
was comparable between HF pregnant animals, HF non-pregnant and control 
pregnant animals. This results suggest that in this animal model there is not an 
imbalance in lipid storage and fatty acid release that would provide an obvious 
rationale for the adipocyte size/adipose mass phentoype. Therefore an alternative 
mechanism may be involved, potentially increased apoptosis of adipocyte. 
Moreover, we observed that pregnancy is associated in control animals with an 
increased adipocyte size, as previously shown by (Zhang et al., 2011).  Adipocyte 
hypertrophy did not correlate with increase adipose tissue mass in either 
mesenteric of subcutaneous depot in control mice. Moreover SVF remained 
unchanged in both control and HF pregnant vs non pregnant mice. Furthermore an 
increased production of IGF1 and possibly free IGF1 during pregnancy was 
highlighted by the microarray and qRT-PCR, suggesting an increase preadipocyte 
differentiation in high fat fed pregnant animals. As shown by Spalding et al., the 
only known plasticity in adipocytes turnover is during puberty. Outwith puberty, 
it has been calculated that the median adipocyte turnover rate is 8.35±6.6% per 
year, with 50% of adipocytes replaced every 8.30 years (Spalding et al., 2007) and 
 
172 
approximately the 10% of fat cells are renewed annually (Spalding et al., 2008) 
and are replaced by their precursors through as yet unknown mechanisms in order 
to maintain cellular homeostasis.  
Data presented in this thesis suggests that pregnancy is a physiological state where 
preadipocyte differentiation and adipocyte turnover is increased compared to 
adulthood, suggesting an important action of the hormonal changes of pregnancy 
in the tight control of adipocytes turnover. Moreover preliminary data presented in 
figure 7.1 highlights the role of ERα in the stimulation of preadipocytes 
differentiation (through IGF1/IGFBP3 control, and possibly also by acting on 
other pathways involved in this process).  
 
7.1.1 Effects of Obesity in pregnancy on glucose homeostasis  
Convergence in the severity of glucose intolerance was observed between HF 
pregnant mice compared to control pregnant mice by the end of pregnancy 
(E18.5). This contrasts with a divergent, exaggerated hyperglycaemia and 
hyperinsulinemia between these two groups at the earlier stage of pregnancy 
(E14.5).  The convergence appears to be largely due to can be due to increasing 
glucose intolerance and hyperinsulinemia, consistent with insulin resistance in 
control animals towards the end of pregnancy (demonstrated by (Zhang et al., 
2011) in the same strain of mice used in this thesis) but a plateau in the severity of 
insulin resistance in HF pregnant animals. Moreover despite the decrease in 
mesenteric fat mass in the HF pregnant mice, no difference was observed in 
mesenteric adipose tissue insulin sensitivity (as measured by PKB 
phosphorylation after insulin stimulation) in HF pregnant mice compared to non 
pregnant mice. This suggest that by the end of pregnancy, other factors besides 
insulin sensitivity of the visceral adipocytes determines overall fat mass and 
adipocyte hypertrophy. An increased availability of estradiol and increased ERα 
activation (that will be fully explored in the following section 7.1.2) was observed 
in the animal model presented in this thesis, and we hypothesized therefore that 
estrogen action could be dominant over insulin in this contest suppressing 
lipogenesis. A study on fully differentiated 3T3-L1 adipocytes stably transfected 
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with ERα, showed decreased triglyceride accumulation and reduced LPL 
expression (Homma et al., 2000), supporting this hypothesis. 
In addition to these findings, we observed an increased PKB phosphorylation in 
mesenteric fat in control animals by E14.5 and no difference between non 
pregnant and E18.5 pregnant controls suggesting that adipose tissue specific 
insulin resistance is not playing a key role in the changes in whole body insulin 
resistance observed with GTT. However it is possible that the activation of other 
up-stream (IRS1) or down-stream (GSK3, FOXO or TCS 2) proteins from PKB 
might be affected in our animal model.  
 
7.1.2 Effects of Obesity in pregnancy on circulating adipokines and 
hormones 
Plasma Leptin levels were increased during pregnancy, suggesting an alternative 
source, possibly the placenta, of production for this protein during pregnancy 
(Hoggard et al., 1997). However whether leptin production by placenta in mouse 
is still controversial: Hoggard and collegues were able to detect leptin at both 
mRNA, (using RT-PCR and in-situ hybridization) and protein (using western 
blot) levels (Hoggard et al., 1997). However other groups were not able to detect 
placenta leptin production in mouse (Kawai et al., 1997; Zhao et al., 2003). 
Moreover, it needs to be considered that estrogen can also stimulate leptin 
production. ERα in vitro up-regulates leptin expression levels (Piermaría et al., 
2003; Yi et al., 2008). Mesenteric fat leptin mRNA was increased by E14.5 in HF 
pregnant mice and increased at plasma protein levels in all our pregnant groups in 
particular in HF E14.5 mice, suggesting a contribution from ERα activation in the 
production of this protein (Piermaría et al., 2003).  
Pregnancy is associated with a reduction in adiponectinHMW levels, independently 
of changes in adipose tissue expansion in both HF and control mice. This could be 
due to the increase in insulin levels, which down-regulate adiponectin synthesis in 
adipocytes, probably through MAPK and PI3K signal pathway (Fasshauer et al., 
2002) in control pregnant mice. The lack of differences in adiponectinHMW levels 
observed in HF pregnant mice compared to HF non pregnant animals, could 
therefore be due to the brake in the worsening of hyperinsulinemia in this animals 
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which therefore is not able to further reduce adiponectin production. Adiponectin 
was observed to be lower in women with gestational diabetes (GDM) compared to 
normal pregnancy (Ranheim et al., 2004), however  in this work no differences 
were observed between HF and control pregnant animals suggesting therefore that 
this animal model is not associated with GDM. 
No differences were observed between HF and control groups in plasma estradiol 
levels at either time point considered during pregnancy, suggesting that obesity 
has no effect on this hormone concentration in plasma. In contrast to estradiol 
levels, higher levels of progesterone were observed in E18.5 HF pregnant mice 
compared to control mice. The decrease in circulating progesterone levels, typical 
of the end of pregnancy, was not therefore observed in  E18.5 HF pregnant mice. 
The lack of progesterone withdrawal could indicate an increased gestational 
length in HF pregnant mice, however no difference in term of gestational length in 
this animal model were observed (Dr V. King unpublished preliminary 
observations).  
 
7.1.3 Generation of an underlying hypothesis to explain changes in 
adipose tissue expansion in obese pregnancy 
A whole genome transcription microarray was conducted to understand the 
molecular changes responsible to the reduced mesenteric fat mass. Pathway 
analysis  revealed up-regulation of mRNA of genes associated with changes in 
adipose tissue morphology, in particular vascular remodelling, production of 
secreted proteins and estrogenic signalling and down-regulation of transcripts of 
proteins involved in de novo lipogenesis and lipid storage, inflammation and 
retinol metabolism. Microarray validation highlighted an increased mRNA 
production of ERα gene in E18.5 HF pregnant mice compared to non pregnant 
animals. Furthermore, the increased transcript levels of this receptor are present 
during a phase of pregnancy where estradiol plasma levels in mice are elevated (± 
2fold increase see 3.3.4), suggesting a possible increase in ligand availability for 
this receptor (and, presumably receptor activation). In addition to ERα, we found 
changes in HSD17b12 expression; this protein converts the less active estrone 
precursor to estradiol in adipose tissue (Bellemare et al., 2009). The increase in 
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mRNA for HSD17b12 at E14.5 could be important in increasing local estradiol 
generation, increasing the activation of ERα at E14.5. Based on the consistency of 
data pointing towards increased estrogen exposure within the fat, and the 
published literature that indicates estrogen action has a beneficial effect on 
adipose tissue biology through ERα, the following hypothesis was generated: 
increased ERα activation in mesenteric fat reduces lipogenesis inflammation and 
limits insulin resistance in HF pregnant mice.  
 
7.1.4 Support for a direct role for ERα activation in reduced mesenteric 
fat mass in pregnancy 
Decreased mRNA levels of genes involved in de novo lipogenesis in HF fed mice 
(ME1, FASN and SCD1) and triglycerides storage (Dgat2) in HF pregnant 
animals indicated a potential mechanism contributing to reduced mesenteric fat 
mass. There was no apparent difference in insulin sensitivity (a major regulator of 
adipocyte lipid accumulation) between the mesenteric adipocytes of the two 
groups that showed contrasting fat mass (HF pregnant and control pregnant) 
suggesting some other signaling pathway may be responsible for reduced mass. 
Of note, increased ERα activation emerged as a cardinal feature of the adipose 
tissue in the HF pregnant mice. ERα activation decreases triglyceride 
accumulation in vitro in 3T3-L1 adipocytes (Homma et al., 2000) and estradiol 
treatment decreased lipogenesis and triglycerides storage in mice in vivo in liver 
(Bryzgalova et al., 2008). ERα deficient mice showed increased expression of 
lipogenic genes and decreased transcription levels of genes involved in lipid 
transport in liver (Bryzgalova et al., 2006). Furthermore, in a parallel study 
estradiol treatment decreased transcription of FASN and SCD1 in liver of leptin 
deficient mice (Gao et al., 2006). Therefore there was strong associative evidence 
that increased ERα activation could be responsible. Indeed, when the hypothesis 
was tested directly in Chub-S7 and primary human adipocytes we observed a 
reduction in genes involved in de novo lipogenesis and triglyceride storage which 




7.1.5 Adipose tissue inflammation 
ERα has also effects on decreasing inflammation (extensively reviewed by 
(Brown et al., 2010)), suggesting that the decrease in mesenteric fat MCP1 and 
TNFα mRNA and decreased pro-inflammatory adipose tissue macrophages can be 
due to ERα receptor activation. 
Moreover, increased ERα activation could be linked with the changes in whole 
body insulin resistance. ERα knock-out mice are diabetic and obese with severe 
hepatic insulin resistance. Our animal model showed attenuation of the expected 
worsening of glucose intolerance in E18.5 HF pregnant mice, with no differences 
in the level of insulin resistance, measured using PKB phosphorylation as a 
marker of insulin signal pathway activation, between HF non pregnant mice and 
E18.5 HF pregnant animals. Furthermore GTT study indicates that by E18.5, HF 
animals have the same degree of glucose intolerance compared to control mice 
suggesting that the levels of glucose intolerance at this stage of pregnancy are not 
abnormally high in HF mice. 
 
To test the hypothesis that activation of ERα directly modulates adipocyte 
lipogenic pathways: fully differentiated Chub-S7 cells were treated with a 
selective ERα agonist, PPT. The experiments were focused on fully differentiated 
cells because the majority of genes identified in the microarray pathway analysis 
are involved in mature adipocyte metabolism. Treatment of Chub-S7 adipocytes 
with PPT confirmed that ERα activation suppressed transcription of genes 
involved in de novo lipogenesis and triglyceride storage. These data support the 
hypothesis that ERα activation suppresses adipocyte lipid storage observed in HF 
pregnant mice. The hypothesis was further supported by evidence for a direct 
action of PPT to suppress primary visceral adipocyte SCD1 mRNA. It is noted 
that further interpretation of the primary human adipocyte data is not possible due 
to limited sample size and hence study power.  
 
7.1.6 Effects of obesity in pregnancy in liver 
In contrast to the reduction in mesenteric fat weight, we observed an increase in 
liver weight and liver triglyceride content in HF pregnant mice. Increased hepatic 
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triglyceride is consistent with the elevated rate of fatty acid release from primary 
visceral adipocytes, and increased portal delivery of free fatty acids. The reduced 
glycogen content of the HF-fed pregnant mice at this point (E18.5) is also 
consistent with hepatic insulin resistance and increased glucose output.  
Analysis of hepatic mRNA levels indicate that ApoCIII-mediated inhibition of 
hepatic lipid uptake does not manifest in HF pregnant mice as pregnancy 
progresses, leading to increased hepatic lipid storage. Moreover mRNA levels for 
Pepck suggests that altered glycogen synthesis/breakdown may be the rate-
limiting step responsible for the observed increase liver glycogen in control E18.5 
mice.  
The regulation of lipid metabolism was complex throughout pregnancy and did 
not reflect the final differences in lipid levels observed in HF pregnant mice. This 
is underlined by the reduced mRNA levels for the enzyme that regulates the final 
step of glycerolipid biosynthesis (GPAT) and a concomitant increase in mRNA 
for the rate-limiting enzyme of β-oxidation (Cpt1a) in HF-fed pregnant mice that 
should predict reduced liver lipid levels rather than the increased levels observed.  
However one of the major limits of this work was that only a few selected genes 
were addressed, with no analysis of protein concentration. Future studies must 
investigate protein and enzyme activity levels. Nevertheless, the increase in β-
oxidation, suggested by CPT1a mRNA in HF pregnant mice and also observed in 
NAFLD patients (Paterson et al., 2004), is not enough to compensate the 
increased liver triglycerides accumulation. Moreover, genes involved in hepatic 
de novo lipogenesis were down regulated (ME1) or unchanged (FASN and Dgat2) 
in HF pregnant mice, suggesting that changes in transcription of genes involved in 
de novo lipogenesis do not contribute to the increased triglycerides storage 
observed in HF pregnant mice.  
A possible explanation for increased triglyceride storage in HF pregnant mice 
could be an excessive influx of fatty acids from mesenteric fat through the portal 
vein. Another possibility could be an impairment of liver triglyceride export due 
to insulin resistance and subsequent PI3-k activation which inhibits ApoB, 
required for assembly and secretion of triglyceride-rich lipoprotein (Björnsson et 
al., 1992; Phung et al., 1997).  
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We also looked at estrogen signaling in liver in order to determine if estrogens 
play a role in the increased liver weight during pregnancy. ERα, has been shown 
to regulate liver lipid metabolism (Bryzgalova et al., 2006; Gao et al., 2006). No 
changes were observed in mRNA levels of ERα and HSD17b12. The changes in 
gene expression of FASN and GPAT we observed are not consistent with altered 
ERα/E2 action highlighted by Bryzgalova and Gao ((Bryzgalova et al., 2006; Gao 
et al., 2006)).   
 
Given the association of fatty liver with steatohepatitis (NASH), we also 
examined mRNA expression of genes of inflammation; in particular MCP1, a 
marker of steatohepatitis (Bertola et al., 2010), and TNFα mRNA, which has 
recently been reported to drive steatohepatitis (Henao-Mejia et al., 2012). mRNA 
analysis suggests that HF pregnant mice do not have increased risk of developing 
NASH compared with controls.  
 
In summary the fatty liver of pregnancy is surprisingly not associated with the 
transcriptional regulation of genes involved in the control of hepatic triglyceride 
uptake, de novo lipogenesis of fatty acid oxidation. 
 
179 
7.2 Future work 
7.2.1 Future work on estrogen hypothesis  
• Investigation of steroids levels in adipose tissue: the elucidation of 
estradiol levels in adipose tissue, in particular mesenteric fat, is important to 
further explore the hypothesized altered ERα activation in HF pregnant mice 
 
• Investigation of ERα activation in adipose tissue: quantification of ERα 
activation in adipose tissue can be obtained by measuring phosphorylated levels 
of this receptor compared with its native form, using western blot techniques. This 
measurement will finally confirm or refute the increase in ERα activation in 
mesenteric fat of HF pregnant animals.  
 
• In vitro study to determine ERα activation role on preadipocytes 
recruitment and differentiation: We focussed our in vitro studies on understanding 
the effect on ERα activation on de novo lipogenesis, triglyceride storage and 
adipocyte metabolism on mature adipocytes and fully differentiated cells because 
the majority of genes highlighted from our microarray pathways analysis play an 
important role in mature cells. However we cannot exclude that ERα could play 
an important role also in preadipocyte recruitment and differentiation. The effect 
of PPT treatment on either preadipocyte metabolism and their differentiating 
potential need to be considered. A preliminary experiment was conducted on 
Chub-S7 cells, at day 3 of differentiation, treating these cells with 1nM, 10nM, 
0.1µM and 1µM of PPT and compared them to vehicle control (Figure 7.1 A-B). 
IGF1 and IGFBP3 mRNAs were assessed using qRT-PCR. In this scenario, PPT 
treatment promoted IGF1 and IGFBP3 (Figure 7.1 A-B) mRNAs suggesting that 
ERα play a role also in preadipocytes differentiation. However Chub-S7 cells 
have limitations (explained in chapter 5), therefore in future experiments we 
propose to use mouse primary preadipocytes and mature adipocytes and treat 
them with PPT. We also plan to treat differentiating mouse primary preadipocytes 




Figure 7.1 Effect of PPT treatment on mRNA levels A. IGF1 and B. IGFBP3 in day 3 
differentiated Chub-S7 (n=6 in each groups), *=P<0.05, **P<0.01 
 
• In vivo approach to test ERα activation role in adipose tissue during 
pregnancy: In order to dissect the tissue-specific role of ERα in the reduction of 
mesenteric fat mass adipose tissue inflammation and brake in the predict 
worsening of insulin resistance,  activation of adipocyte specific ERα should be 
explored. This is not easy in vivo because PPT treatment will have effects on other 
organs, therefore the use of an adipocytes specific ERα knock-in or knock-out 
mice could be considered. 
 
7.2.2 Future work on animal model characterization 
•Investigation of adipose tissue mass expansion at the beginning of pregnancy and 
at post-partum: we demonstrated that mesenteric fat mass is reduced as early as 
E14.5, and the effect is maximal at this time point (no further reduction) and that 
its reduction is maintained throughout pregnancy. Further investigation of earlier 
time points during pregnancy will provide a better understanding of the 
environment (hormonal levels, stage of fetal development, placenta formation, 
maternal and fetal cross talk) in which this phenomenon happens.  To understand 
if this effect is “reversible” and for how long the pregnancy “environment” could 
affect adipose tissue, investigation of adipose tissue distribution needs to be 
characterised postpartum. For this purpose adipose tissue mass expansion could 





















































































Analysis of these distinct hormonal windows, preferably using a non-invasive 
imaging method to pinpoint the crucial time points, will give us a better 
understanding on the rate of “recovery” of mesenteric fat expansion and also 
information on hormonal change i.e. prolactin in the mesenteric fat reduction. 
 
•Investigation of adipocytes apoptosis: In this work we observed that despite the 
reduction in mesenteric fat mass in HF pregnant mice, adipocyte hypertrophy was 
maintained. A potential mechanism that may be involved in the “disappearance” 
of adipocytes in mesenteric fat could be apoptosis. To investigate this 
phenomenon we could measure caspase 3 activity, which drives apoptosis. 
Caspase 3 could be detected in tissue by immunohistochemistry or in vitro with 
fluorimetric immunosorbent enzyme assay (FIENA). Other marker of apoptosis 
that can be investigated are: annexin V, a marker of chage in membrane 
composition that can be detected by immunohistochemitry, and DNA 
fragmentation, a biochemical hallmark that the apoptosis is not reversibe and 
could be studied using terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) staining or with ELISA. To understand the role of increased 
ERα activation in adipocyte apoptosis, primary adipocytes, will be stimulated 
with different concentration of PPT after which marker of apoptosis will be 
quantified. 
 
• Investigation of energy expenditure and eating behavior: one of the major events 
that could contribute to the reduce fat mass expansion in pregnant mice is 
increased energy expenditure. However in the animal model presented in this 
thesis we observed a specific curtailment in mesenteric fat adipose tissue but not 
subcutaneous fat. If energy expenditure is increased in HF pregnant mice, it will 
likely decrease overall adiposity in this animals, therefore affecting subcutaneous 
fat as well. It must be considered that leptin can cause a selective reduction of 
visceral fat by activating the ventromedial hypothalamus (VMH) nuclei and 
therefore modulating catecholamines (norepinephrine and epinephrine) production 
(Satoh et al., 1999). Catecholamines act preferentially by activating β-adrenergic 
receptors (Lands et al., 1967), which are more active in intra-abdominal compared 
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with subcutaneous fat (Arner, 1995), and hence they specifically reduce 
mesenteric fat. However catecholamines can also increase UCP1 (a key molecule 
that control thermogenesis) in brown adipose tissue by acting on β-adrenergic 
receptor (Cousin et al., 1992; Himms-Hagen et al., 1994; Guerra et al., 1998). For 
this reason characterization of UCP1 production in brown fat should be monitored 
as well. 
To measure energy expenditure metabolic cages could be used. This type of cage 
will allow us to measure oxygen consumption, drinking and feeding behavior and 
also urine and faeces collection. This information will be fundamental to 
understand if the observed phenotype is due to increased activity of HF mice 
during pregnancy or to decreased food intake and will give us the possibility to 
monitor electrolyte and protein secretion (i.e. free fatty acids) from urine and 
feces.  
Another important tissue that can regulate energy expenditure, through body 
temperature control (see 1.2.1), is brown adipose tissue. Characterization of UCP1 
levels and of the factors that contribute to its production (PPARγ, PGC1α and β3 
adrenergic receptor) would give us the opportunity to understand if HF pregnant 
mice has reduced mesenteric fat expansion due to increase body temperature. 
Furthermore, appetite and food intake control mediated from the brain in this 
mouse model during pregnancy still need to be completely elucidated.  
 
•Investigation of ectopic triglyceride deposition: we demonstrate that liver has 
increased triglyceride storage during pregnancy in HF mice. However liver is not 
the only organ which can have ectopic triglyceride storage, other organs (such as 
muscle) and their triglyceride level need therefore to be investigated to fully 
elucidate the negative impact of the decrease mesenteric fat mass and subsequent 
free fatty acids release from this depot. Furthermore, proof that the release of free 
fatty acids from mesenteric fat in to portal vein is detrimental for other organs 
needs to be established. Moreover the mechanism involved in increase liver 
triglycerides still need to be established. A possible mechanism responsible for 
this could be the impairment in liver triglyceride export due to insulin resistance 
and subsequent PI3-k activation (Björnsson et al., 1992; Phung et al., 1997), 
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however this still needs to be tested. In muscle we observed a decrease in PKB 
phosphorylation at E14.5 during pregnancy in HF mice, but not at the end of 
pregnancy, suggesting an altered lipid storage in muscle at E14.5 in HF pregnant 
mice. Therefore the measurement of PKB phosphorylation in liver as well could 
explain if the increased liver triglycerides content in HF pregnant mice could be 
due to insulin resistance.   
 
•Investigation of maternal singnalling and their effect on placenta in obese mice: 
As discussed in the Introduction, PPARα and in particular the γ isoform play an 
crucial role in adipocytes biology, in particular regulating fatty acids storage and 
glucose metabolism. PPARα mRNA levels did not changed between our groups in 
our microarray and subsequent validation (data not shown). Despite the lack of 
changing in PPARα gene expression, it will be important clarify the role of 
PPARγ in this mouse model. PPARγ mediates infact adipocytes hypertrophy in 
HF fed mice and it  is also involved in the placental development, throphoblast 
invasion and placental fat metabolism (as highlighted by Yoel Sadovsky research 
and extensively reviewed by Schaiff WT et al 2006) 
 
•Investigation of liver function during pregnancy in obese mice: Liver is a 
dynamic organ during pregnancy, and standard physiologic changes occur in this 
organ during pregnancy. Pregnancy is associated with increase serum alkaline 
phosphatase (AP) in the third trimester (Bacq et al., 1996). In pregnant women, 
total and free bilirubin concentrations are lower during all three trimesters (Bacq 
et al., 1996). Moreover conjugated bilirubin and g-glutamyl transpeptidase (GGT) 
activity are decreased during the second and third trimesters. Furthermore serum 
5’-nucleotidase activity is higher in the second and third trimesters (Bacq et al., 
1996). Obesity is also associated with changes in liver complication rates (see 
1.2.9) To understand if obesity and pregnancy are associated with worsening in 
liver function, the liver function studies, presented earlier should be repeated in 




•Investigation of insulin sensitivity: Whole body glucose ‘clamp’ studies could be 
help quantify insulin sensitivity of individual organs. This is deduced from 
infusion of labeled glucose tracers at a supraphysiological hyperinsulinaemia, 
with varied infusion of exogenous glucose to achieve a steady state 
(euglycaemia).  However it may be difficult to gain ethical approval to conduct 
these studies in pregnant mice.  
 
•Investigation of hormone production in pregnancy: a better characterization of 
the hormones produced by placenta in our experimental animals will be important 
to better characterize the environment in which the phenotype that we observed 
occurs.  
 
7.3 General thesis conclusion 
This work revealed that obesity is associated with a reduction of mesenteric fat 
expansion, adipose tissue inflammation and a constraint of the predicted 
worsening of insulin resistance during pregnancy. An open question approach 
highlighted the role of altered ERα activation in mesenteric fat in our mouse 
model of obesity during pregnancy. We therefore hypothesised that altered ERα 
activation/increased estradiol presence in mesenteric fat may be the underlying 
reason for the reduced fat mass, lipogenesis and improved inflammatory profile, 
and ultimately, effects a brake on the expected worsening of insulin resistance in 
HF pregnant mice. The identification of increased ERα activation role in vitro on 
reducing transcription of genes involved in de novo lipogenesis and triglyceride 
storage , together with data from the literature, (previously discussed) support this 
hypothesis. The identification of the detailed molecular pathway responsible for 
these changes would provide potential therapeutic targets for selectively curtain 
mesenteric (visceral) fat mass expansion and improving whole body glucose 
tolerance and could potentially be effective in both female and male obese 
subjects. 
Nevertheless, this animal model did not replicate any of the adverse outcomes 
typical of pregnancy in human obese subjects, therefore it is not so useful to study 
pregnancy complications. However this model could underling the reasons why 
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some  obese subjects, despite their excess body fat mass, do not present any 
pregnancy adverse outcomes; helping therefore the understanding of the 
physiological changes in “healthy” obese pregnant subjects and subsequently the 









Ailhaud, G., E. Amri, S. Bardon, S. Barcellini-Couget, B. Bertrand, R.M. Catalioto, 
C. Dani, A. Doglio, C. Forest, and D. Gaillard. 1991. Growth and differentiation of 
regional adipose tissue: molecular and hormonal mechanisms. Int J Obes Relat 
Metab Disord. 15 Suppl 2:87–90. 
Akkaoui, M., I. Cohen, C. Esnous, V. Lenoir, M. Sournac, J. Girard, and C. Prip 
Buus. 2009. Modulation of the hepatic malonyl-CoA–carnitine palmitoyltransferase 
1A partnership creates a metabolic switch allowing oxidation of de novofatty acids. 
Biochem. J. 420:429–438. 
Akyol, A., S.C. Langley-Evans, and S. McMullen. 2009. Obesity induced by 
cafeteria feeding and pregnancy outcome in the rat. Br. J. Nutr. 102:1601–1610. 
Almind, K., M. Manieri, W.I. Sivitz, S. Cinti, and C.R. Kahn. 2007. Ectopic brown 
adipose tissue in muscle provides a mechanism for differences in risk of metabolic 
syndrome in mice. Proc. Natl. Acad. Sci. U.S.A. 104:2366–2371. 
Arita, Y., S. Kihara, N. Ouchi, M. Takahashi, K. Maeda, J. Miyagawa, K. Hotta, I. 
Shimomura, T. Nakamura, K. Miyaoka, H. Kuriyama, M. Nishida, S. Yamashita, K. 
Okubo, K. Matsubara, M. Muraguchi, Y. Ohmoto, T. Funahashi, and Y. Matsuzawa. 
1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 
Biochem. Biophys. Res. Commun. 257:79–83. 
Arner, P. 1995. Differences in lipolysis between human subcutaneous and omental 
adipose tissues. Ann. Med. 27:435–438. 
Asarian, L., and N. Geary. 2006. Modulation of appetite by gonadal steroid 
hormones. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 361:1251–1263. 
Assimacopoulos-Jeannet, F., S. Brichard, F. Rencurel, I. Cusin, and B. Jeanrenaud. 
1995. In vivo effects of hyperinsulinemia on lipogenic enzymes and glucose 
 
187 
transporter expression in rat liver and adipose tissues. Metab Clin Exp. 44:228–233. 
Aubin, D., A. Gagnon, and A. Sorisky. 2005. Phosphoinositide 3-kinase is required 
for human adipocyte differentiation in culture. Int J Obes Relat Metab Disord. 
29:1006–1009. 
Bacq, Y., O. Zarka, J.F. Bréchot, N. Mariotte, S. Vol, J. Tichet, and J. Weill. 1996. 
Liver function tests in normal pregnancy: a prospective study of 103 pregnant 
women and 103 matched controls. Hepatology. 23:1030–1034. 
Bahary, N., R.L. Leibel, L. Joseph, and J.M. Friedman. 1990. Molecular mapping of 
the mouse db mutation. Proc. Natl. Acad. Sci. U.S.A. 87:8642–8646. 
Bai, Y., S. Zhang, K.S. Kim, J.K. Lee, and K.H. Kim. 1996. Obese gene expression 
alters the ability of 30A5 preadipocytes to respond to lipogenic hormones. J. Biol. 
Chem. 271:13939–13942. 
Barbour, L.A., C.E. McCurdy, T.L. Hernandez, J.P. Kirwan, P.M. Catalano, and J.E. 
Friedman. 2007. Cellular mechanisms for insulin resistance in normal pregnancy and 
gestational diabetes. Diabetes Care. 30 Suppl 2:S112–9. 
Bastard, J.-P., M. Maachi, J.T. Van Nhieu, C. Jardel, E. Bruckert, A. Grimaldi, J.-J. 
Robert, J. Capeau, and B. Hainque. 2002. Adipose tissue IL-6 content correlates with 
resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin 
Endocrinol Metab. 87:2084–2089. 
Bedogni, G., L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani. 
2005. Prevalence of and risk factors for nonalcoholic fatty liver disease: the 
Dionysos nutrition and liver study. Hepatology. 42:44–52. 
Bellemare, V., P. Laberge, S. Noel, A. Tchernof, and V. Luu-The. 2009. Differential 
estrogenic 17beta-hydroxysteroid dehydrogenase activity and type 12 17beta-
hydroxysteroid dehydrogenase expression levels in preadipocytes and differentiated 
adipocytes. J Steroid Biochem Mol Biol. 114:129–134. 
Benjamini, Y. 1995. Controlling the false discovery rate: a practical and powerful 
 
188 
approach to multiple testing. Journal of the Royal Statistical Society Series B …. 
Bertola, A., S. Bonnafous, R. Anty, S. Patouraux, M.-C. Saint-Paul, A. Iannelli, J. 
Gugenheim, J. Barr, J.M. Mato, Y. Le Marchand-Brustel, A. Tran, and P. Gual. 
2010. Hepatic expression patterns of inflammatory and immune response genes 
associated with obesity and NASH in morbidly obese patients. PLoS ONE. 5:e13577. 
Björnsson, O.G., J.M. Duerden, S.M. Bartlett, J.D. Sparks, C.E. Sparks, and G.F. 
Gibbons. 1992. The role of pancreatic hormones in the regulation of lipid storage, 
oxidation and secretion in primary cultures of rat hepatocytes. Short- and long-term 
effects. Biochem. J. 281 ( Pt 2):381–386. 
Boden, G., X. Chen, J.W. Kolaczynski, and M. Polansky. 1997. Effects of prolonged 
hyperinsulinemia on serum leptin in normal human subjects. J. Clin. Invest. 
100:1107–1113. 
Boney, C.M., A. Verma, R. Tucker, and B.R. Vohr. 2005. Metabolic syndrome in 
childhood: association with birth weight, maternal obesity, and gestational diabetes 
mellitus. Pediatrics. 115:e290–6. 
Boney, C.M., B.M. Moats-Staats, A.D. Stiles, and A.J. D'Ercole. 1994. Expression of 
insulin-like growth factor-I (IGF-I) and IGF-binding proteins during adipogenesis. 
Endocrinology. 135:1863–1868. 
Boney, C.M., H. Sekimoto, P.A. Gruppuso, and A.R. Frackelton. 2001. Src family 
tyrosine kinases participate in insulin-like growth factor I mitogenic signaling in 
3T3-L1 cells. Cell Growth Differ. 12:379–386. 
Boney, C.M., P.A. Gruppuso, R.A. Faris, and A.R. Frackelton. 2000. The critical 
role of Shc in insulin-like growth factor-I-mediated mitogenesis and differentiation 
in 3T3-L1 preadipocytes. Mol. Endocrinol. 14:805–813. 
Boomsma, C.M., M.J.C. Eijkemans, E.G. Hughes, G.H.A. Visser, B.C.J.M. Fauser, 
and N.S. Macklon. 2006. A meta-analysis of pregnancy outcomes in women with 
polycystic ovary syndrome. Hum. Reprod. Update. 12:673–683. 
 
189 
Breitling, R., P. Armengaud, A. Amtmann, and P. Herzyk. 2004. Rank products: a 
simple, yet powerful, new method to detect differentially regulated genes in 
replicated microarray experiments. FEBS Lett. 573:83–92. 
Brook, R.D., R.L. Bard, P.F. Bodary, D.T. Eitzman, S. Rajagopalan, Y. Sun, and 
A.M. Depaoli. 2007. Blood pressure and vascular effects of leptin in humans. Metab 
Syndr Relat Disord. 5:270–274. 
Bruun, J.M., A.S. Lihn, S.B. Pedersen, and B. Richelsen. 2005. Monocyte 
chemoattractant protein-1 release is higher in visceral than subcutaneous human 
adipose tissue (AT): implication of macrophages resident in the AT. J Clin 
Endocrinol Metab. 90:2282–2289. 
Brown, L.M., L. Gent, K. Davis, and D.J. Clegg. 2010. Metabolic impact of sex 
hormones on obesity. Brain Res. 1350:77–85. 
Bryzgalova, G., H. Gao, B. Ahren, J.R. Zierath, D. Galuska, T.L. Steiler, K. 
Dahlman-Wright, S. Nilsson, J.-A. Gustafsson, S. Efendic, and A. Khan. 2006. 
Evidence that oestrogen receptor-alpha plays an important role in the regulation of 
glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia. 49:588–
597. 
Bryzgalova, G., L. Lundholm, N. Portwood, J.-A. Gustafsson, A. Khan, S. Efendic, 
and K. Dahlman-Wright. 2008. Mechanisms of antidiabetogenic and body weight-
lowering effects of estrogen in high-fat diet-fed mice. Am. J. Physiol. Endocrinol. 
Metab. 295:E904–12. 
Butte, N.F. 2000. Carbohydrate and lipid metabolism in pregnancy: normal 
compared with gestational diabetes mellitus. Am. J. Clin. Nutr. 71:1256S–61S. 
Cai, D., M. Yuan, D.F. Frantz, P.A. Melendez, L. Hansen, J. Lee, and S.E. Shoelson. 
2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-
beta and NF-kappaB. Nat. Med. 11:183–190. 
Campfield, L.A., F.J. Smith, Y. Guisez, R. Devos, and P. Burn. 1995. Recombinant 
mouse OB protein: evidence for a peripheral signal linking adiposity and central 
 
190 
neural networks. Science. 269:546–549. 
Cao, L., E.Y. Choi, X. Liu, A. Martin, C. Wang, X. Xu, and M.J. During. 2011. 
White to brown fat phenotypic switch induced by genetic and environmental 
activation of a hypothalamic-adipocyte axis. Cell Metab. 14:324–338. 
Cao, J., J.-L. Li, D. Li, J.F. Tobin, and R.E. Gimeno. 2006. Molecular identification 
of microsomal acyl-CoA:glycerol-3-phosphate acyltransferase, a key enzyme in de 
novo triacylglycerol synthesis. Proc. Natl. Acad. Sci. U.S.A. 103:19695–19700. 
Carmen, G.-Y., and S.-M. Víctor. 2006. Signalling mechanisms regulating lipolysis. 
Cell. Signal. 18:401–408. 
Carr, M.C. 2003. The emergence of the metabolic syndrome with menopause. J Clin 
Endocrinol Metab. 88:2404–2411. 
Cartier, A., I. Lemieux, N. Alméras, A. Tremblay, J. Bergeron, and J.-P. Després. 
2008. Visceral obesity and plasma glucose-insulin homeostasis: contributions of 
interleukin-6 and tumor necrosis factor-alpha in men. J Clin Endocrinol Metab. 
93:1931–1938. 
Catalano, P.M., E.D. Tyzbir, R.R. Wolfe, J. Calles, N.M. Roman, S.B. Amini, and 
E.A. Sims. 1993. Carbohydrate metabolism during pregnancy in control subjects and 
women with gestational diabetes. Am. J. Physiol. 264:E60–7. 
Catalano, P.M., L. Huston, S.B. Amini, and S.C. Kalhan. 1999. Longitudinal changes 
in glucose metabolism during pregnancy in obese women with normal glucose 
tolerance and gestational diabetes mellitus. Am J Obstet Gynecol. 180:903–916. 
Catalano, P.M., S.E. Nizielski, J. Shao, L. Preston, L. Qiao, and J.E. Friedman. 2002. 
Downregulated IRS-1 and PPARgamma in obese women with gestational diabetes: 
relationship to FFA during pregnancy. Am. J. Physiol. Endocrinol. Metab. 
282:E522–33. 
Cederberg, A., L.M. Grønning, B. Ahren, K. Taskén, P. Carlsson, and S. Enerbäck. 
2001. FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, 
 
191 
and diet-induced insulin resistance. Cell. 106:563–573. 
Chan, S.S.Y., L.J. Schedlich, S.M. Twigg, and R.C. Baxter. 2009. Inhibition of 
adipocyte differentiation by insulin-like growth factor-binding protein-3. Am. J. 
Physiol. Endocrinol. Metab. 296:E654–63. 
Christoffersen, C.T., H. Tornqvist, C.J. Vlahos, D. Bucchini, J. Jami, P. De Meyts, 
and R.L. Joshi. 1998. Insulin and Insulin-like Growth Factor-I Receptor Mediated 
Differentiation of 3T3-F442A Cells into Adipocytes: Effect of PI 3-Kinase 
Inhibition* 1. Biochem. Biophys. Res. Commun. 246:426–430. 
Cinti, S., C. Zancanaro, A. Sbarbati, M. Cicolini, P. Vogel, D. Ricquier, and S. 
Fakan. 1989. Immunoelectron microscopical identification of the uncoupling protein 
in brown adipose tissue mitochondria. Biol. Cell. 67:359–362. 
Coleman, R.A., and D.P. Lee. 2004. Enzymes of triacylglycerol synthesis and their 
regulation. Prog. Lipid Res. 43:134–176. 
Cousin, B., S. Cinti, and M. Morroni. 1992. Occurrence of brown adipocytes in rat 
white adipose tissue: molecular and morphological characterization. Journal of cell 
…. 
Cypess, A.M., S. Lehman, G. Williams, I. Tal, D. Rodman, A.B. Goldfine, F.C. Kuo, 
E.L. Palmer, Y.-H. Tseng, A. Doria, G.M. Kolodny, and C.R. Kahn. 2009. 
Identification and importance of brown adipose tissue in adult humans. N. Engl. J. 
Med. 360:1509–1517. 
D'Eon, T.M., S.C. Souza, M. Aronovitz, M.S. Obin, S.K. Fried, and A.S. Greenberg. 
2005. Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic 
and non-genomic regulation of lipogenic and oxidative pathways. J. Biol. Chem. 
280:35983–35991. 
Dandona, P., R. Weinstock, K. Thusu, E. Abdel-Rahman, A. Aljada, and T. Wadden. 
1998. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J 
Clin Endocrinol Metab. 83:2907–2910. 
 
192 
Darimont, C., I. Zbinden, O. Avanti, P. Leone-Vautravers, V. Giusti, P. Burckhardt, 
A.M.A. Pfeifer, and K. Macé. 2003. Reconstitution of telomerase activity combined 
with HPV-E7 expression allow human preadipocytes to preserve their differentiation 
capacity after immortalization. Cell Death Differ. 10:1025–1031. 
Darimont, C., O. Avanti, I. Zbinden, P. Leone-Vautravers, R. Mansourian, V. Giusti, 
and K. Macé. 2006. Liver X receptor preferentially activates de novo lipogenesis in 
human preadipocytes. Biochimie. 88:309–318. 
Day, C.P. 2005. Natural history of NAFLD: remarkably benign in the absence of 
cirrhosis. Gastroenterology. 129:375–378. 
Day, C.P., and O.F. James. 1998. Steatohepatitis: a tale of two "hits"? 
Gastroenterology. 114:842–845. 
de Castro, J., J. Sevillano, J. Marciniak, R. Rodriguez, C. González-Martín, M. 
Viana, O.H. Eun-suk, S.H. de Mouzon, E. Herrera, and M.P. Ramos. 2011. 
Implication of low level inflammation in the insulin resistance of adipose tissue at 
late pregnancy. Endocrinology. 152:4094–4105. 
Denison, F.C., K.A. Roberts, S.M. Barr, and J.E. Norman. 2010. Obesity, pregnancy, 
inflammation, and vascular function. Reproduction (Cambridge, England). 140:373–
385. 
Dennis, G.J., B. Sherman, D. Hosack, J. Yang, W. Gao, H. Lane, and R. Lempicki. 
2003. DAVID: Database for Annotation, Visualization, and Integrated Discovery. 
Genome Biol. 4:P3. 
Desbriere, R., V. Vuaroqueaux, V. Achard, S. Boullu-Ciocca, M. Labuhn, A. Dutour, 
and M. Grino. 2006. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is 
increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity 
(Silver Spring). 14:794–798. 
Dina, C., D. Meyre, S. Gallina, E. Durand, and A. Körner. 2007. Variation in FTO 
contributes to childhood obesity and severe adult obesity. Nat. Genet. 
 
193 
Donnelly, K.L., C.I. Smith, S.J. Schwarzenberg, J. Jessurun, M.D. Boldt, and E.J. 
Parks. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in 
patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115:1343–1351. 
Duncan, D.T.P.N.Z.B. 2010. WebGestalt2: an updated and expanded version of the 
Web-based Gene Set Analysis Toolkit. BMC Bioinformatics. 11:10. 
Duncan, R.E., M. Ahmadian, K. Jaworski, E. Sarkadi-Nagy, and H.S. Sul. 2007. 
Regulation of lipolysis in adipocytes. Annu. Rev. Nutr. 27:79–101. 
Eckardstein, Von, A., and H. Holz. 1991. Apolipoprotein C-III (Lys58----Glu). 
Identification of an apolipoprotein C-III variant in a family with 
hyperalphalipoproteinemia. Journal of Clinical …. 
Egan, J.J., A.S. Greenberg, M.K. Chang, S.A. Wek, M.C. Moos, and C. Londos. 
1992. Mechanism of hormone-stimulated lipolysis in adipocytes: translocation of 
hormone-sensitive lipase to the lipid storage droplet. Proc. Natl. Acad. Sci. U.S.A. 
89:8537–8541. 
Elbers, J.M., H. Asscheman, J.C. Seidell, J.A. Megens, and L.J. Gooren. 1997. Long-
term testosterone administration increases visceral fat in female to male transsexuals. 
J Clin Endocrinol Metab. 82:2044–2047. 
Enzi, G., M. Gasparo, P.R. Biondetti, D. Fiore, M. Semisa, and F. Zurlo. 1986. 
Subcutaneous and visceral fat distribution according to sex, age, and overweight, 
evaluated by computed tomography. Am. J. Clin. Nutr. 44:739–746. 
Fain, J.N., A.K. Madan, M.L. Hiler, P. Cheema, and S.W. Bahouth. 2004. 
Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and 
adipocytes from visceral and subcutaneous abdominal adipose tissues of obese 
humans. Endocrinology. 145:2273–2282. 
Farmer, S.R. 2006. Transcriptional control of adipocyte formation. Cell Metab. 
4:263–273. 
Fasshauer, M., J. Klein, S. Neumann, M. Eszlinger, and R. Paschke. 2002. Hormonal 
 
194 
regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem. Biophys. 
Res. Commun. 290:1084–1089. 
Fernandes, F.S., F.L.C. Sardinha, M. Badia-Villanueva, P. Carulla, E. Herrera, and 
M.G. Tavares do Carmo. 2012. Dietary lipids during early pregnancy differently 
influence adipose tissue metabolism and fatty acid composition in pregnant rats with 
repercussions on pup's development. Prostaglandins Leukot. Essent. Fatty Acids. 
86:167–174. 
Feuerer, M., L. Herrero, D. Cipolletta, A. Naaz, J. Wong, A. Nayer, J. Lee, A.B. 
Goldfine, C. Benoist, S. Shoelson, and D. Mathis. 2009. Lean, but not obese, fat is 
enriched for a unique population of regulatory T cells that affect metabolic 
parameters. Nat. Med. 15:930–939. 
Flint, D.J., M.T. Travers, M.C. Barber, N. Binart, and P.A. Kelly. 2005. Diet-induced 
obesity impairs mammary development and lactogenesis in murine mammary gland. 
Am. J. Physiol. Endocrinol. Metab. 288:E1179–87. 
Foryst-Ludwig, A., M. Clemenz, S. Hohmann, M. Hartge, C. Sprang, N. Frost, M. 
Krikov, S. Bhanot, R. Barros, A. Morani, J.-A. Gustafsson, T. Unger, and U. 
Kintscher. 2008. Metabolic actions of estrogen receptor beta (ERbeta) are mediated 
by a negative cross-talk with PPARgamma. PLoS Genet. 4:e1000108. 
Frayling, T.M., N.J. Timpson, M.N. Weedon, and E. Zeggini. 2007. A common 
variant in the FTO gene is associated with body mass index and predisposes to 
childhood and adult obesity. Science. 
Fredrikson, G., P. Strålfors, N.O. Nilsson, and P. Belfrage. 1981. Hormone-sensitive 
lipase of rat adipose tissue. Purification and some properties. J. Biol. Chem. 
256:6311–6320. 
Friedman, J.E., T. Ishizuka, J. Shao, L. Huston, T. Highman, and P. Catalano. 1999. 
Impaired glucose transport and insulin receptor tyrosine phosphorylation in skeletal 
muscle from obese women with gestational diabetes. Diabetes. 48:1807–1814. 
Gaillard, D., M. Wabitsch, B. Pipy, and R. Negrel. 1991. Control of terminal 
 
195 
differentiation of adipose precursor cells by glucocorticoids. J. Lipid Res. 32:569–
579. 
Galtier-Dereure, F., C. Boegner, and J. Bringer. 2000. Obesity and pregnancy: 
complications and cost. Am. J. Clin. Nutr. 71:1242S–8S. 
Gao, H., G. Bryzgalova, E. Hedman, A. Khan, S. Efendic, J.-A. Gustafsson, and K. 
Dahlman-Wright. 2006. Long-term administration of estradiol decreases expression 
of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: a possible 
mechanism is through direct regulation of signal transducer and activator of 
transcription 3. Mol. Endocrinol. 20:1287–1299. 
Gautier, L., L. Cope, B. Bolstad, and R. Irizarry. 2004. affy--analysis of Affymetrix 
GeneChip data at the probe level. Bioinformatics. 20:307–315. 
Gentleman, R., V. Carey, D. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis, L. 
Gautier, Y. Ge, J. Gentry, K. Hornik, T. Hothorn, W. Huber, S. Iacus, R. Irizarry, F. 
Leisch, C. Li, M. Maechler, A. Rossini, G. Sawitzki, C. Smith, G. Smyth, L. Tierney, 
J. Yang, and J. Zhang. 2004. Bioconductor: open software development for 
computational biology and bioinformatics. Genome Biol. 5:R80. 
Ghilardi, N., S. Ziegler, A. Wiestner, R. Stoffel, M.H. Heim, and R.C. Skoda. 1996. 
Defective STAT signaling by the leptin receptor in diabetic mice. Proc. Natl. Acad. 
Sci. U.S.A. 93:6231–6235. 
Ginsberg, H.N., N.A. Le, I.J. Goldberg, J.C. Gibson, A. Rubinstein, P. Wang-
Iverson, R. Norum, and W.V. Brown. 1986. Apolipoprotein B metabolism in 
subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein 
CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. 
J. Clin. Invest. 78:1287–1295. 
Greenberg, A.S., J.J. Egan, S.A. Wek, M.C. Moos, C. Londos, and A.R. Kimmel. 
1993. Isolation of cDNAs for perilipins A and B: sequence and expression of lipid 




Grohmann, M., M. Sabin, J. Holly, J. Shield, E. Crowne, and C. Stewart. 2005. 
Characterization of differentiated subcutaneous and visceral adipose tissue from 
children: the influences of TNF-alpha and IGF-I. J. Lipid Res. 46:93–103. 
Grosfeld, A., J. Andre, S. Hauguel-de Mouzon, E. Berra, J. Pouyssegur, and M. 
Guerre-Millo. 2002. Hypoxia-inducible factor 1 transactivates the human leptin gene 
promoter. J. Biol. Chem. 277:42953–42957. 
Guerra, C., R.A. Koza, H. Yamashita, K. Walsh, and L.P. Kozak. 1998. Emergence 
of brown adipocytes in white fat in mice is under genetic control. Effects on body 
weight and adiposity. J. Clin. Invest. 102:412–420. 
Guh, D.P., W. Zhang, N. Bansback, Z. Amarsi, C.L. Birmingham, and A.H. Anis. 
2009. The incidence of co-morbidities related to obesity and overweight: a 
systematic review and meta-analysis. BMC Public Health. 9:88. 
Gunderson, E.P., B. Sternfeld, M.F. Wellons, R.A. Whitmer, V. Chiang, C.P. 
Quesenberry, C.E. Lewis, and S. Sidney. 2008. Childbearing may increase visceral 
adipose tissue independent of overall increase in body fat. Obesity (Silver Spring). 
16:1078–1084. 
Hada, Y., T. Yamauchi, H. Waki, A. Tsuchida, K. Hara, H. Yago, O. Miyazaki, H. 
Ebinuma, and T. Kadowaki. 2007. Selective purification and characterization of 
adiponectin multimer species from human plasma. Biochem. Biophys. Res. Commun. 
356:487–493. 
Haeseleer, F., G.-F. Jang, Y. Imanishi, C.A.G.G. Driessen, M. Matsumura, P.S. 
Nelson, and K. Palczewski. 2002. Dual-substrate specificity short chain retinol 
dehydrogenases from the vertebrate retina. J. Biol. Chem. 277:45537–45546. 
Haisenleder, D.J., A.H. Schoenfelder, E.S. Marcinko, L.M. Geddis, and J.C. 
Marshall. 2011. Estimation of estradiol in mouse serum samples: evaluation of 
commercial estradiol immunoassays. Endocrinology. 152:4443–4447. 
Hamza, M.S., S. Pott, V.B. Vega, J.S. Thomsen, G.S. Kandhadayar, P.W.P. Ng, K.P. 
Chiu, S. Pettersson, C.L. Wei, Y. Ruan, and E.T. Liu. 2009. De-Novo Identification 
 
197 
of PPARγ/RXR Binding Sites and Direct Targets during Adipogenesis. PLoS ONE. 
4:e4907. 
Hanson, R. 2003. Glyceroneogenesis revisited. Biochimie. 85:1199–1205. 
HAPO Study Cooperative Research Group. 2009. Hyperglycemia and Adverse 
Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. 
Diabetes. 58:453–459. 
Hara, K., M. Horikoshi, T. Yamauchi, H. Yago, O. Miyazaki, H. Ebinuma, Y. Imai, 
R. Nagai, and T. Kadowaki. 2006. Measurement of the high-molecular weight form 
of adiponectin in plasma is useful for the prediction of insulin resistance and 
metabolic syndrome. Diabetes Care. 29:1357–1362. 
Harrison, S.A., S. Torgerson, and P.H. Hayashi. 2003. The natural history of 
nonalcoholic fatty liver disease: a clinical histopathological study. Am. J. 
Gastroenterol. 98:2042–2047. 
Hauguel-de Mouzon, S., J. Lepercq, and P. Catalano. 2006. The known and unknown 
of leptin in pregnancy. Am J Obstet Gynecol. 194:1537–1545. 
Heid, I.M., C. Vollmert, A. Hinney, A. Döring, F. Geller, H. Löwel, H.-E. 
Wichmann, T. Illig, J. Hebebrand, F. Kronenberg, KORA Group. 2005. Association 
of the 103I MC4R allele with decreased body mass in 7937 participants of two 
population based surveys. J. Med. Genet. 42:e21. 
Heine, P.A., J.A. Taylor, G.A. Iwamoto, D.B. Lubahn, and P.S. Cooke. 2000. 
Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. 
Proc. Natl. Acad. Sci. U.S.A. 97:12729–12734. 
Heinonen, M.V., A.K. Purhonen, P. Miettinen, M. Pääkkönen, E. Pirinen, E. Alhava, 
K. Akerman, and K.H. Herzig. 2005. Apelin, orexin-A and leptin plasma levels in 
morbid obesity and effect of gastric banding. Regul. Pept. 130:7–13. 
Henao-Mejia, J., E. Elinav, C. Jin, L. Hao, W.Z. Mehal, T. Strowig, C.A. Thaiss, 
A.L. Kau, S.C. Eisenbarth, M.J. Jurczak, J.-P. Camporez, G.I. Shulman, J.I. Gordon, 
 
198 
H.M. Hoffman, and R.A. Flavell. 2012. Inflammasome-mediated dysbiosis regulates 
progression of NAFLD and obesity. Nature. 482:179–185. 
Hepburn, I.S., and R.R. Schade. 2008. Pregnancy-associated liver disorders. Dig. 
Dis. Sci. 53:2334–2358. 
Hétu, P.-O., and D. Riendeau. 2007. Down-regulation of microsomal prostaglandin 
E2 synthase-1 in adipose tissue by high-fat feeding. Obesity (Silver Spring). 15:60–
68. 
Higuchi, N., M. Kato, Y. Shundo, H. Tajiri, M. Tanaka, N. Yamashita, M. Kohjima, 
K. Kotoh, M. Nakamuta, R. Takayanagi, and M. Enjoji. 2008. Liver X receptor in 
cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty 
liver disease. Hepatol. Res. 38:1122–1129. 
Himms-Hagen, J., J. Cui, E. Danforth, D.J. Taatjes, S.S. Lang, B.L. Waters, and T.H. 
Claus. 1994. Effect of CL-316,243, a thermogenic beta 3-agonist, on energy balance 
and brown and white adipose tissues in rats. Am. J. Physiol. 266:R1371–82. 
Hinney, A., and J. Hebebr. 2008. Polygenic Obesity in Humans. Obes Facts. 1:35–
42. 
Hoggard, N., L. Hunter, J. Duncan, L. Williams, P. Trayhurn, and J. Mercer. 1997. 
Leptin and leptin receptor mRNA and protein expression in the murine fetus and 
placenta. Proc. Natl. Acad. Sci. U.S.A. 94:11073–11078. 
Holm, C. 2003. Molecular mechanisms regulating hormone-sensitive lipase and 
lipolysis. Biochem. Soc. Trans. 31:1120–1124. 
Holzenberger, M., G. Hamard, R. Zaoui, P. Leneuve, B. Ducos, C. Beccavin, L. 
Périn, and Y. Le Bouc. 2001. Experimental IGF-I receptor deficiency generates a 
sexually dimorphic pattern of organ-specific growth deficits in mice, affecting fat 
tissue in particular. Endocrinology. 142:4469–4478. 
Homko, C.J., E. Sivan, E.A. Reece, and G. Boden. 1999. Fuel metabolism during 
pregnancy. Semin. Reprod. Endocrinol. 17:119–125. 
 
199 
Homma, H., H. Kurachi, Y. Nishio, T. Takeda, T. Yamamoto, K. Adachi, K. 
Morishige, M. Ohmichi, Y. Matsuzawa, and Y. Murata. 2000. Estrogen suppresses 
transcription of lipoprotein lipase gene. Existence of a unique estrogen response 
element on the lipoprotein lipase promoter. J. Biol. Chem. 275:11404–11411. 
Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman. 1993. Adipose expression of 
tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 
259:87–91. 
Hotamisligil, G.S., P. Arner, J.F. Caro, R.L. Atkinson, and B.M. Spiegelman. 1995. 
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity 
and insulin resistance. J. Clin. Invest. 95:2409–2415. 
Hua, X., C. Yokoyama, J. Wu, M.R. Briggs, M.S. Brown, J.L. Goldstein, and X. 
Wang. 1993. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that 
stimulates transcription by binding to a sterol regulatory element. Proc. Natl. Acad. 
Sci. U.S.A. 90:11603–11607. 
Huang da, W., B. Sherman, and R. Lempicki. 2009. Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 
4:44–57. 
INGALLS, A.M., M.M. DICKIE, and G.D. SNELL. 1950. Obese, a new mutation in 
the house mouse. J. Hered. 41:317–318. 
Inouye, K.E., H. Shi, J.K. Howard, C.H. Daly, G.M. Lord, B.J. Rollins, and J.S. 
Flier. 2007. Absence of CC chemokine ligand 2 does not limit obesity-associated 
infiltration of macrophages into adipose tissue. Diabetes. 56:2242–2250. 
Jensen, M.D. 1998. Diet effects on fatty acid metabolism in lean and obese humans. 
Am. J. Clin. Nutr. 67:531S–534S. 
Jones, H.N., L.A. Woollett, N. Barbour, P.D. Prasad, T.L. Powell, and T. Jansson. 
2009. High-fat diet before and during pregnancy causes marked up-regulation of 




Juge-Aubry, C.E., E. Somm, V. Giusti, A. Pernin, R. Chicheportiche, C. Verdumo, 
F. Rohner-Jeanrenaud, D. Burger, J.-M. Dayer, and C.A. Meier. 2003. Adipose tissue 
is a major source of interleukin-1 receptor antagonist: upregulation in obesity and 
inflammation. Diabetes. 52:1104–1110. 
Kadowaki, T., T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and K. Tobe. 2006. 
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the 
metabolic syndrome. J. Clin. Invest. 116:1784–1792. 
Kaestner, K.H., J.R. Flores-Riveros, J.C. McLenithan, M. Janicot, and M.D. Lane. 
1991. Transcriptional repression of the mouse insulin-responsive glucose transporter 
(GLUT4) gene by cAMP. Proc. Natl. Acad. Sci. U.S.A. 88:1933–1937. 
Kahn, S.E., R.L. Hull, and K.M. Utzschneider. 2006. Mechanisms linking obesity to 
insulin resistance and type 2 diabetes. Nature. 444:840–846. 
Kashima, H., T. Shiozawa, T. Miyamoto, A. Suzuki, J. Uchikawa, M. Kurai, and I. 
Konishi. 2009. Autocrine stimulation of IGF1 in estrogen-induced growth of 
endometrial carcinoma cells: involvement of the mitogen-activated protein kinase 
pathway followed by up-regulation of cyclin D1 and cyclin E. Endocr Relat Cancer. 
16:113–122. 
Kawai, M.M., M.M. Yamaguchi, T.T. Murakami, K.K. Shima, Y.Y. Murata, and 
K.K. Kishi. 1997. The Placenta Is Not the Main Source of Leptin Production in 
Pregnant Rat: Gestational Profile of Leptin in Plasma and Adipose Tissues. Biochem. 
Biophys. Res. Commun. 240:798–802. 
Kelley, D.E., M. Mokan, J.A. Simoneau, and L.J. Mandarino. 1993. Interaction 
between glucose and free fatty acid metabolism in human skeletal muscle. J. Clin. 
Invest. 92:91–98. 
Kern, P.A., S. Ranganathan, C. Li, L. Wood, and G. Ranganathan. 2001. Adipose 
tissue tumor necrosis factor and interleukin-6 expression in human obesity and 
insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280:E745–51. 
Khor, V.K., M.H. Tong, Y. Qian, and W.-C. Song. 2008. Gender-specific expression 
 
201 
and mechanism of regulation of estrogen sulfotransferase in adipose tissues of the 
mouse. Endocrinology. 149:5440–5448. 
Kinoshita, T., and M. Itoh. 2006. Longitudinal variance of fat mass deposition during 
pregnancy evaluated by ultrasonography: the ratio of visceral fat to subcutaneous fat 
in the abdomen. Gynecol. Obstet. Invest. 61:115–118. 
Kirchgessner, T.G., K.T. Uysal, S.M. Wiesbrock, M.W. Marino, and G.S. 
Hotamisligil. 1997. Tumor necrosis factor-alpha contributes to obesity-related 
hyperleptinemia by regulating leptin release from adipocytes. J. Clin. Invest. 
100:2777–2782. 
Kirkland, J.L., C.H. Hollenberg, S. Kindler, and W.S. Gillon. 1994. Effects of age 
and anatomic site on preadipocyte number in rat fat depots. J Gerontol. 49:B31–5. 
Kirwan, J.P., S. Hauguel-de Mouzon, J. Lepercq, J.-C. Challier, L. Huston-Presley, 
J.E. Friedman, S.C. Kalhan, and P.M. Catalano. 2002. TNF-alpha is a predictor of 
insulin resistance in human pregnancy. Diabetes. 51:2207–2213. 
Klotz, D., S. Hewitt, P. Ciana, M. Raviscioni, J. Lindzey, J. Foley, A. Maggi, R. 
DiAugustine, and K. Korach. 2002. Requirement of estrogen receptor-alpha in 
insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence 
for IGF-1/estrogen receptor cross-talk. J. Biol. Chem. 277:8531–8537. 
Klover, P.J., A.H. Clementi, and R.A. Mooney. 2005. Interleukin-6 depletion 
selectively improves hepatic insulin action in obesity. Endocrinology. 146:3417–
3427. 
Klöting, N., M. Blüher, and I. Klöting. 2006. The polygenetically inherited metabolic 
syndrome of WOKW rats is associated with insulin resistance and altered gene 
expression in adipose tissue. Diabetes Metab. Res. Rev. 22:146–154. 
Kolak, M., J. Westerbacka, V.R. Velagapudi, D. Wågsäter, L. Yetukuri, J. 
Makkonen, A. Rissanen, A.-M. Häkkinen, M. Lindell, R. Bergholm, A. Hamsten, P. 
Eriksson, R.M. Fisher, M. Oresic, and H. Yki-Järvinen. 2007. Adipose tissue 
inflammation and increased ceramide content characterize subjects with high liver fat 
 
202 
content independent of obesity. Diabetes. 56:1960–1968. 
Kotronen, A., T. Seppänen-Laakso, J. Westerbacka, T. Kiviluoto, J. Arola, A.-L. 
Ruskeepää, M. Oresic, and H. Yki-Järvinen. 2009. Hepatic stearoyl-CoA desaturase 
(SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in 
the nonalcoholic human fatty liver. Diabetes. 58:203–208. 
Koutsari, C., and M.D. Jensen. 2006. Thematic review series: patient-oriented 
research. Free fatty acid metabolism in human obesity. J. Lipid Res. 47:1643–1650. 
Ladyman, S.R., D.M. Fieldwick, and D.R. Grattan. 2012. Suppression of leptin-
induced hypothalamic JAK/STAT signalling and feeding response during pregnancy 
in the mouse. Reproduction (Cambridge, England). 144:83–90. 
Lands, A.M., A. Arnold, J.P. McAuliff, F.P. Luduena, and T.G. Brown. 1967. 
Differentiation of receptor systems activated by sympathomimetic amines. Nature. 
214:597–598. 
Large, V., S. Reynisdottir, D. Langin, K. Fredby, M. Klannemark, C. Holm, and P. 
Arner. 1999. Decreased expression and function of adipocyte hormone-sensitive 
lipase in subcutaneous fat cells of obese subjects. J. Lipid Res. 40:2059–2066. 
Lee, K.-W., L.J. Cobb, V. Paharkova-Vatchkova, B. Liu, J. Milbrandt, and P. Cohen. 
2007. Contribution of the orphan nuclear receptor Nur77 to the apoptotic action of 
IGFBP-3. Carcinogenesis. 28:1653–1658. 
Leonardsson, G., J.H. Steel, M. Christian, V. Pocock, S. Milligan, J. Bell, P.-W. So, 
G. Medina-Gomez, A. Vidal-Puig, R. White, and M.G. Parker. 2004. Nuclear 
receptor corepressor RIP140 regulates fat accumulation. Proc. Natl. Acad. Sci. 
U.S.A. 101:8437–8442. 
Liu, B., H.Y. Lee, S.A. Weinzimer, D.R. Powell, J.L. Clifford, J.M. Kurie, and P. 
Cohen. 2000. Direct functional interactions between insulin-like growth factor-
binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and 
apoptosis. J. Biol. Chem. 275:33607–33613. 
 
203 
Liu, H.-F., M.-X. Gui, H. Dong, X. Wang, and X.-W. Li. 2012. Differential 
expression of AdipoR1, IGFBP3, PPARγ and correlative genes during porcine 
preadipocyte differentiation. In Vitro Cell. Dev. Biol. Anim. 48:54–60. 
Livingstone, D.E., G.C. Jones, K. Smith, P.M. Jamieson, R. Andrew, C.J. Kenyon, 
and B.R. Walker. 2000. Understanding the role of glucocorticoids in obesity: tissue-
specific alterations of corticosterone metabolism in obese Zucker rats. 
Endocrinology. 141:560–563. 
Locher, L.F., N. Meyer, E.-M. Weber, J. Rehage, U. Meyer, S. Dänicke, and K. 
Huber. 2011. Hormone-sensitive lipase protein expression and extent of 
phosphorylation in subcutaneous and retroperitoneal adipose tissues in the 
periparturient dairy cow. J. Dairy Sci. 94:4514–4523. 
Lowell, B.B., V. S-Susulic, A. Hamann, J.A. Lawitts, J. Himms-Hagen, B.B. Boyer, 
L.P. Kozak, and J.S. Flier. 1993. Development of obesity in transgenic mice after 
genetic ablation of brown adipose tissue. Nature. 366:740–742. 
López-Tinoco, C., M. Roca, A. Fernández-Deudero, A. García-Valero, F. Bugatto, 
M. Aguilar-Diosdado, and J.L. Bartha. 2012. Cytokine profile, metabolic syndrome 
and cardiovascular disease risk in women with late-onset gestational diabetes 
mellitus. Cytokine. 58:14–19. 
Löllmann, B., S. Grüninger, A. Stricker-Krongrad, and M. Chiesi. 1997. Detection 
and quantification of the leptin receptor splice variants Ob-Ra, b, and, e in different 
mouse tissues. Biochem. Biophys. Res. Commun. 238:648–652. 
Luan, Y., T. Hirashima, Z.-W. Man, M.-W. Wang, K. Kawano, and T. Sumida. 
2002. Pathogenesis of obesity by food restriction in OLETF rats-increased intestinal 
monoacylglycerol acyltransferase activities may be a crucial factor. Diabetes Res. 
Clin. Pract. 57:75–82. 
Lumeng, C., J. Bodzin, and A. Saltiel. 2007a. Obesity induces a phenotypic switch in 
adipose tissue macrophage polarization. J. Clin. Invest. 117:175–184. 
Lumeng, C., S. Deyoung, J. Bodzin, and A. Saltiel. 2007b. Increased inflammatory 
 
204 
properties of adipose tissue macrophages recruited during diet-induced obesity. 
Diabetes. 56:16–23. 
Lumeng, C.N., I. Maillard, and A.R. Saltiel. 2009. T-ing up inflammation in fat. Nat. 
Med. 15:846–847. 
Lumeng, C.N., J.B. DelProposto, D.J. Westcott, and A.R. Saltiel. 2008. Phenotypic 
switching of adipose tissue macrophages with obesity is generated by spatiotemporal 
differences in macrophage subtypes. Diabetes. 57:3239–3246. 
Maffei, M., H. Fei, G.H. Lee, C. Dani, P. Leroy, Y. Zhang, R. Proenca, R. Negrel, G. 
Ailhaud, and J.M. Friedman. 1995. Increased expression in adipocytes of ob RNA in 
mice with lesions of the hypothalamus and with mutations at the db locus. Proc. 
Natl. Acad. Sci. U.S.A. 92:6957–6960. 
Makkonen, J., J. Westerbacka, M. Kolak, J. Sutinen, A. Cornér, A. Hamsten, R.M. 
Fisher, and H. Yki-Järvinen. 2007. Increased expression of the macrophage markers 
and of 11beta-HSD-1 in subcutaneous adipose tissue, but not in cultured monocyte-
derived macrophages, is associated with liver fat in human obesity. Int J Obes Relat 
Metab Disord. 31:1617–1625. 
Malik, V.S., M.B. Schulze, and F.B. Hu. 2006. Intake of sugar-sweetened beverages 
and weight gain: a systematic review. Am. J. Clin. Nutr. 84:274–288. 
Margetic, S., C. Gazzola, G.G. Pegg, and R.A. Hill. 2002. Leptin: a review of its 
peripheral actions and interactions. Int J Obes Relat Metab Disord. 26:1407–1433. 
Martin, A.M., H. Berger, R. Nisenbaum, A.Y. Lausman, S. MacGarvie, C. Crerar, 
and J.G. Ray. 2009. Abdominal visceral adiposity in the first trimester predicts 
glucose intolerance in later pregnancy. Diabetes Care. 32:1308–1310. 
Masuzaki, H., J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, and 
J.S. Flier. 2001. A transgenic model of visceral obesity and the metabolic syndrome. 
Science. 294:2166–2170. 
Maury, E., and S.M. Brichard. 2010. Adipokine dysregulation, adipose tissue 
 
205 
inflammation and metabolic syndrome. Mol. Cell. Endocrinol. 314:1–16. 
Mayes, J.S., and G.H. Watson. 2004. Direct effects of sex steroid hormones on 
adipose tissues and obesity. Obes Rev. 5:197–216. 
McCormack, J., and G. Greenwald. 1974. Progesterone and oestradiol-17beta 
concentrations in the peripheral plasma during pregnancy in the mouse. J. 
Endocrinol. 62:101–107. 
Michailidou, Z., M.D. Jensen, D.A. Dumesic, K.E. Chapman, J.R. Seckl, B.R. 
Walker, and N.M. Morton. 2007. Omental 11beta-hydroxysteroid dehydrogenase 1 
correlates with fat cell size independently of obesity. Obesity (Silver Spring). 
15:1155–1163. 
Miki, H., T. Yamauchi, R. Suzuki, K. Komeda, A. Tsuchida, N. Kubota, Y. 
Terauchi, J. Kamon, Y. Kaburagi, J. Matsui, Y. Akanuma, R. Nagai, S. Kimura, K. 
Tobe, and T. Kadowaki. 2001. Essential role of insulin receptor substrate 1 (IRS-1) 
and IRS-2 in adipocyte differentiation. Mol. Cell. Biol. 21:2521–2532. 
Mise, H., N. Sagawa, T. Matsumoto, S. Yura, H. Nanno, H. Itoh, T. Mori, H. 
Masuzaki, K. Hosoda, Y. Ogawa, and K. Nakao. 1998. Augmented placental 
production of leptin in preeclampsia: possible involvement of placental hypoxia. J 
Clin Endocrinol Metab. 83:3225–3229. 
Mizutani, T., Y. Nishikawa, H. Adachi, T. Enomoto, H. Ikegami, H. Kurachi, T. 
Nomura, and A. Miyake. 1994. Identification of estrogen receptor in human adipose 
tissue and adipocytes. J Clin Endocrinol Metab. 78:950–954. 
Mokdad, A.H., E.S. Ford, B.A. Bowman, W.H. Dietz, F. Vinicor, V.S. Bales, and 
J.S. Marks. 2003. Prevalence of obesity, diabetes, and obesity-related health risk 
factors, 2001. JAMA. 289:76–79. 
Moreira, F.A., and J.A.S. Crippa. 2009. The psychiatric side-effects of rimonabant. 
Rev Bras Psiquiatr. 31:145–153. 
Morioka, T., E. Asilmaz, J. Hu, J.F. Dishinger, A.J. Kurpad, C.F. Elias, H. Li, J.K. 
 
206 
Elmquist, R.T. Kennedy, and R.N. Kulkarni. 2007. Disruption of leptin receptor 
expression in the pancreas directly affects beta cell growth and function in mice. J. 
Clin. Invest. 117:2860–2868. 
Morton, N.M. 2010. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a 
cause and therapeutic target in metabolic disease. Mol. Cell. Endocrinol. 316:154–
164. 
Morton, N.M., J.M. Paterson, H. Masuzaki, M.C. Holmes, B. Staels, C. Fievet, B.R. 
Walker, J.S. Flier, J.J. Mullins, and J.R. Seckl. 2004. Novel adipose tissue-mediated 
resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase 
type 1-deficient mice. Diabetes. 53:931–938. 
Morton, N.M., V. Densmore, M. Wamil, L. Ramage, K. Nichol, L. Bünger, J.R. 
Seckl, and C.J. Kenyon. 2005. A polygenic model of the metabolic syndrome with 
reduced circulating and intra-adipose glucocorticoid action. Diabetes. 54:3371–3378. 
Moynihan, A.T., M.P. Hehir, S.V. Glavey, T.J. Smith, and J.J. Morrison. 2006. 
Inhibitory effect of leptin on human uterine contractility in vitro. Am J Obstet 
Gynecol. 195:504–509. 
Muise-Helmericks, R.C., H.L. Grimes, A. Bellacosa, S.E. Malstrom, P.N. Tsichlis, 
and N. Rosen. 1998. Cyclin D expression is controlled post-transcriptionally via a 
phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem. 273:29864–
29872. 
Nguyen, M., S. Favelyukis, A. Nguyen, D. Reichart, P. Scott, A. Jenn, R. Liu-Bryan, 
C. Glass, J. Neels, and J. Olefsky. 2007. A subpopulation of macrophages infiltrates 
hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 
2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282:35279–35292. 
Nielsen, S., Z. Guo, C.M. Johnson, D.D. Hensrud, and M.D. Jensen. 2004. 
Splanchnic lipolysis in human obesity. J. Clin. Invest. 113:1582–1588. 
Nishimura, S., I. Manabe, M. Nagasaki, K. Eto, H. Yamashita, M. Ohsugi, M. Otsu, 
K. Hara, K. Ueki, S. Sugiura, K. Yoshimura, T. Kadowaki, and R. Nagai. 2009. 
 
207 
CD8+ effector T cells contribute to macrophage recruitment and adipose tissue 
inflammation in obesity. Nat. Med. 15:914–920. 
Pal, D., S. Dasgupta, R. Kundu, S. Maitra, G. Das, S. Mukhopadhyay, S. Ray, S.S. 
Majumdar, and S. Bhattacharya. 2012. Fetuin-A acts as an endogenous ligand of 
TLR4 to promote lipid-induced insulin resistance. Nat. Med. 
Paolisso, G., A. Gambardella, L. Amato, R. Tortoriello, A. D'Amore, M. Varricchio, 
and F. D'Onofrio. 1995. Opposite effects of short- and long-term fatty acid infusion 
on insulin secretion in healthy subjects. Diabetologia. 38:1295–1299. 
Pasquali, R., L. Gagliardi, V. Vicennati, A. Gambineri, D. Colitta, L. Ceroni, and F. 
Casimirri. 1999. ACTH and cortisol response to combined corticotropin releasing 
hormone-arginine vasopressin stimulation in obese males and its relationship to body 
weight, fat distribution and parameters of the metabolic syndrome. Int J Obes Relat 
Metab Disord. 23:419–424. 
Paterson, J.M., N.M. Morton, C. Fievet, C.J. Kenyon, M.C. Holmes, B. Staels, J.R. 
Seckl, and J.J. Mullins. 2004. Metabolic syndrome without obesity: Hepatic 
overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. 
Proc. Natl. Acad. Sci. U.S.A. 101:7088–7093. 
Paulsen, S.K., S.B. Pedersen, S. Fisker, and B. Richelsen. 2007. 11Beta-HSD type 1 
expression in human adipose tissue: impact of gender, obesity, and fat localization. 
Obesity (Silver Spring). 15:1954–1960. 
Pedersen, S.B., J.M. Bruun, F. Hube, K. Kristensen, H. Hauner, and B. Richelsen. 
2001. Demonstration of estrogen receptor subtypes alpha and beta in human adipose 
tissue: influences of adipose cell differentiation and fat depot localization. Mol. Cell. 
Endocrinol. 182:27–37. 
Pedersen, S.B., M. Jønler, and B. Richelsen. 1994. Characterization of regional and 
gender differences in glucocorticoid receptors and lipoprotein lipase activity in 
human adipose tissue. J Clin Endocrinol Metab. 78:1354–1359. 
Phung, T.L., A. Roncone, K.L. Jensen, C.E. Sparks, and J.D. Sparks. 1997. 
 
208 
Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of 
apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic 
reticulum. J. Biol. Chem. 272:30693–30702. 
Piermaría, J., G. Cónsole, M. Perelló, G. Moreno, R.C. Gaillard, and E. Spinedi. 
2003. Impact of estradiol on parametrial adipose tissue function: evidence for 
establishment of a new set point of leptin sensitivity in control of energy metabolism 
in female rat. Endocrine. 20:239–245. 
Piro, S., D. Spampinato, L. Spadaro, C.E. Oliveri, F. Purrello, and A.M. Rabuazzo. 
2008. Direct apoptotic effects of free fatty acids on human endothelial cells. Nutr 
Metab Cardiovasc Dis. 18:96–104. 
Pirro, M., P. Mauriège, A. Tchernof, B. Cantin, G.R. Dagenais, J.-P. Després, and B. 
Lamarche. 2002. Plasma free fatty acid levels and the risk of ischemic heart disease 
in men: prospective results from the Québec Cardiovascular Study. Atherosclerosis. 
160:377–384. 
Pockros, P.J., R.L. Peters, and T.B. Reynolds. 1984. Idiopathic fatty liver of 
pregnancy: findings in ten cases. Medicine (Baltimore). 63:1–11. 
Poskitt, E.M.E. 2009. Countries in transition: underweight to obesity non-stop? Ann 
Trop Paediatr. 29:1–11. 
Prentki, M., E. Joly, W. El-Assaad, and R. Roduit. 2002. Malonyl-CoA signaling, 
lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the 
etiology of diabetes. Diabetes. 51 Suppl 3:S405–13. 
Price, T.M., and S.N. O'Brien. 1993. Determination of estrogen receptor messenger 
ribonucleic acid (mRNA) and cytochrome P450 aromatase mRNA levels in 
adipocytes and adipose stromal cells by competitive polymerase chain reaction 
amplification. J Clin Endocrinol Metab. 77:1041–1045. 
Ramachenderan, J., J. Bradford, and M. McLean. 2008. Maternal obesity and 
pregnancy complications: a review. Aust N Z J Obstet Gynaecol. 48:228–235. 
 
209 
Ramsay, J.E., W.R. Ferrell, L. Crawford, A.M. Wallace, I.A. Greer, and N. Sattar. 
2002. Maternal obesity is associated with dysregulation of metabolic, vascular, and 
inflammatory pathways. J Clin Endocrinol Metab. 87:4231–4237. 
Ranheim, T., F. Haugen, A.C. Staff, K. Braekke, N.K. Harsem, and C.A. Drevon. 
2004. Adiponectin is reduced in gestational diabetes mellitus in normal weight 
women. Acta obstetricia et gynecologica Scandinavica. 83:341–347. 
Rasouli, N., and P.A. Kern. 2008. Adipocytokines and the metabolic complications 
of obesity. J Clin Endocrinol Metab. 93:S64–73. 
Resi, V., S. Basu, M. Haghiac, L. Presley, J. Minium, B. Kaufman, S. Bernard, P.M. 
Catalano, and S. Hauguel-de Mouzon. 2012. Molecular inflammation and adipose 
tissue matrix remodeling precede physiologic adaptations to pregnancy. Am. J. 
Physiol. Endocrinol. Metab. 
Reyes, H., L. Sandoval, A. Wainstein, J. Ribalta, S. Donoso, G. Smok, H. 
Rosenberg, and M. Meneses. 1994. Acute fatty liver of pregnancy: a clinical study of 
12 episodes in 11 patients. Gut. 35:101–106. 
Reynisdottir, S., D. Langin, K. Carlström, C. Holm, S. Rössner, and P. Arner. 1995. 
Effects of weight reduction on the regulation of lipolysis in adipocytes of women 
with upper-body obesity. Clin. Sci. 89:421–429. 
Richelsen, B. 1986. Increased alpha 2- but similar beta-adrenergic receptor activities 
in subcutaneous gluteal adipocytes from females compared with males. Eur. J. Clin. 
Invest. 16:302–309. 
Ricquier, D., L. Casteilla, and F. Bouillaud. 1991. Molecular studies of the 
uncoupling protein. The FASEB journal. 
Risch, N., and K. Merikangas. 1996. The Future of Genetic Studies of Complex 
Human Diseases. Science. 273:1516–1517. 
Roesch, D.M. 2006. Effects of selective estrogen receptor agonists on food intake 
and body weight gain in rats. Physiol. Behav. 87:39–44. 
 
210 
Rosen, E.D., and O.A. MacDougald. 2006. Adipocyte differentiation from the inside 
out. Nat. Rev. Mol. Cell Biol. 7:885–896. 
Rotter, V., I. Nagaev, and U. Smith. 2003. Interleukin-6 (IL-6) induces insulin 
resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, 
overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 
278:45777–45784. 
Rutkowski, J.M., K.E. Davis, and P.E. Scherer. 2009. Mechanisms of obesity and 
related pathologies: the macro- and microcirculation of adipose tissue. FEBS J. 
276:5738–5746. 
Saberi, M., N.-B. Woods, C. de Luca, S. Schenk, J.C. Lu, G. Bandyopadhyay, I.M. 
Verma, and J.M. Olefsky. 2009. Hematopoietic cell-specific deletion of toll-like 
receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed 
mice. Cell Metab. 10:419–429. 
Sabio, G., M. Das, A. Mora, Z. Zhang, J.Y. Jun, H.J. Ko, T. Barrett, J.K. Kim, and 
R.J. Davis. 2008. A stress signaling pathway in adipose tissue regulates hepatic 
insulin resistance. Science. 322:1539–1543. 
Sakoda, H., T. Ogihara, M. Anai, M. Funaki, K. Inukai, H. Katagiri, Y. Fukushima, 
Y. Onishi, H. Ono, M. Fujishiro, M. Kikuchi, Y. Oka, and T. Asano. 2000. 
Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition 
of glucose transport rather than insulin signal transduction. Diabetes. 49:1700–1708. 
Sargin, H., M. Sargin, H. Gozu, A. Orcun, G. Baloglu, M. Ozisik, M. Seker, and O. 
Uygur-Bayramicli. 2005. Is adiponectin level a predictor of nonalcoholic fatty liver 
disease in nondiabetic male patients? World J. Gastroenterol. 11:5874–5877. 
Satoh, N.N., Y.Y. Ogawa, G.G. Katsuura, Y.Y. Numata, T.T. Tsuji, M.M. Hayase, 
K.K. Ebihara, H.H. Masuzaki, K.K. Hosoda, Y.Y. Yoshimasa, and K.K. Nakao. 
1999. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-
induced increase in catecholamine secretion. Diabetes. 48:1787–1793. 
Scavo, L.M., M. Karas, M. Murray, and D. Leroith. 2004. Insulin-like growth factor-
 
211 
I stimulates both cell growth and lipogenesis during differentiation of human 
mesenchymal stem cells into adipocytes. J Clin Endocrinol Metab. 89:3543–3553. 
Schaeffler, A., P. Gross, R. Buettner, C. Bollheimer, C. Buechler, M. Neumeier, A. 
Kopp, J. Schoelmerich, and W. Falk. 2009. Fatty acid-induced induction of Toll-like 
receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling 
with innate immunity. Immunology. 126:233–245. 
Schaiff, W.T., Y. Barak, and Y. Sadovsky. 2006. The pleiotropic function of PPAR 
gamma in the placenta. Mol. Cell. Endocrinol. 249:10–15. 
doi:10.1016/j.mce.2006.02.009. 
Schedlich, L.J., A. Muthukaruppan, M.K. O'Han, and R.C. Baxter. 2007. Insulin-like 
growth factor binding protein-5 interacts with the vitamin D receptor and modulates 
the vitamin D response in osteoblasts. Mol. Endocrinol. 21:2378–2390. 
Schedlich, L.J., M.K. O'Han, G.M. Leong, and R.C. Baxter. 2004. Insulin-like 
growth factor binding protein-3 prevents retinoid receptor heterodimerization: 
implications for retinoic acid-sensitivity in human breast cancer cells. Biochem. 
Biophys. Res. Commun. 314:83–88. 
Schedlich, L.J., S.L. Le Page, S.M. Firth, L.J. Briggs, D.A. Jans, and R.C. Baxter. 
2000. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is 
mediated by the importin beta subunit. J. Biol. Chem. 275:23462–23470. 
Scott, D.K. 1998. The Repression of Hormone-activated PEPCK Gene Expression by 
Glucose Is Insulin-independent but Requires Glucose Metabolism. Journal of 
Biological Chemistry. 273:24145–24151. 
Sengenès, C., M. Berlan, I. De Glisezinski, M. Lafontan, and J. Galitzky. 2000. 
Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 
14:1345–1351. 
Shi, Y., and P. Burn. 2004. Lipid metabolic enzymes: emerging drug targets for the 
treatment of obesity. Nat Rev Drug Discov. 3:695–710. 
 
212 
Shrago, E., H. Lardy, and R. Nordlie. 1963. Metabolic and hormonal control of 
phosphoenolpyruvate carboxykinase and malic enzyme in rat liver. Journal of 
Biological . 
Shulman, G.I. 2000. Cellular mechanisms of insulin resistance. J. Clin. Invest. 
106:171–176. 
Siegrist-Kaiser, C.A., V. Pauli, C.E. Juge-Aubry, O. Boss, A. Pernin, W.W. Chin, I. 
Cusin, F. Rohner-Jeanrenaud, A.G. Burger, J. Zapf, and C.A. Meier. 1997. Direct 
effects of leptin on brown and white adipose tissue. J. Clin. Invest. 100:2858–2864. 
Slavin, B.G., J.M. Ong, and P.A. Kern. 1994. Hormonal regulation of hormone-
sensitive lipase activity and mRNA levels in isolated rat adipocytes. J. Lipid Res. 
35:1535–1541. 
Smith, P., L. Wise, R. Berkowitz, C. Wan, and C. Rubin. 1988. Insulin-like growth 
factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J. Biol. 
Chem. 263:9402–9408. 
Smyth, G. 2004. Linear models and empirical bayes methods for assessing 
differential expression in microarray experiments. Stat Appl Genet Mol Biol. 
3:Article3. 
Song, M.J., K.H. Kim, J.M. Yoon, and J.B. Kim. 2006. Activation of Toll-like 
receptor 4 is associated with insulin resistance in adipocytes. Biochem. Biophys. Res. 
Commun. 346:739–745. 
Soukas, A., N.D. Socci, B.D. Saatkamp, S. Novelli, and J.M. Friedman. 2001. 
Distinct transcriptional profiles of adipogenesis in vivo and in vitro. J. Biol. Chem. 
276:34167–34174. 
Souza, S.C., L.M. de Vargas, M.T. Yamamoto, P. Lien, M.D. Franciosa, L.G. Moss, 
and A.S. Greenberg. 1998. Overexpression of perilipin A and B blocks the ability of 




Spalding, K., E. Arner, and P. Westermark. 2007. Dynamics of Adipocyte Turnover 
in Humans. Nature. 
Spalding, K.L., E. Arner, P.O. Westermark, and S. Bernard. 2008. Dynamics of fat 
cell turnover in humans. Nature. 
Speakman, J., C. Hambly, S. Mitchell, and E. Król. 2008. The contribution of animal 
models to the study of obesity. Lab. Anim. 42:413–432. 
Stauffer, S.R., C.J. Coletta, R. Tedesco, G. Nishiguchi, K. Carlson, J. Sun, B.S. 
Katzenellenbogen, and J.A. Katzenellenbogen. 2000. Pyrazole ligands: structure-
affinity/activity relationships and estrogen receptor-alpha-selective agonists. J. Med. 
Chem. 43:4934–4947. 
Steinberg, H.O., M. Tarshoby, R. Monestel, G. Hook, J. Cronin, A. Johnson, B. 
Bayazeed, and A.D. Baron. 1997. Elevated circulating free fatty acid levels impair 
endothelium-dependent vasodilation. J. Clin. Invest. 100:1230–1239. 
Steppan, C.M., and M.A. Lazar. 2002. Resistin and obesity-associated insulin 
resistance. Trends Endocrinol. Metab. 13:18–23. 
Stewart, F.M., D.J. Freeman, J.E. Ramsay, I.A. Greer, M. Caslake, and W.R. Ferrell. 
2007. Longitudinal assessment of maternal endothelial function and markers of 
inflammation and placental function throughout pregnancy in lean and obese 
mothers. J Clin Endocrinol Metab. 92:969–975. 
Stojiljkovic, M.P., D. Zhang, H.F. Lopes, C.G. Lee, T.L. Goodfriend, and B.M. 
Egan. 2001. Hemodynamic effects of lipids in humans. Am. J. Physiol. Regul. Integr. 
Comp. Physiol. 280:R1674–9. 
Straczkowski, M., S. Dzienis-Straczkowska, A. Stêpieñ, I. Kowalska, M. 
Szelachowska, and I. Kinalska. 2002. Plasma interleukin-8 concentrations are 
increased in obese subjects and related to fat mass and tumor necrosis factor-alpha 
system. J Clin Endocrinol Metab. 87:4602–4606. 
Suganami, T., T. Mieda, M. Itoh, Y. Shimoda, Y. Kamei, and Y. Ogawa. 2007. 
 
214 
Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice 
carrying a Toll-like receptor 4 mutation. Biochem. Biophys. Res. Commun. 354:45–
49. 
Surwit, R.S., C.M. Kuhn, C. Cochrane, J.A. McCubbin, and M.N. Feinglos. 1988. 
Diet-induced type II diabetes in C57BL/6J mice. Diabetes. 37:1163–1167. 
Surwit, R.S., M.N. Feinglos, J. Rodin, and A. Sutherland. 1995. Differential effects 
of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J 
mice. Metabolism. 
Taha, C., and A. Klip. 1999. The insulin signaling pathway. J. Membr. Biol. 169:1–
12. 
Tansey, J.T., A.M. Huml, R. Vogt, K.E. Davis, J.M. Jones, K.A. Fraser, D.L. 
Brasaemle, A.R. Kimmel, and C. Londos. 2003. Functional studies on native and 
mutated forms of perilipins. A role in protein kinase A-mediated lipolysis of 
triacylglycerols. J. Biol. Chem. 278:8401–8406. 
Thomas, E.L., G. Hamilton, N. Patel, R. O'Dwyer, C.J. Doré, R.D. Goldin, J.D. Bell, 
and S.D. Taylor-Robinson. 2005. Hepatic triglyceride content and its relation to body 
adiposity: a magnetic resonance imaging and proton magnetic resonance 
spectroscopy study. Gut. 54:122–127. 
Tomimatsu, T., M. Yamaguchi, T. Murakami, K. Ogura, M. Sakata, N. Mitsuda, T. 
Kanzaki, H. Kurachi, M. Irahara, A. Miyake, K. Shima, T. Aono, and Y. Murata. 
1997. Increase of mouse leptin production by adipose tissue after midpregnancy: 
gestational profile of serum leptin concentration. Biochem. Biophys. Res. Commun. 
240:213–215. 
Tontonoz, P., J.B. Kim, R.A. Graves, and B.M. Spiegelman. 1993. ADD1: a novel 
helix-loop-helix transcription factor associated with adipocyte determination and 
differentiation. Mol. Cell. Biol. 13:4753–4759. 
Tsigos, C., V. Hainer, A. Basdevant, N. Finer, M. Fried, E. Mathus-Vliegen, D. 
Micic, M. Maislos, G. Roman, Y. Schutz, H. Toplak, B. Zahorska-Markiewicz, 
 
215 
Obesity Management Task Force of the European Association for the Study of 
Obesity. 2008. Management of obesity in adults: European clinical practice 
guidelines. Obes Facts. 1:106–116. 
Turgeon, J.L., M.C. Carr, P.M. Maki, M.E. Mendelsohn, and P.M. Wise. 2006. 
Complex actions of sex steroids in adipose tissue, the cardiovascular system, and 
brain: Insights from basic science and clinical studies. Endocr. Rev. 27:575–605. 
Unger, R.H., Y.T. Zhou, and L. Orci. 1999. Regulation of fatty acid homeostasis in 
cells: novel role of leptin. Proc. Natl. Acad. Sci. U.S.A. 96:2327–2332. 
Uysal, K.T., S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil. 1997. Protection 
from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 
389:610–614. 
Vague, J., J.M. Meignen, and J.F. Negrin. 1984. Effects of testosterone and estrogens 
on deltoid and trochanter adipocytes in two cases of transsexualism. Horm. Metab. 
Res. 16:380–381. 
Villena, J.A., B. Viollet, F. Andreelli, A. Kahn, S. Vaulont, and H.S. Sul. 2004. 
Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated 
protein kinase-alpha2 subunit. Diabetes. 53:2242–2249. 
Wang, S., K.G. Soni, M. Semache, S. Casavant, M. Fortier, L. Pan, and G.A. 
Mitchell. 2008. Lipolysis and the integrated physiology of lipid energy metabolism. 
Mol. Genet. Metab. 95:117–126. 
Weisberg, S.P., D. Hunter, R. Huber, J. Lemieux, S. Slaymaker, K. Vaddi, I. Charo, 
R.L. Leibel, and A.W. Ferrante. 2006. CCR2 modulates inflammatory and metabolic 
effects of high-fat feeding. J. Clin. Invest. 116:115–124. 
Wilson-Fritch, L., S. Nicoloro, M. Chouinard, M.A. Lazar, P.C. Chui, J. Leszyk, J. 
Straubhaar, M.P. Czech, and S. Corvera. 2004. Mitochondrial remodeling in adipose 




Windler, E., and R.J. Havel. 1985. Inhibitory effects of C apolipoproteins from rats 
and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the 
perfused rat liver. J. Lipid Res. 26:556–565. 
Winer, S., Y. Chan, G. Paltser, D. Truong, H. Tsui, J. Bahrami, R. Dorfman, Y. 
Wang, J. Zielenski, F. Mastronardi, Y. Maezawa, D.J. Drucker, E. Engleman, D. 
Winer, and H.-M. Dosch. 2009. Normalization of obesity-associated insulin 
resistance through immunotherapy. Nat. Med. 15:921–929. 
Wu, H., X. Perrard, Q. Wang, J. Perrard, V. Polsani, P. Jones, C. Smith, and C. 
Ballantyne. 2010. CD11c expression in adipose tissue and blood and its role in diet-
induced obesity. Arterioscler Thromb Vasc Biol. 30:186–192. 
Xu, H., G.T. Barnes, Q. Yang, G. Tan, D. Yang, C.J. Chou, J. Sole, A. Nichols, J.S. 
Ross, L.A. Tartaglia, and H. Chen. 2003. Chronic inflammation in fat plays a crucial 
role in the development of obesity-related insulin resistance. J. Clin. Invest. 
112:1821–1830. 
Yang, Q., T.E. Graham, N. Mody, F. Preitner, O.D. Peroni, J.M. Zabolotny, K. 
Kotani, L. Quadro, and B.B. Kahn. 2005. Serum retinol binding protein 4 contributes 
to insulin resistance in obesity and type 2 diabetes. Nature. 436:356–362. 
Yang, X., S. Enerbäck, and U. Smith. 2003. Reduced expression of FOXC2 and 
brown adipogenic genes in human subjects with insulin resistance. Obes. Res. 
11:1182–1191. 
Yi, K., J. Shin, H. Seo, J. Lee, M. Oh, T. Kim, H. Saw, S. Kim, and J. Hur. 2008. 
Role of estrogen receptor-alpha and -beta in regulating leptin expression in 3T3-L1 
adipocytes. Obesity (Silver Spring). 16:2393–2399. 
Yin, D., S.D. Clarke, J.L. Peters, and T.D. Etherton. 1998. Somatotropin-dependent 
decrease in fatty acid synthase mRNA abundance in 3T3-F442A adipocytes is the 
result of a decrease in both gene transcription and mRNA stability. Biochem. J. 331 ( 
Pt 3):815–820. 
Young, E.H., N.J. Wareham, and S. Farooqi. 2007. The V103I polymorphism of the 
 
217 
MC4R gene and obesity: population based studies and meta-analysis of 29 563 
individuals. International journal of …. 
Zeyda, M., and T. Stulnig. 2007. Adipose tissue macrophages. Immunol Lett. 
112:61–67. 
Zeyda, M., K. Gollinger, E. Kriehuber, F. Kiefer, A. Neuhofer, and T. Stulnig. 2010. 
Newly identified adipose tissue macrophage populations in obesity with distinct 
chemokine and chemokine receptor expression. Int J Obes (Lond). 34:1684–1694. 
Zhang, B., S. Kirov, and J. Snoddy. 2005. WebGestalt: an integrated system for 
exploring gene sets in various biological contexts. Nucleic acids research. 33:W741. 
Zhang, L., T. Sugiyama, N. Murabayashi, T. Umekawa, N. Ma, Y. Kamimoto, Y. 
Ogawa, and N. Sagawa. 2011. The inflammatory changes of adipose tissue in late 
pregnant mice. J. Mol. Endocrinol. 47:157–165. 
Zhang, Y., R. Proenca, M. Maffei, M. Barone, L. Leopold, and J.M. Friedman. 1994. 
Positional cloning of the mouse obese gene and its human homologue. Nature. 
372:425–432. 
Zhao, J., K.L. Townsend, L.C. Schulz, T.H. Kunz, C. Li, and E.P. Widmaier. 2004. 
Leptin receptor expression increases in placenta, but not hypothalamus, during 
gestation in Mus musculus and Myotis lucifugus. Placenta. 25:712–722. 
Zhao, J.J., T.H.T. Kunz, N.N. Tumba, L.C.L. Schulz, C.C. Li, M.M. Reeves, and 
E.P.E. Widmaier. 2003. Comparative analysis of expression and secretion of 
placental leptin in mammals. Am. J. Physiol. Regul. Integr. Comp. Physiol. 
285:R438–R446. 
Zimmermann, R., J.G. Strauss, G. Haemmerle, G. Schoiswohl, R. Birner-
Gruenberger, M. Riederer, A. Lass, G. Neuberger, F. Eisenhaber, A. Hermetter, and 
R. Zechner. 2004. Fat mobilization in adipose tissue is promoted by adipose 
triglyceride lipase. Science. 306:1383–1386. 






“Imagination is more important than knowledge. 
For knowledge is limited to all we now know and 
understand, while imagination embraces the entire 
world, and all there ever will be to know and 
understand.” 
Albert Einstein  
